¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>ÃĵØÂåÃÄ
ªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2014/7/22 ¤W¤È 09:05:58
ÃÒ¥æ©Ò­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Ö­ã¡C

1.¨Æ¹êµo¥Í¤é:103/07/21

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«ö­pµe¶i¦æ(¥ç§Y¬ü°êFDA®Ö­ã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç­pµe)¡C

6. ¦]À³±¹¬I:¶i¦æ¤½§i¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©x­û«Øij¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C

(2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C



¶}ª©·|­û¡u¥ý¶i¡v½Ðºô¤Íµo¨¥µÛ­«©ó²z©Ê°Q½×·sÃĶi«×¡AµL¿×¤£²z©Êªº¥´À£¡A½Ð¦Ü¨ä¥Lª©°Ï¡A¤À¬y¬O¬°¤F¦³§Q§ë¸ê¤H·j´M

·|­û¡GDHL10147526  µoªí®É¶¡:2024/3/27 ¤U¤È 03:04:40²Ä 10056 ½g¦^À³
³o»Ý­n­@¤ß¡A2026/B ¡AET/PMF ®³¨ìor ±N®³¨ìÃÄÃÒ¡AÀ³¸Ó¦³¤@ªi¡A°£«DÀ禬¤ÓÄê¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2024/3/26 ¤U¤È 06:23:14²Ä 10055 ½g¦^À³
³oªi±q316¤¸¶R¨ì330¤¸¡A®M¤F28±i......Äêªd§ß¤£¤WÀð¡Aµ¥«Ý3¤ëÀ禬¤½¥¬´Á«Ý¦³¦n®ø®§
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GABC10134671  µoªí®É¶¡:2024/3/26 ¤U¤È 05:27:28²Ä 10054 ½g¦^À³
½ßºG¤F
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2024/3/20 ¤W¤È 11:23:10²Ä 10053 ½g¦^À³
¦U¦ì§ë¸ê¤H³Ìªñ¦³¨S¦³¯d·N¨ìÃĵØÃĪº¨«¶Õ¡A¤T¤ë¥÷ªº¤ëÀ禬¬OÀ³¸Ó¥i¥H´Á«Ýªº¡A¥»¤H¦ô­pÀ³¸Ó·|¦¨ªø¨ì6»õ¥H¤W

ªÑ»ù¨«¶Õ¤]¸ò¤§«e¦³©Ò¤£¦P¡A²{¦b¨«¶Õ®æ§½³£¬O¶}§C¨«°ª¡AªÑ»ù·|ÀHµÛ¤ëÀ禬¨B¨B°ª¡A§ë¸ê¤H¤£­n¿ù¹L§G§½ªº¾÷·|

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2024/3/12 ¤W¤È 10:30:59²Ä 10052 ½g¦^À³
ªñ´Á¥u­n¦³¨£¦^ÀɧY¥i°u¶q©Ó±µ¡A3¤ë¤ëÀ禬¥i´Á«Ý©Ê°ª¡AªÑ»ù½L¾ã¦V¤W.......¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2024/3/7 ¤U¤È 04:27:56²Ä 10051 ½g¦^À³
ÃĵØÃĪº§ë¸ê¤H¤U¤È¦n

¥»¤H¤§«e¦bªÑ»ùº¦¯}500¤¸«á¡A¤@ª½¨Ó¦^¾Þ§@¡A¦b³Ì«á¤@¦¸µo¦æ®ü¥~GDR»{ÁÊ415¤¸¶^¯}®É´N¤w¥¢¥h«H¤ß

«ùªÑ¥þ¼Æ¥X²M¡A¦³¤@¥b­ì¦]¬O¤ëÀ禬¿ð¿ð¨S¸ò¤WªÑ»ù¦P¨B¡A²M¤ß¦a¥h¤j³°¹ï©¤©ñªÅ®È¹C10­Ó¤ë¡Aµu¯²¥|³B¹Cª±¨ü¤H¥Í

¤µ¦~ªº2¤ëÀ禬½T¹êÆZ«G²´ªº¡AªÑ»ù¤]¶^¦Ü¥iªø´Á«ù¦³ªº§ë¸êÂI¡A¨Ì½u«¬¨Ó¬Ý­n¶^¯}309¤¸¾÷²v¤w¤£°ª¡A

¬ü°ê°õ¦æ¾P°â¦³ªÖ©wªº¦¨ÁZÅã²{¡A3¤ëªºÀ禬§ó¦³´Á«Ý©Ê¤F¡A«Øij¥[½X¶R¶i«ù¦³¡A§Æ±æ¤µ¦~©³¥i±æ¤ëÀ禬¯¸¤W7~8»õ¥H¤W¡AªÑ»ù¯¸¤W400À³¤£Ãø~Ãĵإ[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/5/9 ¤U¤È 07:30:52²Ä 10050 ½g¦^À³
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) 6446 ÃĵØÃÄ ¡@¤½¥q´£¨Ñ

§Ç¸¹ 1 µo¨¥¤é´Á 112/05/09 µo¨¥®É¶¡ 18:12:28

µo¨¥¤H ªL°êÄÁ µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü (02)26557688

¥D¦®

¥»¤½¥q¥N¤l¤½¥qPharmaEssentia Singapore Pte. Ltd

¤½§i¥Ó½Ð·sÃÄBESREMi¡]Ropeginterferon alfa-2b¡^·s¥[©Y

¤W¥«³\¥iÃÒ¡A¾AÀ³¯g¬°¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^

²Å¦X±ø´Ú ¡@²Ä 10 ´Ú ¨Æ¹êµo¥Í¤é 112/05/09

»¡©ú

1.¨Æ¹êµo¥Í¤é:112/05/09

2.¬ãµo·sÃĦWºÙ©Î¥N¸¹:BESREMi¡]Ropeginterferon alfa-2b, §YP1101¡^

3.¥Î³~:¥Î©óªvÀø¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g¡]Polycythemia Vera , PV¡^±wªÌ¡C

4.¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q:¥Ó½Ð·s¥[©Y¤W¥«³\¥iÃÒ

5.¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q(½Ð»¡©ú¥Ø«e¤§¬ãµo¶¥¬q«YÄÝ´£¥X¥Ó½Ð/³q¹L®Ö­ã/¤£³q¹L®Ö­ã

¡A­Y¥¼³q¹LªÌ¡A½Ð»¡©ú¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡F¥t½Ð»¡©ú¥¼¨Ó¸gÀç¤è¦V¤Î¤w§ë

¤J²Ö¿n¬ãµo¶O¥Î):

(1)´£¥X¥Ó½Ð/³q¹L®Ö­ã/¤£³q¹L®Ö­ã/¦U´Á¤HÅé¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG/µo¥Í¨ä¥L¼vÅT

·sÃĬãµo¤§­«¤j¨Æ¥ó¡G

¥»¤½¥q¤§·s¥[©Y¤l¤½¥qPharmaEssentia Singapore Pte. Ltd¤w¦V·s¥[©Y½Ã¥Í¬ì¾Ç

§½¡]Health Sciences Authority, HSA¡^¥Ó½Ð·sÃÄBESREMi 500mcg/mL solution

for injection in prefilled syringe¡]Ropeginterferon alfa-2b¡^¤§¤W¥«³\¥i

ÃÒ¡A¾AÀ³¯g¬°¯u©Ê¬õ¦å²y¼W¦h¯g¡C

(2)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¥¼¹F²Î­p¤W

ÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G

¤£¾A¥Î¡C

(3)¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¹F²Î­p¤WµÛ

·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G

¤£¾A¥Î¡C

(4)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G

¦Ò¶q¥¼¨Ó¥«³õ¦æ¾Pµ¦²¤¡A«O»Ù¤½¥q¤Î§ë¸ê¤HÅv¯q¡A¼È¤£¤½¶}´¦ÅS¡C

6.±N¦A¶i¦æ¤§¤U¤@¶¥¬q¬ãµo(½Ð»¡©ú¹w­p§¹¦¨®É¶¡¤Î¹w­pÀ³­t¾á¤§¸q°È):

·s¥[©YHSA¨ü²z¤W¥«³\¥iÃҥӽСC

(1)¹w­p§¹¦¨®É¶¡¡G¨Ì·Ó·s¥[©YHSA¨ü²z®×¥ó®Éµ{¡C

(2)¹w­pÀ³­t¾á¤§¸q°È¡GµL¡C

7.¥«³õ²{ªp:

¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^¬°°©Åè¼W¥Í©Ê¸~½F¡]MPN¡^¯e¯fªº¤@ºØ¡AÁöµM¬õ¦å²yªº¹L«×

¼W¥[³Ì¬°ÅãµÛ¡A¦ý¦b¤j¦h¼Æ±¡ªp¤U¡A¥Õ¦å²y©M¦å¤pªO¤]·|¤É°ª¡CPV±wªÌµo¥Í¤ß¦åºÞ

¨Öµo¯gªº­·ÀI«Ü°ª¡A¦p¦å®ê¡B®ê¶ëµ¥¡A©Î´c¤Æ¬°Ä~µo©Ê°©ÅèÅÖºû¤Æ©Î«æ©Ê°©Åè¥Õ¦å¯f

¡]AML¡^¡A¼vÅT¯f±w¦s¬¡»P¥Í¬¡«~½è¡C®Ú¾Ú¥«³õ¬ã¨s¡A·s¥[©Y¬ù¦³500¦WPV±wªÌ¡A¥Ø«e

Á{§ÉªvÀø¥]¬A©ñ¦å¡B·Rªv½¦Ån¡]Hydroxyurea, HU¡^¡B¤zÂZ¯Àµ¥¡C

8.¨ä¥LÀ³±Ô©ú¨Æ¶µ(­Y¨Æ¥óµo¥Í©Î¨Mij¤§¥DÅé«YÄݤ½¶}µo¦æ¥H¤W¤½¥q¡A

¥»«h­«¤j°T®§¦P®É²Å¦XÃÒ¨é¥æ©öªk¬I¦æ²Ó«h²Ä7±ø²Ä8´Ú©Ò©w

¹ïªÑªFÅv¯q©ÎÃÒ¨é»ù®æ¦³­«¤j¼vÅT¤§¨Æ¶µ):

Ropeginterferon alfa-2b¤wÀò¼Ú·ù¡B¥xÆW¡B·ç¤h¡B¥H¦â¦C¡BÁú°ê¡B¿Dªù¡B¬ü°ê¤Î¤é¥»

®Ö­ã¨Ï¥Î©ó¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g±wªÌ

9.·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë

¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/4/27 ¤W¤È 10:30:01²Ä 10049 ½g¦^À³
¤w¬Ý¨ì¤@¤BÂI¦¨ªG¡A¥u­n±zªÖ§V¤O©Î³\·LÁ¡¤§¤O¶°¤Ö¦¨¦h¡A¥²©w¯à¦¨¤Ï§ðªº¸¹¨¤.......
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/4/26 ¤U¤È 10:01:58²Ä 10048 ½g¦^À³
­É¨÷¾lÃB³Ñ14438±i¡A¤µ¤éÁÙ¨÷12374±i¡A­É¨÷ªº¤pªÑªF¦A¥[§â«lcall¦^­É¨÷¡Aµ²§ô¦¹ªi±þ½L¤Ï¤â¬°§ð.......¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/4/25 ¤U¤È 09:12:58²Ä 10047 ½g¦^À³
ÃÒ¥æ©Ò¸ê®ÆÃĵØÃĭɨé¾lÃB26145±i¡A³o¤G¤Ñ­n¨DÁÙ¨é¤~¤d¾l±i¡A®Ú¥»°_¤£¤F§@¥Î

­É¨éªºªÑªF­Ì¤d¸U§O¦³¡A§Ú¤â¤¤«ù¦³­É¥X¨é¨Ã¤£¼vÅTº¦¶^ªº¤ßºA¡A¶°¤Ö¦¨¦h´N¦¨¥~¸ê§|±þªÑ¥ÁªºÄw½X¡A®³¨ì¤@ÂIÂIªº§Q®§¡A¿éºG¤F®t»ù........¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/4/25 ¤W¤È 08:51:08²Ä 10046 ½g¦^À³

­º­¶ > °]¸g¬Fµ¦

°]¸g«C¬õ¿O¡n¥~¸êÂy±þÃĵØÃÄ

2023/04/25 05:30

ªñ´ÁÃĵØÃĪѻùÀWÀW¯}©³¡A¬Q¦¬½L»ù380.5¤¸¡A¤w³Ð¤U¹O10­Ó¤ë¨Ó·s§C¡A°ªÀɶR¶iªº§ë¸ê¤H«sÂE¹M³¥¡A±qªÑ»ù§Þ³N­±¨Ó¬Ý¡A´X­Ó¤ëªº¤jÀY³¡§Î¦¨¡Aµu´Á­n¤ÏÂà¦ü¥G¤£¤Ó®e©ö¡C¡]¤¤¥¡ªÀ¸ê®Æ·Ó¡^

¦]®³¨ì¬ü°êÃÄÃÒ¡A¥[¤W¦³©ú¬P±i¶vÚ¬»{Áʨp¶ÒªÑ²¼¥[«ù¡A¥h¦~ÃĵØÃÄ¡]6446¡^ªÑ»ù¤@«×½Ä¤W622¤¸¡Aºaµn¥Í§ÞªÑªÑ¤ý¡A¥«­È§ó°ª¹F1800»õ¤¸¥H¤W¡A³Ð¤U¥Í§ÞªÑ¤§³Ì¡A¥h¦~12¤ë¨Ã¯Ç¤JMSCI¦¨¤ÀªÑ¡A¤@®É¤§¶¡¡AªÑªF¨«¸ô³£¦³­·¡B·Ù¬O­·¥ú¡C

¤£¹Lªñ´ÁÃĵØÃĪѻùÀWÀW¯}©³¡A¬Q¦¬½L»ù380.5¤¸¡A¤w³Ð¤U¹O10­Ó¤ë¨Ó·s§C¡A°ªÀɶR¶iªº§ë¸ê¤H«sÂE¹M³¥¡A±qªÑ»ù§Þ³N­±¨Ó¬Ý¡A´X­Ó¤ëªº¤jÀY³¡§Î¦¨¡Aµu´Á­n¤ÏÂà¦ü¥G¤£¤Ó®e©ö

ÃĵØÃĪñ´Áµo¦æGDR¡A¶Ò¸ê¶W¹L140»õ¤¸¡A¤]³Ð¥Í§ÞªÑ¤§³Ì¡A§ë¸ê¤H­ì¥»¥H¬°ÃĵØÃĪѻù¤U¶^¡A¬O¦]¬°¥~¸ê¥´À£ªÑ»ù¡A­n§âGDR©w»ù°µ§C¡A¦ý4¤ë¤¤GDR©w»ù§¹¦¨¡A´«ºâ·s¥x¹ô¨CªÑ415¤¸¡A¤W¶gÃĵØÃĪѻù¤£¦ý¨S¤î¶^¡A¤Ï¦Ó«ùÄò¯}©³¡AªÑªF¤@Áy¿ù´j¡C

ÃĵØÃĪѪF¤@©wı±o«Ü¸Þ²§¡A©ú©ú¥h¦~³QMSCI¯Ç¤J¦¨¤ÀªÑ«á¡A¡u¥~¸ê«ùªÑ®w¦s¡v¤]¬O¼W¥[¡A¦ý¬°¦óªÑ»ù³o´X­Ó¤ë¨Ó«o¬O¤£º¦¤Ï¶^¡H¬Ý¬Ý¹L¥h¯E¹©¡]4174¡^ªº«e¨Ò¡A¦ü¥G¦³¸ñ¥i´`¡C

2015¦~11¤ë¯E¹©¤]³QMSCI¯Ç¤J¦¨¤ÀªÑ¡A¦b¨º¤§«e¥~¸ê´NÀWÀW¶R¶W¡A¦ý¦P¤@®É¶¡¥~¸ê­É¨é½æ¥X©ñªÅ¤]¦P¨B¼W¥[¡Aª½¨ì¹j¦~¯E¹©¸Ñª¼¥¢§Q¡A¥~¸ê­É¨é©ñªÅ¤´¤£ÃP¤â¡A¤@«×¶W¹L2¸U¦h±i¡A·í®É¤]¬O¥~¸ê«ùªÑ®w¦s¼W¥[¡A¦ý«oÀWÀW½æ¥XáèÀ£ªÑ»ù¡A³Ì«áª½¨ì¯E¹©ªÑ»ù¶^¨ì¨¦©³¡A¥~¸ê¤Ï¤â¶R¶W¡B®w¦s¤j´î¡A¤@³õÂy±þ¤~§i§¹¦¨¡C

·í¥~¸ê¦VªÑªF­É¨é®É¡A¦]ªÑ²¼¤w­Éµ¹¥~¸ê¡A´Nºâ¬O¥~¸êªº«ùªÑ¡A·|Åý¥~¸ê«ùªÑ®w¦s¼W¥[¡A¦Ó¥~¸ê­É¨é«á½æ¥X©ñªÅ¡A¦b¥~¸ê¶i¥X¤W´N·|¥X²{½æ¶W¡A¦pªG­É¨Ó¨é¨S¦³©ñªÅ¡A®w¦sÁÙ·|¼W¥[¡F²{¦bÃĵØÃĪº±¡ªp´N¬O¦p¦¹¡A2¤ëªì¹A¾ä¦~«á¡A¥~¸ê­É¨é½æ¥X±i¼Æ¶È3¤d¦h±i¡A¨ì¤W¶g¤­¤w°ª¹F2.1¸U±i¡A¦ý¦P¤@®É¶¡¡A¥~¸ê©é©R½æ¶W¡Aµ²ªG«ùªÑÁ`®w¦sÁÙ¼W¥[200±i¡C

­Y·Ó¯E¹©ªº«e¨Ò¡A·í¥~¸ê­É¨é½æ¥X¦^¸É¡B¥X²{«ùÄò¶R¶W®É¡AªÑ»ù¤~·|¸¨©³¡A¦ý¦p¤µÃĵØÃÄÁÙ¦h¤F¤@­ÓGDR¥iÅý¥~¸ê®M§QªºªÅ¶¡¡A©Ò¥H³o³õÂy±þ¡Aµu´Á¶¡¦ü¥GÁÙ¨Sµ²§ô¡AªÑªF®£©ÈÁÙ¦³±o·Î¼õ¡I

­É¨éªº¤pªÑªF­Ì¡Acall¦^­É¨é®Â½Ã¸Ó¦³ªº´LÄY¡A±z§ÚÀ³¥X¤@¥÷¤O........¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/4/24 ¤W¤È 09:31:13²Ä 10045 ½g¦^À³
«Ü­«­nªº°T®§¡I¡I

Åý§Ú­Ì¤@°_¤ÏÀ»§a¡I

¤é¥»Ãĵý¹L¤F¡I¤T¤ë·~ÁZ¤w¨ì3.48»õ¡I§Ú­ÌªºªÑ»ù«o±q500¦hÀ£¦^¨ì387.5¡A±zı±o¦X²z¶Ü¡H

­ì¥»¥H¬°À£»ù¬O¬°¤FG D R©w»ù¡A¦p¤µG D R¤]©w»ù¤F¡A¹w´Á·|¶}©l©¹¤W©Ô©ï¡A¦p¤µ«o¤£º¦¤Ï¶^¡I«U¤ªµs¥ç¦³¹D¡A¦p¤µ¬Ý¨Ó¥L­Ì¬O­n¤@G¤T¦Y¡A´N¬O­n¦Y°®©ÙºÉ¡I

¥L­Ì²{¦b§@ªk«Ü²³æ¡A¨C¤ÑÁÙ¬O¥ýÄ~Äò­É¨é½æ¥XÀ£»ù¡AÅý¤j®a¤£´±¶Ã°Ê¡A¬Æ¦Ü»s³y´HÂÍ®ÄÀ³¡AµM«á¦A§C»ù¶R¶iÁÙ¨é¡A³o´X¤Ñ³z¹L³oºØ¤è¦¡¥­§¡¨C¤Ñ³£ÁÙ¤F200¦h±i­É¨é¡I°O±o¥L­Ì¤§«e¬O±q500¦h½æ¤U¨Óªº¡A²{¦b387.5¶R¦^´N¥i¥HÁÙ¨é¤F¡A¨º¬OÁȤF¦h¤Ö¡H²{¦bªº­É¨éÁÙ¦³27000±i¡A¥H³oºØ¨C¤ÑÀ£»ùÁÙ200±iªº§@ªk¡A§Ú­ÌªºªÑ»ù¥u·|¤Ñ¤Ñ¶^¡I­n¶^¨ì¨º¸Ì¡HµL©³¬}¡I³o¥sµs¤wµL¹D¡I

·Pı§Ú­ÌÃĵؤͫܦh¬O¦³ÃѤ§¤h¡A°Z¯à¾D¤H¦p¦¹µLµø¤Î½î½ñ¡I§Ú­Ì¥²¶·¤ÏÀ»¡I

¨º¦p¦ó¦^À»¡H«Ü²³æ¡AÅ¥¹L­ì´ö¤Æ­ì¥Û¶Ü¡H¥L­Ì¦Y¦h¤F®ø¤Æ¤£¨}¡AÅý§Ú­Ì¥Î­ì´ö¨ÓÀ°¥L­Ì®ø¤Æ¡I¤°»ò¬O­ì´ö¡H¨º´N¬O§Ú­Ì¤â¤W³Q­É¨«ªº¨é¡I

¨ä¹ê¤§«e¦³¨ÇµØ¤Í¤w½Ð¤j®acall¦^­É¨é¡A¦ý¦pªG¨S¦³¤èªk¡A¤j®a¥u·|Æ[±æ¡A³Ì«á¥u·|¬y¬°¹D¼w©IÆ~¡C

§Ú²{¦b´£¥Xªº¤èªk«Ü²³æ¡A¥u­n¨â¨BÆJ¡G

1. ¦pªG¦P·N¤p§Ìªº»¡ªk¤Î§@ªk¡A½ÐÀ°¥»¤å«öÆg¡C

³o¬O¦¨¤£¦¨¥\ªº°ò¥Û¤ÎÃöÁä¡A¦]¬°³o¬O¥Nªí¤j®a¦@ÃѪº§Î¦¨¡A¥»¸s¦³5000¤H¡A¦pªG«Ü¦h¤H³£ÃÙ¦P¤F³£«öÆg¤F¥Nªí§Ú­Ì¤j®a¦³¦@ÃѤF¡I¥L´N¤@©w·|¦¨¡A¤£¦A¥u¬O¹D¼w©IÆ~¡I¡]´Nºâ±z¨S¦³­É¨é¥X¥h¤]½Ð«öÆg¡A¹Îµ²¤~·|¦³¤O¶q¡I¡^

2. ½ÐÃÙ¦PªºÃĵؤͬP´Á¤@°¨¤Wcall¦^±zªº­É¨é¡I¤£ºÞ±z¬O¤£¬O¤j¤á¡A±zªºcall¦^³£µ´¹ï¦³À°§U¡I¥u­n¤j®a¦P¤ß¤@­P¡A¬P´Á¤@±z¤@©w·|¬Ý¨ì¦¨ªG¡I

¬Ý¹L¶Â·tºaÄ£¶Ü¡HÅý§Ú­Ì¤@°_ºûÅ@§Ú­Ì¸Ó¦³ªº»ù­È§a¡I

³Ì«á¡A¦pªG±zÃÙ¦P¡A°£¤F«öÆg¡A½Ð¤£­nµo¤å¡A¤£µM·|¬~ª©¡A«á­±¶i¨Óªº¤H¡A´N¬Ý¤£¨ì¦¹¤å¤F¡I

ÁÙ¦³¡A¥i¥H¹w´Á¦³¨Ç¼ç¥ñ¦b¥»¸s²Õªº®M§Q¦P¸ô¤H·|¥X²{¤@¨Ç¤Ï¹ï©Î¦ü¬O¦Ó«D©Î¤Ï±a­·¦Vªº»y¨¥¡A½Ð°í©w«H¤ß¤Å¦^À»¥H§K¬~ª©¡I

#¦³½Ð­É¨éªºÃĵØÃĤpªÑªF¶°¤¤¤õ¤O¦b¤µ¡B©ú¤G¤Ñcall¦^­É¨é¡A±z­É¥XªºªÑ²¼§Q®§»·¤£¤Î¨C¤Ñ¶^0.5%¡A®Â½Ã¦Û¤v¤â¤¤«ùªÑªºªÑ»ù.........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/4/24 ¤W¤È 09:15:18²Ä 10044 ½g¦^À³
«Ü­«­nªº°T®§¡I¡I

Åý§Ú­Ì¤@°_¤ÏÀ»§a¡I

¤é¥»Ãĵý¹L¤F¡I¤T¤ë·~ÁZ¤w¨ì3.48»õ¡I§Ú­ÌªºªÑ»ù«o±q500¦hÀ£¦^¨ì387.5¡A±zı±o¦X²z¶Ü¡H

­ì¥»¥H¬°À£»ù¬O¬°¤FG D R©w»ù¡A¦p¤µG D R¤]©w»ù¤F¡A¹w´Á·|¶}©l©¹¤W©Ô©ï¡A¦p¤µ«o¤£º¦¤Ï¶^¡I«U¤ªµs¥ç¦³¹D¡A¦p¤µ¬Ý¨Ó¥L­Ì¬O­n¤@G¤T¦Y¡A´N¬O­n¦Y°®©ÙºÉ¡I

¥L­Ì²{¦b§@ªk«Ü²³æ¡A¨C¤ÑÁÙ¬O¥ýÄ~Äò­É¨é½æ¥XÀ£»ù¡AÅý¤j®a¤£´±¶Ã°Ê¡A¬Æ¦Ü»s³y´HÂÍ®ÄÀ³¡AµM«á¦A§C»ù¶R¶iÁÙ¨é¡A³o´X¤Ñ³z¹L³oºØ¤è¦¡¥­§¡¨C¤Ñ³£ÁÙ¤F200¦h±i­É¨é¡I°O±o¥L­Ì¤§«e¬O±q500¦h½æ¤U¨Óªº¡A²{¦b387.5¶R¦^´N¥i¥HÁÙ¨é¤F¡A¨º¬OÁȤF¦h¤Ö¡H²{¦bªº­É¨éÁÙ¦³27000±i¡A¥H³oºØ¨C¤ÑÀ£»ùÁÙ200±iªº§@ªk¡A§Ú­ÌªºªÑ»ù¥u·|¤Ñ¤Ñ¶^¡I­n¶^¨ì¨º¸Ì¡HµL©³¬}¡I³o¥sµs¤wµL¹D¡I

·Pı§Ú­ÌÃĵؤͫܦh¬O¦³ÃѤ§¤h¡A°Z¯à¾D¤H¦p¦¹µLµø¤Î½î½ñ¡I§Ú­Ì¥²¶·¤ÏÀ»¡I

¨º¦p¦ó¦^À»¡H«Ü²³æ¡AÅ¥¹L­ì´ö¤Æ­ì¥Û¶Ü¡H¥L­Ì¦Y¦h¤F®ø¤Æ¤£¨}¡AÅý§Ú­Ì¥Î­ì´ö¨ÓÀ°¥L­Ì®ø¤Æ¡I¤°»ò¬O­ì´ö¡H¨º´N¬O§Ú­Ì¤â¤W³Q­É¨«ªº¨é¡I

¨ä¹ê¤§«e¦³¨ÇµØ¤Í¤w½Ð¤j®acall¦^­É¨é¡A¦ý¦pªG¨S¦³¤èªk¡A¤j®a¥u·|Æ[±æ¡A³Ì«á¥u·|¬y¬°¹D¼w©IÆ~¡C

§Ú²{¦b´£¥Xªº¤èªk«Ü²³æ¡A¥u­n¨â¨BÆJ¡G

1. ¦pªG¦P·N¤p§Ìªº»¡ªk¤Î§@ªk¡A½ÐÀ°¥»¤å«öÆg¡C

³o¬O¦¨¤£¦¨¥\ªº°ò¥Û¤ÎÃöÁä¡A¦]¬°³o¬O¥Nªí¤j®a¦@ÃѪº§Î¦¨¡A¥»¸s¦³5000¤H¡A¦pªG«Ü¦h¤H³£ÃÙ¦P¤F³£«öÆg¤F¥Nªí§Ú­Ì¤j®a¦³¦@ÃѤF¡I¥L´N¤@©w·|¦¨¡A¤£¦A¥u¬O¹D¼w©IÆ~¡I¡]´Nºâ±z¨S¦³­É¨é¥X¥h¤]½Ð«öÆg¡A¹Îµ²¤~·|¦³¤O¶q¡I¡^

2. ½ÐÃÙ¦PªºÃĵؤͬP´Á¤@°¨¤Wcall¦^±zªº­É¨é¡I¤£ºÞ±z¬O¤£¬O¤j¤á¡A±zªºcall¦^³£µ´¹ï¦³À°§U¡I¥u­n¤j®a¦P¤ß¤@­P¡A¬P´Á¤@±z¤@©w·|¬Ý¨ì¦¨ªG¡I

¬Ý¹L¶Â·tºaÄ£¶Ü¡HÅý§Ú­Ì¤@°_ºûÅ@§Ú­Ì¸Ó¦³ªº»ù­È§a¡I

³Ì«á¡A¦pªG±zÃÙ¦P¡A°£¤F«öÆg¡A½Ð¤£­nµo¤å¡A¤£µM·|¬~ª©¡A«á­±¶i¨Óªº¤H¡A´N¬Ý¤£¨ì¦¹¤å¤F¡I

ÁÙ¦³¡A¥i¥H¹w´Á¦³¨Ç¼ç¥ñ¦b¥»¸s²Õªº®M§Q¦P¸ô¤H·|¥X²{¤@¨Ç¤Ï¹ï©Î¦ü¬O¦Ó«D©Î¤Ï±a­·¦Vªº»y¨¥¡A½Ð°í©w«H¤ß¤Å¦^À»¥H§K¬~ª©¡I

#¦³½Ð­É¨éªºÃĵØÃĤpªÑªF¶°¤¤¤õ¤O¦b¤µ¡B©ú¤G¤ÑCO¦^­É¨é¡A±z­É¥XªºªÑ²¼§Q®§»·¤£¤Î¨C¤Ñ¶^0.5%¡A®Â½Ã¦Û¤v¤â¤¤«ùªÑªºªÑ»ù.........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/3/27 ¤U¤È 05:47:29²Ä 10043 ½g¦^À³
­è¦n´N¤½¥¬ÃĵØÃÄ®³¨ì¤é¥»ÃÄÃÒ

Google½Ķ¡]­«ÂI¡^

·s»Dµo¥¬

´L·qªº·s»D¬É¤H¤h¡A

2023 ¦~ 3 ¤ë 27 ¤é Pharma Essentia Japan Co., Ltd.

¥Î©óªvÀø¯u©Ê¬õ²Ó­M¼W¦h¯gªº¡§BESREMi® ¥Ö¤Uª`®g 250 £gg ª`®g¾¹¡B500 £gg ª`®g¾¹¡¨Àò±o¥Í²£©M¾P°â³\¥i

― Pharma Essentia Japan ªº²Ä¤@­Ó²£«~½Ï¥Í©ó³Ð·sªº¡§¦ìÂI¿ï¾Ü©Ê³æ»E¤A¤G¾J¤Æ§Þ³N¡¨¥­¥x¡A¦b¤é¥»Àò±o§å­ã ―

PharmaEssentia Japan Co., Ltd.¡]Á`³¡¡GªF¨Ê¡AÁ`µô­Ý­º®u°õ¦æ©x¡GKatsuya Yonezu¡A3 ¤ë 27 ¤é¡APharma Essentia Japan¡^«Å¥¬§ÜÀù¾¯/lopeg ¤zÂZ¯À £\-2b »s¾¯¡§Bethlemi 🄬🄬 ¥Ö¤Uª`®g 250 £gg ª`®g¾¹¡A500 £ggª`®g¾¹¡¨¡]³q¥Î¦WºÙ¡Glopeg ¤zÂZ¯À alfa-2b¡A§Ú­Ì«Ü°ª¿³¦a³qª¾±z¡A§Ú­Ì¤wÀò±o«p¥Í³Ò°Ê¬Ùªº¥Í²£©M¾P°â³\¥i¡A¥Î©ó Bethlemi®¡^§@¬°ªvÀø¯u©Ê¬õ²Ó­M¼W¦h¯g (PV)¡]¦³­­¥Î©ó²{¦³ªvÀø¤£¥R¤À©Î¤£¾A·íªº±¡ªp¡^¡C

¸Ó§å­ã°ò©ó¤@¨t¦CÁ{§É¶}µo­p¹ºªºµ²ªG¡A¥]¬A¤é¥» II ´ÁÁ{§É¸ÕÅç¡]¬ã¨s A19-201¡^¡C

Bethlemi®¬O¤@ºØ·s«¬ªø®Ä³æ»E¤A¤G¾J²ã®ò»Ä¤zÂZ¯À¡A»P¶Ç²Î»E¤A¤G¾J¤zÂZ¯À¬Û¤ñ¦³±æ©µªøµ¹ÃĶ¡¹j¡C PVªvÀøªº­º­n¥Ø¼Ð¬O¹w¨¾¦å®ê§Î¦¨¡A¦ÓÀR¯ß¤Á¶}³N¡B§Ü¦å¤pªOªvÀø¡B²Ó­M´î·ÀªvÀø¥H¤Î¤À¤l¹v¦VÃĪ«ªº¥X²{¨Ï±o³q¹L±±¨î¦å²Ó­M¤ñ®e¤ô¥­¨Ó¹w¨¾¦å®ê§Î¦¨¨ú±o¤Fªø¨¬ªº¶i¨B¡C ¦ý¥t¤@¤è­±¡A±±¨î¯gª¬¡B¹w¨¾¯e¯f¶i®iµ¥ÂåÀø»Ý¨D¤´¥¼±o¨ìº¡¨¬¡A¤H­Ì­¢¤Á´Á«Ý¯à°÷´£¨Ñ·sªvÀø¿ï¾ÜªºÃĪ«ªº¬ãµo©MÀò§å¡C

§Ú­Ì¤½¥q¶}µo©MÂåÀø³¡ªùÁ`¸g²z Toshiaki Sato »¡¡G¡§¬°¤F¹ê²{§Ú­Ì¡¥§ó¦nªº¬ì¾Ç¡A§ó¦nªº¥Í¬¡¡¦ªºÄ@´º¡A§Ú­Ì¤@ª½¦b§V¤O¶}µo¯u©Ê¬õ²Ó­M¼W¦h¯gªº·sªvÀøÃĪ«¡C¦¬ÁÊ»s³y©M¦¹¦¸Àò§å¤W¥«¡A±N¬°µ¥«Ý¸ÓÃĪº±wªÌ´£¨Ñ·sªºªvÀø¿ï¾Ü¡A¬O§Ú­ÌÁÚ¥Xªº¤@¤j¨B¡C§Ú­Ì±NÄ~Äò¦bÃĪ«¶}µo¤WÄ~Äò§V¤O¡C¡¨

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/3/27 ¤U¤È 05:13:25²Ä 10042 ½g¦^À³
¨Ì«e5¦¸ªº¨p¶Ò®×¨Ó¬Ý¡AÀ£§CªÑ»ù«á¨ú±o¨p¶Ò©w»ù»{ÁÊ«á¡AªÑ»ù³£¬O±j¯P¤Ï¼u¡A4¤ëªì¨ú±o©w»ù«á

§ë¸ê¤H¤£§{¿ï¾Ü³o¬q®É¶¡¡AªÑ»ù§CÂI¶R¶i®É¾÷¡A¤Îµ¥«Ý4¤ë¤é¥»ÃÄÃÒ¨ú±o§Q¦h¡A¦¹®É¬O¤£¿ùªº®É¶¡ÂI

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2023/3/27 ¤U¤È 03:24:49²Ä 10041 ½g¦^À³
¡³¡³§ë¸êÃĵØÃÄ°O¨Æ¡³¡³

(¤åªø·V¤J¡A¥»½g¶È¬O­Ó¤H²{¶¥¬q§ë¸êÃĵØÃĤ߱¡¼g·Ó¡AµL§ë¸ê«Øij¡A§ë¸ê½Ð¦Û¦æ§PÂ_­t³d)¡C

¡·¨f§ó´µ¤p»¡¡mÂù«°°O¡n¶}ÀY¼g¹D¡G¡u³o¬O³Ì¦nªº®É¥N¡A¤]¬O³ÌÃaªº®É¥N¡v¡FÃĵØÃĤ½¥q¥Ø«e¥Ó½Ð®ü¥~¦s°U¾ÌÃÒDR¤¤¡A¨C¤é³õ¥~¦³¹dÃB°t¹ï¥æ©ö¡F­É¨é½æ¥X¨C¤é³Ð·s°ª¥B§Q²vöt°ª¡F¥~¸ê¨C¤é½æ¥X¡A«ùªÑ«o¤£´î¤Ï¼W³Ð·s°ª¡A¯u¤£ª¾¥~¸ê³ýĪùؽ椰ÃÄ¡H±©ªÑ»ù¨C¤é½w¶^¡A«o¬O¤£ª§ªº¨Æ¹ê¡A¦ý©Ò¶^¦³­­¡A¹ï«ùªÑ¦¨¥»§Cªº¡A¨S¤°·Pı¡F¦ý¹ï«ùªÑ¦¨¥»°ªªº¡A®M¨c¤£Ä@°±·lªÌ¡A¦ü¥G¥u¯àÀqÀqÂI¾\ºq¤â§õ¨ÎÁ¨ªº¡y·Î¼õ¡z¡A¦Û§Ú¦w¼¢¡C¦ý¬Û«H4¤ë10¤éDR¥Í®Ä¤é¡A©¡®É¤½¥qÀ³·|¥H³Ì§Öªº¤u§@¤é¡A¶Ò±o¸êª÷¡A­Y¯à¦¨¥\¶Ò±o¦Ê»õ¥H¤W¡A¥²¯à±q¡y¤j¤H¡z·n¨­¤@Åܦ¨¡y¥¨¤H¡z¡C³o¬q´Á¶¡¡yDR®ÄÀ³¡z©Ò³y¦¨ªÑ»ù¼È®É©ÊªºªiÄi¡AÀ³¸Ó·|­«·s¦^¨ìÁͶզV¤Wªº­y¹D¡C

¡·¦^¾Ð¹L©¹¡A±q2016¦~12¤ë6¤é¡Aªk°êJean-Jacques Kiladjian¡A©ó¬ü°ê¦å²G¾Ç¦~·|¡A¤½¥¬P1101¤T´Á¸Ñ¦®¼Æ¾Ú¡A¨ã²Î­p¾Ç¤W·N¸q¹LÃö¡A²Ä¤@®É¶¡©óJean-Jacques Kiladjianªº°ï¯S(Twitter)¡A°ê»Ú¤£¤ÖªºMPN±M®a¡A¯É¯ÉÄm¤W®¥ÁH¡A¤ß·Q·í¤éªÑ»ùÀ³¬O¤jº¦¯Sº¦¡A·Q¤£¨ì·í¤éªÑ»ù¡A¥«³õ¸ÑŪ¶È¤£¦H©óHu¡AªÑ»ùÃz¶qªø¶Â¡A±q¦¹´N¶}±Ò¤FÃĵØÃÄ©R¹B¦h¦ßªº¦~¥N¡A¦p¼Ú·ùÃÄÃÒ¥ç¬O¤@©µ¦A©µ¡F¥¼¨ã¼Ú·ù©t¨àÃĸê®æ¡F»PAOP¤Ï¥Ø¦¨¤³¡A¤Ï¾D¨DÀv50»õ¡F¬ü°êÃÄÃҥӽХç¬O¤@ªi¤T§é¡AAOP¤£Ä@´£¨Ñ¼Æ¾Ú¡A¥B­±Á{¬Ì±¡¤zÂZ¡A­ì2011¦~3¤ëÀ³¨ú±oÃÄÃÒ¡A¦]FDAµLªk«e¨Ó¬d¼t¡A¨úÃҮɶ¡³Q­¢©µÌX¡F¤½¥q¦h¦¸²¨©¿¥¼¦p¹ê¦p´Á¤½¥¬¸ê°T¡A¹ð¾DÂd¶R­«»@¡A¬Æ¦Ü­±Á{·¥¦D¡A¦C¤J¥þÃB¥æ³Îµ¥¨Æ¶µ¡A¬Ò¥O§ë¸ê¤H®Æ·Q¤£¨ì¡A´Á¶¡ªÑ»ùµL±¡¤U¶^¡A¤w¶^¨ìÃhºÃ¤H¥Í¡AÃhºÃ¦Û¤vªº¿ï¾Ü¡A¤£¤Ö§ë¸ê¤H¥ç¿ï¾Ü»·¥h¡C»¡¹ê¦bªº³o¬q´Á¶¡DR¥Ó½Ð¡A©Ò³y¦¨ªÑ»ù¤U¶^ªº¤@®É­·«B¡A¹ï·Ó¤§«e¤½¥q©Ò­±Á{ªº¦UºØ¨g­·¼É«B¡A¹ê¬O¤£­È¤@´£¡C

¡·°O±o­õ¾Ç®a¥§ªö»¡¹L¡G¡y¨º¨Ç¤£¯à±þ¦º§Úªº¡A³£¨Ï§Ú§ó°í±j¡z¡F2021¦~9¤ë¤U¦¯FDA©ó¬Ì±¡ÄY®m¤§»Ú¡A¤£»·¤d¨½¬£©x­û«e¨Ó¤¤¬ì¬d¼t¡AÅ㨣¹ïP1101ªº­«µø¡A¶}±Ò¤F¥t¤@®°§Æ±æ¤§µ¡¡C2021¦~11¤ë13¤é¬ü°êFDA¤½¥¬ÃÄÃÒ¤§«e¡A¿ï¾Ü¬Û«H°í«ù¤U¨Óall in§ë¸ê¤H¡A©Ò±o¦^³ø¬O¬ü°êÃÄÃÒ¤½¥¬«á¡AªÑ»ù¤@¬P´Á³sÄò5¤Ñ¶}½L´N¬Oº¦¶^ªO¡A¤@»ù¨ì©³²¢¬üªºªG¹ê¡A¥ý¤£½×§ë¸êªº¬ÕÁ«¡A¤@½ú¤lªº§ë¸ê¡A´¿¸g«ù¦³¤@ÀɪѲ¼5¤Ñ§¡¬Oº¦°±ªO¡A¥ç¬O­È±o¡C

¡·¥Ø«e¡A­Y­n¬ã¨sÃĵØÃĪº¸ê°T»á¦h¡A¦pBesremi¦ó®É¨ú±o¤é¥»PVÃÄÃÒ(·Pı¤é¥»¤ñ¼Ú¬ü¶¶§Q)¡B¤jÆW°Ï©Î¤j³°ÃÄÃÒ¶i«×¡F¦U¶µ¾AÀ³¯gÁ{§É¶i«×¡A¦pET¤T´Á¦¬®×´Áµ{¤Î«áÄòÃÄÃÒ¶i«×¡FBesremi¬ü°ê«OÀIº¯³z¡BÂå¾Ç¤¤¤ß¤ÎªÀ°ÏÂå°|¯f¤Hº¯³z²v¡FPVÄvª§¹ï¤âProtagonistÁ{§É¶i«×¡FETÄvª§¹ï¤âBomedemstatÁ{§É¶i«×µ¥¡A¬Ò¦³Â×´IÃD§÷¡A¥i¨Ñ¬ã¨s¡C­Y¤£·Q¦Û¦æ¬ã¨s¡A¥ç¥i°Ñ·ÓªÑ¥«¦P¾Ç·|¹F¤H¦Ñ·Ý©Î°­¤â©ö¥Í(µL±ÀÂˤ§·N)¡A§¡¦³¬Û·í±M·~²`¤J¨£¸Ñ¡A¥i¨Ñ¾Ç²ß°Ñ¦Ò¤§³B¡C

¡·µM¦p¤µ³Ì­«­nªº·íÄݬü°ê¥«³õ¡A¥h¦~¤½¥q·s»D¬Ò¹ï¥~ºÙ¤ëÀ禬¥i±æÂù¦ì¼Æ¦¨ªø¡F¦p¤µ¤w§ï¤f¤µ¦~¯f¤H¼Æ¨C©u³£¦³Âù¦ì¼Æ¦¨ªø¡A¤£ª¾¬O§_»P¯f¤H¨Ï¥Î°w¾¯¼Æ¶q¦³Ãö¡A¥H2022¦~1¤ë¥÷°_³°Äò¨Ï¥Î¤§¯f±w¦Ó¨¥¡A­Y©ó2023¦~°_¦³±æ³°Äò¹F¦¨§¹¥þ¦å²G¾Ç¤ÏÀ³¡AµL¶·¨C2¶g¬I¥´1°w¡A¶È¨C¤ë¬I¥´¤@°w¡A©¡®É¶O¥Î¤£ª¾¸Ó¦p¦ó­p»ù¡C­Y¥H°w¾¯­p»ù¡AÀ禬¶Õ¥²·|¨ü¼vÅT¡A¤£¹L¡A­Ó¤H¥H¬°§Y¨Ï¦p¦¹¡A¥ç¬O¤@¸ôªø¦h¡A¥H¬ü°ê¨C¦~·s¶i¯f±w6¤d¦h¤H¡A¥[¤W­ì¦³¯f±w¡AÂå¾Ç¶i¨B±wªÌ¹Ø©R©µªø¡A¥u­n¨Ï¥Î¯f±wªvÀø®ÄªG¦n¡A°Æ§@¥Î§C¡A¥Í¬¡½è¶q¦n¡A¤@¥¹¦bÂå®v¤Î¯f±w¶¡«Ø¥ß¨}¦n¤f¸O¡A¬y¶Ç¶}¨Ó¡A¥²©w·|¥[³t¤£½×¬O°ª§C­·ÀI±wªÌªºº¯³z²v¡C¥Ø«e¡A­Ó¤H±q¬ÛÃöMPNªÀ¸sÆ[¹î¡A¬Û«H¤½¥q©Ò¨¥¯f¤H¼Æ¨C©u³£¦³Âù¦ì¼Æ¦¨ªø¡AÀ³·|¹F¼Ð¡C¥B¥HJakafi¨C¦~¹F20¸U¬ü¤¸©ÎPegasys¨C¦~¹F6¸U¬ü¤¸¡A¬Û«H¤£½×±qBesremiªº»ù®æ¡B®ÄªG¦n¡A°Æ§@¥Î§Cµ¥¦Ó¨¥¡A¨ãÄvª§¤O¡A§ó¦³§U©ó¥[³t¯f¤Hº¯³z²v¡C¬Û«H¡A¥u­n¯f¤H¼Æ«ùÄò¤£Â_¼W¥[¡AÀ禬¥²©w·|¤£Â_¼Wªø¡C¥t¥~¡A­Y¤é¥»ÃÄÃÒ¦p´Á¶¶§Q¨ú±o¡A¤é¥»À禬¡A¥ç¥i¼ÖÆ[´Á«Ý¡C

¡·ºîÆ[­Ó¤H¹ïÃĵØÃĪº¦h¦~§ë¸ê¤ß±o¡A¥u¦³4­Ó¦r¡y¿ï¾Ü¬Û«H¡z¡A¦p¥²´Iºôªº¥ý¶i¤j¡A¦­¹w¨¥ÃĵØÃĪѻù¤W¬Ý500¤¸¡F¡³¸³¨Æªø¦³·P©óÃĵØÃĤ½¥q»ù­Èªø´Á³Q§C¦ô¡A©ó2021¦~4¤ë¥÷¦¨¥ßÃĵØÃĪѪFLine¸s²Õ¡F¨C·íªÑ»ù©ó­·«BÄÆ·n¤§»Ú¡A¸s²Õ¤º¡³¡³Á`¬O¥X¨Ó«H¤ß³Û¸Ü¡A²²¤ÄÄ©úÃĵØÃļçÂ䧻ù­Èµ¥¡A¦p¦P¬ù¸t¸gªº¥X®J¤Î°Oµ¥®Ñ¤¤©Ò°O¸üªº¼¯¦è¡A¹³¯«¤@¯ëªº¥ýª¾¹w¨¥¦¨¯u¡A­Y¦³½t±µÄ²©Î¨üÁÜ¥[¤J¸s²Õ¡A¿ï¾Ü¬Û«H¨Ã°í«ù¡AµL¶·§@¥ô¦ó¨Æ¡A¥u­n±q¦Ê¤¸¥H¤U©ê¦í¨ì²{¦b¡A§¡¯à¨É¦³Â׺ӪºªG¹ê¡C

¡·¤T¦ìªø´Á®È¬ü¥Í§Þ±M®a¡AÄ@·Nªð»OÄw¿ì¤@¶¡¥H¥þ¥@¬ÉµØ¤HÃļt¬°¨Ï©R¡A³W¹º¡y¬ãµo¡B»s³y¡BÀç¾P¡z¡A¥H¤@±øÀs¤è¦¡µ¦²¤¡A¶}±Ò¥xÆW¥Í§Þ·~«e©Ò¥¼¦³ªº¸gÀç¼Ò¦¡¡A¤T¦ìªøªÌ¯ÝÃhÃü²¤¡B®æ§½¤§¤j¡A¹ê¥O¤H·q¨Ø¡C»¡¹ê¦bªº­Ó¤H¥u¬O¤@­Ó¤p´²¤á¡A¤£¨ã¥Í§Þ±M·~¡A¤]¤£ª¾¹D¤½¥q¬O§_·|¦¨¥\¡A¥u¦³¡y¿ï¾Ü¬Û«H¡z¡A­Y¦¨¥\ÃĵØÃıNÁÚ¦V°ê»Ú¡A·B¬ü¼Ú¬ü°ê»Ú¤j¼t¡A§Y¨Ï¤£¦¨¥\¨Ì¥Ø«eªÑ»ù¡A¹ï­Ó¤H¦Ó¨¥¥çµL©Ò·l¥¢¡C

¡·³Ì«á¡A¤Þ¥Î®}§Ó¼¯¸Ö¶°¡y§Ú±N¦b¯í¯í¤H®ü¤¤¥h´M§ä¨º°ß¤@ªºÆF»î¦ñ«Q¡A±o¤§§Ú©¯¡F¤£±o§Ú©R¡z¡C´«¨¥¤§¡A§Ú±N¦bªÑ®ü¤¤©ê¨c¦³¾÷·|¦¨¬°¥Í§Þ¤d¤¸ªÑ¡A¡y±o¤§§Ú©¯¡A¨£ÃÒ¾ú¥v¡F¤£±o§Ú©R¡A¦p¦¹¦Ó¤w¡z¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ß´Hªº¤Ñ¤~10150249  µoªí®É¶¡:2023/2/5 ¤U¤È 12:27:04²Ä 10040 ½g¦^À³
¤@¾ã¦~¹L¥h¤F¡A¬ü°êÀ禬¯uªº¨S¦³¦p§Ú·Q¹³¤¤ªº¦¨ªø,¥H³oºØÀ禬­n¼µ¦í¥Ø«e§Úı±oªÑ»ù¤£®e©ö¡A¼µ¦í¤j·§´N¬O¤@¨Ç¥¼µoªº¨Æ¥ó

AOP->¥¼ª¾

¦a°Ï±ÂÅv->µ¥

ET¸Ñª¼ÆÜÃÄÃÒÆܽæ -> ³oÁÙ¤[

¤é¥»ÃÄÃÒÆܮֻùÆܽæ -> ·|¤£·|¹F¨ìÅãµÛÀ禬¡A­n¦h¤[

¨ä¥¦

2022»¡¦pªGAOPÁÙ¿ú·|Á«Âà¬Õ ¤W¬Ý80EÀ禬(¨S°O¿ùªº¸Ü)->¨S¹F¦¨

¥¼¨Ó·s¼t¹w¦ôªº¤T¦Ê¦h»õÀ禬¡A¥H¥Ø«eºØºØª¬ªp¥ý¥´­Ó¤T§é?§C¨ì­úªºÀç¯q²v´N¤£»¡¤F¡C

«ù¦³ÃĵØÁÚ¤J²Ä¤C¦~¡AÁöµMµLªk¹³¤@¨Ç¯«¤H­è¦n2021¦~¶R¤J«á¦~©³¼Qµo¡A¥Ø«eÀò§Q¤]ÁÙ¥i¥H¡A

¦ý¤]¬Oµ¥¤F¦n¤[¤~µ¥¨ìªº¡C

¦³¨Ç¦a¤è¤]¤£¯àÁ¿Ãĵتº¤£¬O¡A³oÃ䤣¾å±o¯à¤£¯à¬Ý¨ì¤@¨Ç§ó«ÈÆ[¤¤¥ßªºµû½×©Î°Q½×¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2023/1/5 ¤W¤È 11:03:22²Ä 10039 ½g¦^À³
¡m¥ÍÂåªÑ¡nÃĵØÃijø³ß ¥Ó½Ð³°ÃÄÃÒ¡BºË·Ç40¸U¦WPV±wªÌ

®É³ø·s»D 2023/01/04 16:20

¡i®É³ø°OªÌ¤ý¶hªä¥x¥_³ø¾É¡jÃĵØÃÄ(6446)¤é«eµo¥¬­«¤j°T®§ªí¥Ü¡A¤w©ó2022¦~12¤ë30¤é¦V¤¤°ê°ê®aÃÄ«~ºÊ·þºÞ²z§½(NMPA)¥Ó½ÐRopeginterferon alfa-2b(²ºÙRopeg¡B§YP1101)¤W¥«³\¥iÃÒ¡A¾AÀ³¯g¬°¯u©Ê¬õ¦å²y¼W¦h¯g(PV)¡AºË·Ç¤j³°¬ù40¸U¦WPV±wªÌ¡C

Ropeg¬°ÃĵØÃĦۦæ¬ãµo¥Í²£ªº³Ð·sªø®Ä«¬¤zÂZ¯À¡A 2019¦~Àò¼Ú·ù®Ö­ã¨Ï¥Î©ó¦¨¤HPV±wªÌ¡A2020¦~«hÀò¥xÆW¡B·ç¤hÃÄÃÒ¡A§ó©ó2021¦~ÀòÁú°ê¤Î¬ü°êFDA®Ö­ã¤W¥«¡C¤é¥»©x¤è¤W¤ë¤w§¹¦¨¬d¼t¡AÃĵØÃĤ饻¹Î¶¤¹ï©ó¤µ¦~¤W¥b¦~¨úÃÒ°ª«×¼ÖÆ[¡AÀR«Ý³qª¾µ²ªG¡C

¦^ÅURopegÀò¼Ú¬ü®Ö­ãÃÄÃÒ¾úµ{¡A¬ü°êFDA¬°¼f¬dRopegªºÃÄÃҥӽЩó·s«aªÍª¢´Á¶¡¯S¦a¨Ó¥x¹ê¦a¬d¼t¡AÃĵØÃĤ@¦¸³q¹L¡F¬ü°êFDA®Ö­ãRopeg¥Î©óPV¬O°ò©óªø´ÁªºÁ{§É¬ã¨s¼Æ¾Ú¡C¼Æ¾ÚÅã¥Ü¸g¹L7.5¦~ªºRopegªvÀø«á¡A¶W¹L6¦¨ªº±wªÌ¥X²{§¹¥þ¦å²G¤ÏÀ³¡A§ó¦³°ª¹F8¦¨±wªÌ¹F¨ì¦å²G¤ÏÀ³¡C§ó¥O¤HÅå©_ªº¬O¬ü°ê¹Î¶¤¦¨¥\¨Ï±oRopeg¨jÀòFDA®Ö­ã¤T­Ó¤ë¤º¡A´NÀò¬ü°ê°ê®aºî¦XÀù¯gºôµ¸(National Comprehensive Cancer Network,NCCN)¦C¬°±ÀÂË°ª­·ÀI¤Î§C­·ÀI¦¨¤HPV±wªÌ¬Ò¥i¨Ï¥ÎªºªvÀø¿ï¶µ¡AµL½×¬O§_±µ¨ü¹L¨ä¥LªvÀø¡C

Ropeg©ó2021¦~¦b¤j³°¶}©lPV²Ä¤G´Á³Ð·s»Î±µ©ÊÁ{§É¸ÕÅç®É¡A¤½¥q¹Î¶¤»¡ªA¤¤°êÃĺʧ½¡A¥H FDA ¦P·N¤§§Ö³t»¼¼W¾¯¶q­p¹º¶i¦æ»Î±µ©Ê¸ÕÅç¡A¥O¤HªY¼¢ªº¬OÀò±o®Ö­ã¡I¦p¤µÁ{§É¼Æ¾ÚÅã¥Ü¦b²Ä24¶g(¥b¦~)ªº§¹¥þ¦å²G¾Ç(CHR)²v¹F¨ì51.8%¡A¼Æ­È¤W¤w»·°ª©óPROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅç¬ã¨s²Ä52¶g(¥þ¦~)ªº43.1%¡C³oµ²ªG¨j©ó¥h¦~©³ASH¥¿¦¡µoªí¡A¤Þ°_¼sªxÃöª`¤Î°Q½×¡C

ÃĵØÃÄ°õ¦æªøªL°êÄÁªí¥Ü¡A¥¼¨Ó­Y¯à¶¶§Q¶V§Ö±N¥Ø¼Ð¾¯¶q¥Î©ó§C­·ÀI±wªÌ¡A¥i±æ¬°§ó¼s¤jªº§C­·ÀI¯f±w±a¨Ó¥¿­±§U¯q¡A¥Ø«e¤wµÛ¤â¶i¦æ¬ü°êÁ{§É¬ã¨s¡A«ùÄò±À°ÊRopeg¦b¬ü°ê¤Î¥þ²yªº¾P°â¡C

®Ú¾Ú¥«³õ¬ã¨s¡A¤j³°¬ù¦³40¸U¦WPV±wªÌ¡C¦]Ropeg¤wÀò¼Ú·ù¡B¥xÆW¡B·ç¤h¡B¥H¦â¦C¡BÁú°ê¤Î¬ü°ê®Ö­ã¥Î©óPV¨Ã¤W¥«¾P°â¡A°jÅT¼ö¯P¡A§ó¹w­p©ó¤µ¦~¤W¥b¦~¦AÀò¤é¥»ÃÄÃÒ¡A¦¹¦¸¥H¤¤°êPVÁ{§É¸ÕÅç«G²´¼Æ¾Ú¥Ó½Ð¤¤°êPVÃÄÃÒ¡Aªk¤H¬Ý¦nRopeg·m§ð¥þ²yPV¥«³õ¼ç¤O¡A¥¼¨Ó¦¨ªø¥i´Á¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ß´Hªº¤Ñ¤~10150249  µoªí®É¶¡:2022/8/17 ¤U¤È 01:47:03²Ä 10038 ½g¦^À³
½Ð°Ý¦³¤H¬Ý¹L¤K¤ëªº¤½¶}»¡©ú®Ñ¶Ü~

¸ÌÀY´£¨ì 115¦~·s¼t¹w¦ôªºÀ禬¬O390.85»õ¡AÀç·~¤ò§Q¬O345»õ¡A¦ýÀç¯q²v«o¥u¦³16.17% (Àç·~§Q¯q¥u³Ñ¤U63.2»õ)

¦³¨â¦Ê¦h»õ­n¥Î¨Ó¶}µo·sÃÄ????

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/8/4 ¤U¤È 08:28:04²Ä 10037 ½g¦^À³
ÃĵØÃĦ¨ªøÁͶյL±e¸mºÃªº¡A¤T¤jªk¤H¤]«ùÄò±j¤O¥[½X¡A§PÂ_§ë¸ê:

ÃĵØÃÄ®³¨ìFDAÃÄÃÒ«á¡AÀ禬ÁÚ¤J¦¨ªø´Á¡AÀ禬¥¼¹F°ª®p´Á«e¡AªÑ»ùÁÙ¬O·|«ùÄò³Ð·s°ª

MSCI©u«×½Õ¾ã±N©¡ ªk¤H¦ô³o¨âÀɦ³¾÷·|¦C¤J

money.udn.com/money/story/5607/6512233?from=edn_search_result

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/7/16 ¤U¤È 12:01:04²Ä 10036 ½g¦^À³
¡·¤@ÁûÃÄ«÷16¦~¡A¤W¥««áÁÙ­n¯à³Ð³y°ª¦~¼W²vªº¹ê»ÚÀ禬¡AÃĵØÂåÃÄ­I«áªº¡u·sÃĬãµoµ¦²¤¤Î°ê»Ú¤Æ§G§½¡v­È±o¤j®a±´°Q¡I​

ÃĵØÂåÃÄ¡u±q·sÃÄ¿ïÃD¨ì¨úÃÒ¡B¦Û¦æ¶}µo¥«³õ¡vªº¥þ²y§G§½µ¦²¤¡A³°Äò¦b¼Ú¡B¬ü¡B¥x¡BÁúµ¥¦U°ê¨ú±oÃÄÃÒ¡Aªñ´Á§ó¿n·¥§G§½¤¤¡B¤é¡B©Ô¤B¬ü¬wµ¥¦a°Ï🌎​

👉ÃĵØÂåÃĪº¦¨¥\¯à§_³Q½Æ»s¡H​

³o¤@¦¸«D±`Ãø±oÁܽШìÃĵØÂåÃĪº¾G¥ü³Ó³Bªø¡A¥H¨ä¦h¦~ªº¡u·sÃĬãµo¤ÎGMP»s³y¡v¸gÅç¡A¬°¤j®a¸ÑªR·sÃÄ°ê»Ú¤Æ§G§½µ¦²¤¤Î¹ê°È¤À¨É¡G​

🔰·sÃĶ}µoµ¦²¤ | ·sÃĶ}µo¿ïÃD»P¾úµ{¤À¨É​

🔰°ê»Ú¤Æ§G§½µ¦²¤ | ÃÄÃҥӽоúµ{¤À¨É​

🔰±q¹êÅç«Ç¦ÜGMP¥Í²£»s³y | §ÞÂà§@·~»P»sµ{½T®Ä¡B©x¤è¬d¼t·Ç³Æ​

µL½×ÃĵØÂåÃijoÁû·sÃÄ«e´º¦p¦ó¡A¦ý¦b¥xÆW¥Í§Þ²£·~µo®i¾úµ{¦Ó¨¥¡A¦Ü¤Ö¬O¡u±q·sÃÄ¡y¿ïÃD¡z¨ì¨úÃÒ¡B¦Û¦æ¶}µo¥«³õ¡vªº§¹¾ã¥Ü½d¡A´Á±æ¦b½Òµ{µ²§ô«á¯à±aµ¹¤j®a¡u¤£¦Pªº«ä¸ôµ¦²¤¡v¡C​

½Òµ{¤é´Á¡G111¦~8¤ë6¤é(¤»)​

¦aÂI¡G¥úÆQ·|ij¤¤¤ß (¥x¥_¥«ªQ¤s°Ï´_¿³¥_¸ô369¸¹7¼Ó)¡C

www.facebook.com/1178112145546532/posts/6099695020054862/?sfnsn=mo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/7/15 ¤U¤È 05:42:39²Ä 10035 ½g¦^À³
¡·¡·Besremi Medicare ³B¤èÃÄ©Ó«O½d³ò

Medicare ³B¤èÃÄ­p¹º¬O§_²[»\ Besremi¡H

¬Oªº¡C95% ªº Medicare ³B¤èÃÄ­p¹º©Ó«O³oºØÃĪ«¡C

¡·¡·¦pªG§Úªº Medicare ³B¤èÃÄ­p¹º©Ó«O Besremi¡A§Ú±N¤ä¥I¦h¤Ö¡H

¤@¡B¦b§K½ßÃB¶¥¬q¡A±z¥i¯à»Ý­n©Ó¾áÃĪ«ªº¥þ³¡¶O¥Î¡C

¦@¥IÃB½d³ò¡G$7383 ¡V $16072

¤G¡B¦b±zªº¦Û¥IÃB±o¨ìº¡¨¬«á¡A±z±N¶i¤J¦Û¥IÃB«á¡]¤]ºÙ¬°ªì©l©Ó«O¡^¶¥¬q¡A¦b¦¹±z¤ä¥I¦@¥IÃB¡A±zªº­p¹º±N¤ä¥I¨ä¾lªºÃĪ«¶O¥Î¡C

¦@¥IÃB½d³ò¡G1846 ¬ü¤¸ ¡V 16072 ¬ü¤¸¡C

¤T¡B¦b¡§²¢²¢°é¬}¡¨¡]¤]ºÙ¬°¡§©Ó«O¯Ê¤f¡¨¡^¶¥¬q¡AMedicare ¬°±zªºÃĪ«©Ó«Oªº½d³ò¦³¤@­ÓÁ{®É­­¨î¡C¦]¦¹¡A±z¥i¯à·|¬°±zªºÃĪ«¤ä¥I§ó¦h¶O¥Î¡C

¦@¥IÃB½d³ò¡G$3197 ¡V $16072

¥|¡B¦b²¢²¢°é«áªÅ¬}¡]¤]ºÙ¬°¨aÃø©Ê©Ó«O¡^¶¥¬q¡AMedicare À³©Ó«O±zªº¤j³¡¤ÀÃĪ«¶O¥Î¡C

¦@¥IÃB½d³ò¡G7 ¬ü¤¸ ¡V 16072 ¬ü¤¸

www.goodrx.com/besremi/medicare-coverage

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/7/15 ¤W¤È 10:49:02²Ä 10034 ½g¦^À³
¤½¥q»Ý­n¸êª÷¡A¬O¬°¤Fªø»·ªº¬ü¦nÄ@´º

»Ý­nÄw±¹¤jµ§¸êª÷ÂX«Ø¼t©Ð

±Ä¥ÎªÑªF²{ª÷¼W¸ê¤è®×¥¿­±¬Ý«Ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/7/15 ¤W¤È 10:00:24²Ä 10033 ½g¦^À³
Ãĵظ­¬Q±ß¤½§i¿ì²z¤½¶Ò¡A¦]À³¸êª÷»Ý¨D«Ø¸m¼t©Ð¤ÎÂX¤j²£¯à¡AªÑ»ù¤µ¤é¤ÏÀ³µuªÅ¡H¤U¶^¡A¥»¤H¬Ýªk¸ÑŪ:

¤½¥q­Y¥¼¬Ý¨ì«e´º»Ý¨D·|«Ø¸m¦Û¤v¼t©Ð¤ÎÂX¤j²£¯à¡H§ë¸ê¤H§O¤Óºò±i¤ÏÀ³¡AµuªÅªø¦h¤Ï¤§¶^²`¾÷·|¨Ó¤F..........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJames Liu10149154  µoªí®É¶¡:2022/6/30 ¤W¤È 11:27:00²Ä 10032 ½g¦^À³
¥ý¶i¤j¥i¥H¦Ò¼{¦A§ï¼ÐÃDÅo~~
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/6/29 ¤U¤È 01:36:46²Ä 10031 ½g¦^À³
¥i³ß¥i¶P500¤¸´ú¸Õ¤@¶g«á¡A¤µ¤é¦¬½L542¤¸¤w³Ð¾ú¥v·s°ª¤F¡A©¹4¦ì¼ÆÁÚ¶i~¥[ªo
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnco10136449  µoªí®É¶¡:2022/6/29 ¤W¤È 11:54:07²Ä 10030 ½g¦^À³
ÁÂÁÂ¥ý¶i¤j¦h¦~¨Óªº¹ªÀy»P¸ê°T¤À¨É¡IÅý§Ú¥i¥H°í«ù¤U¥h¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/6/29 ¤W¤È 11:09:07²Ä 10029 ½g¦^À³
²{¦b¤T¤jªk¤H¨C¤Ñ·m¶R¡A±j¶ÕµLªk¾×.......©ê¨c¬ÝÀ¸¡AÃĵØÃÄPV±wªÌ¨Ï¥Î¤H¼Æ¶V¨Ó¶V¦h¬OµLªk§ïÅܪº

ªÑ»ù©¹¤W§ð°í´Á«Ý¦­¤é½Ä4¦ì¼Æ~¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G0  µoªí®É¶¡:2022/6/28 ¤W¤È 08:44:42²Ä 10028 ½g¦^À³
©I¥sAnderson¤j¡A¬Æ©À¡I¸g¹L±z¨º¨Ç¦~...ªººÊ·þ»P¼®¤O«ü±Ð¡AÅýÃĵتGµM¥X²³¤@ÅD¼È©~·sÃļ­º
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G»«¹£­ô10144807  µoªí®É¶¡:2022/6/27 ¤U¤È 05:05:23²Ä 10027 ½g¦^À³
¥ý¶i¤j

§Ú¬O¹j¾Àª©¬P¬Pªº»«¹£👋

¥ý¸ò°í«ù¨ì©³ªºÃĵؤͻ¡Án®¥³ß

°í«ù7¦~¯uªº¤£Â²³æ👍

»¡500¤µ¤Ñ¯uªº¨ì500👍

­n¸ò¤ß²z¯À½è±j¤jªºµØÃĤ;Dzß

³o´X¦~§Ú¤]¦³¦bÆ[¹îÃĵت©

¤]¬OªÑ»ù¤£¦n®É ¸¨¤«¤U¥Ûªº¤@°ï

­n°í«ù¤U¥h¯uªº«Ü¤£®e©ö

¤@°_¥[ªo ¥xÆW¥Í§Þ¤@°_¦@¦n

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2022/6/27 ¤U¤È 04:53:09²Ä 10026 ½g¦^À³
¤p¥¿¥¿¡A§A¤Ó±j¤F¡AÃĵتº¤H¥i¯à¤]¨S§A¨º»ò²M·¡.

¤]®¥³ß§AAll In ,°]´I¦Û¥Ñ.

³o°£¤F§V¤O¡A¤]­n¦³«i®ð. ¯S§O¬OAll In

·PÁ§Aªº¤À¨É.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/6/27 ¤U¤È 04:13:09²Ä 10025 ½g¦^À³
(­Y¦³¿ù»~¡A½Ð¥H¤½¥q¥¿¦¡¤½§i¬°·Ç)

³ü¡BÃĵØÃÄ2022¤U¥b¦~¦æ¨Æ¾ä¡G

¤@¡B2022¦~7¤ë¥÷¡G

(¤@)7¤ë25¤é¡G

Àò³qª¾P1101°·«Oµ¹¥I(6¤ë16¤éijµ{°Q½×­YÀò³q¹L)¡B9¤ë1¤é¥¿¦¡¯Ç¤J°·«Oµ¹¥I¡C(°Ñ¦ÒÃh¯S¦åÄ_°·«O®×¡G109¦~12¤ë17¤éijµ{°Q½×¡F110¦~1¤ë25¤é³qª¾µ¹¥I¡F3¤ë1¤é°·«O¥¿¦¡µ¹¥I)¡C

(¤G)7¤ë28¤é¦Ü31¤é¡G

°Ñ®i¨È¬w¥Í§Þ¤j®i¡CÅu¦ì¸¹½X¡GR207¡C¥x¥_«n´ä®iÄýÀ]¡C

(¤T)¤é¥ú©Ê¨¤¤Æ¯g¡]AK¡^¥xÆWÃÄÃÒ¡G

110¦~11¤ë22¤é¥Ó½Ð¡AÃÄ«~¤W¥«³\¥iÃÒ¼f¬d®É¶¡¥Ñ¤@¯ëªº360¤ÑÁYµu¬°180¤Ñ¡C

(¥|)Âd¶R´IÂd200«ü¼Æªº¦¨¤ÀªÑ¡G

110¦~9¤ë7¤é³Q§R°£¡AÂd¶R´IÂd200«ü¼Æªº¦¨¤ÀªÑ­q©ó¨C¦~¤@¤ë¡B¥|¤ë¡B¤C¤ë©M¤Q¤ë¼f®Ö¡C

¤G¡B2022¦~8¤ë¥÷¡G

(¤@)¬ü°ê¼¯®Ú¥v¤¦§Q(MSCI)¥þ²y¤¤¤p«¬«ü¼Æ¡G

2016¦~11¤ë³Q¯Ç¤J¡A±©¬dµL³Q§R°£½T¤Á¤é´Á¡HMSCI¦¨¤ÀªÑ©ó¨C¦~2¤ë¡B5¤ë¡B8¤ë¡B11¤ë½Õ¾ã¡C

(¤G)¥xÆW«ü¼Æ¤½¥q¥xÆW¤W¥«¤WÂd¥Í§ÞÂåÀøªÑ»ù«ü¼Æ¦¨¥÷ªÑ¡G

110¦~10¤ë1¤é³Q§R°£¡C¨C¦~2¤ë¡B5¤ë¡B8¤ë¡B11¤ë©w´Á¼f®Ö¡C

¤T¡B2022¦~9¤ë¥÷¡G

­^°ê´I®É¥þ²y«ü¼Æ(FTSE)¡G

2017¦~3¤ë¯Ç¤J¡A±©¬dµL³Q§R°£½T¤Á¤é´Á¡H(FTSE)¦¨ªÑ¥÷©ó¨C¦~3¤ë¡B6¤ë¡B9¤ë¡B12¤ë½Õ¾ã¡C

¥|¡B2022¦~12¤ë¥÷¡G

(¤@)12¤ë10¤é¦Ü13¤é 2022 ASH¬ü°ê¦å²G¦~·|¡G

1.Tiziano Barbui±Ð±Â¥i¯àµoªí PV Low-PV (NCT03003325)(¶}©l¡G2017¦~2¤ë2¤é¡F§¹¦¨¡G2022¦~6¤ë)¤G¦~Á{§Éµ²ªG½×¤å¡C

2.¤¶²ÐP1101 ET¤T´ÁÁ{§É±¡§Î¡C

(¤G) P1101 ET¤T´ÁÁ{§É¡A¯f±w160¤H¦¬®×§¹¦¨¡C

¤­¡B¨ä¥L¡G

(¤@)ÃĵØÃÄ¿DªùPVÃÄÃÒ¡G

2¤ë14¤é¦V¿DªùÃĪ«ºÊ·þºÞ²z§½¥Ó½Ð¶i¤fÃÄ«~¹w¥ý³\¥i¡A¦ô­p1­Ó¤ë§¹¦¨¼f¬d¡C

(¤G)·s«aªÍª¢¤T´ÁÁ{§Éµ²ªG¡G

4¤ë21¤é¤½§i·s«aªÍª¢¤T´ÁÁ{§É¸ÕÅç¡A¥Ø¼Ð¦¬®×94¤H¡A¤@¥¹¶¶§Q¸Ñª¼¡A±Nª§¨ú½ÃºÖ³¡³q¹Lºò«æ±ÂÅv³\¥iEUA¡C

(¤T)AOP¤À¼í®×¤J±b¡G

5¤ë16¤éªk»¡·|¡AªL°õ¦æªøªí¥Ü¡A­YAOP¤À¼í®×¤J±b¡A2022¦~¥i±æÂà¬Õ¡C

(¥|)ÃĵØÃıÂÅv°ê»ÚÃļt©Ô¤B¬ü¬w®×¡G

5¤ë29¤é­«°T«Å¥¬¸³¨Æ·|³q¹L»P¬Y°ê»ÚÃļt¨ó°Ó¡AÂù¤è­Y¶¶§Q¹F¦¨¨óij¡A±N§â¨u¨£¦åÀù·sÃÄRopeginterferon alfa-2bªº©Ô¤B¬ü¬w¸g¾PÅv±ÂÅv¸ÓÃļt¡AÅý°ê»Ú¥¬§½§ó§¹¾ã¡C

(¤­)P1101Áú°ê°·«Oµ¹¥I®×¡G

2021¦~10¤ë13¤éÀò±oÁú°êPVÃÄÃÒ¡AÃĵØÃÄÁú°ê¹Î¶¤¦V°ê®a°·±d«OÀI§½¥Ó½Ð±NBesremi¯Ç¤J°·«Oµ¹¥I¡C

¶L¡B2023¦~¦æ¨Æ¾ä¡G

¤@¡B2023¦~4¤ë¥÷¡G¨ú±o¤é¥»PVÃÄÃÒ¡C

111¦~4¤ë28¤é¥Ó½Ð¤é¥»ÃÄÃÒ¡A¹w­p¼f¬d®É¶¡¬ù¤@¦~

¤G¡B¥Ó½Ð¤¤°êPVÃÄÃÒ¡C

°Ñ¡B¸É¥R¨ä¥L¡G

¡·¬ü°êÂåÀø«OÀIÂл\±¡§Î¡G

5¤ë16¤éªk»¡·|¡AªL°õ¦æªø¤w»¡©ú¡A¹w©w½Í§´ªº«OÀIÂл\²v¤w¹F¼Ð(«D«ü¥þ¬ü«OÀI¤½¥q®a¼Æ¦Ê¤À¤§80%)¡A·|³°Äò½Í§´¨ä¥L«OÀI¡C¦h¤@®a«OÀI¡A«h¦h¤@¥÷À禬¡C6¤ë¥÷«OÀI¡G first carolina care¡FAdvantage U for University of Utah Retirees (PPO)¡C7¤ë¥÷«OÀI¡GAllways health partners¡C

¡·P1101 PVÄvª§ÃĪ«¡G

PTGX¤½¥qPVÃĪ«Rusfertide¤G´ÁÁ{§É¼Æ¾Ú¦ü¥G¤£¿ù¡A±©¤w³QFDAºM¾P¬ð¯}©ÊÀøªk¡A¥B®£¦³­PÀùºÃ¼{¡C

¡·P1101 ETÄvª§ÃĪ«¡G

bomedemstat¤G´ÁÁ{§É¼Æ¾Ú¦ü¥G¤£¿ù¡A«ùÄò°lÂÜÁ{§É¶i«×»Pµ²ªG¡C

¡·P1101ªvÀø¦­´Á°©ÅèÅÖºû¤ÆÁ{§É¡G

©ó2021¦~8¤ë1¤é¶}©l¡A¥Ñ­»´ä¤j¾Ç°õ¦æ¡A¥l¶Ò50¤H¡A©ó2025¦~7¤ë31¤é§¹¦¨¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/6/27 ¤W¤È 10:37:47²Ä 10024 ½g¦^À³
ÃĵØÃĨ«¹L¦h¦~¨Óªº­·­·«B«Bªº¤é¤l¡A§Ú­Ìªº¥Ø¼ÐFDAÃÄÃÒ¤w¸g¨ì¤â¡A¹ê²{°]´I¦Û¥Ñªº²Ä¤@¨B¡A©ú¦~¤é¥»/¤j³°³£¦³¾÷·|³°Äò®³¨ìÃÄÃÒ

·PÁÂÃĵØÃħë¸ê¤Hºô¤Íªº¤ä«ù¡A®É¶¡ªø¹F7¦~¦h¤@¸ô¨«¨ÓÁ}¨¯¡A¤@¤Á³£¬O­È±oªº¡AÃĵØÃĦb¬ü°ê¥«³õ¡A±wªÌ¦³15¸U¤H¤f¡A«OÀIÂл\²v¦³80%¡Aµ¥©ó¦³12¸U¤H¤f¦³«OÀI¡A

¤@­Ó¤HªvÀøªº¶O¥Î¬ONT500¸U¤¸¡A­Y¹F¨ì1¸U¤H¨Ï¥ÎÃĵØÃĦ~¦¬¤J´N¦³500»õ

¤W¦¸¦b·s»D´CÅ馳¤@¦ì¦W¼L¦ô­p¡A¹F¨ì1¸U¤H¨Ï¥ÎÃĵØÃÄ1¦~ªºEPS¥i¹F110¤¸¡A§Ú­Ì«O¦u¥´§é¦ô­p75¤¸¡A¨º»ò´N«Ü¦³·Q¹³ªÅ¶¡¡AÃĵØÃĬü°ê¤l¤½¥q½Õ¬dªì¦ô¡A¬ü°ê·|¹F¨ì8¸U¤H¨Ï¥ÎPV

¸Õ°Ý¤@¤U¤K¸U¤H¨Ï¥Î¡AÃĵØÃĪºEPS·|¹F¨ì¦h¤Ö¡H

ÁÚ¦V500¤¸¥u¬O²Ä¤@¨B¡AÃĵØÃĪº¯»µ·­Ì¦bªø´Á«ù¦³°í«ù3~5¦~¡A500¤¸¥i¯àÁÙ·|¦b½´X­¿

¦³«H¤ßªº¦AÄ~Äò°í«ù¡A¥Ø«e½Õ°ª»ù¬°4¦ì¼Æ¥H¤W¡AÅý§Ú­Ì¦AÄ~Äò¬Ý¤U¥h.........

¦b¦¹³Â·Ð¥²´Iºôª©¥D¬O§_¥i¥H±NÃĵØÃĪº¼ÐÃD§ï¦^¨Ó¡uªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W¡v

¦A¦¸·PÁÂ¥²´Iºôª©¥D~ÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/6/27 ¤W¤È 09:00:36²Ä 10023 ½g¦^À³
²×©ó¡A¨ì¤F500¤¸¡CÂÔ¦V¥ý¶i¤j­P·N»P·PÁ¡C

¥»ª©­ì¼ÐÃD(ÃĵØÃÄ«e´º¡Bªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W)¡A±q2014¦~7¤ë22¤é¶}©l¥Ñ¥ý¶i¤j¶}ÅPª©­¶¶K¤åµo¨¥¡A¸g¾ú7¦~º©ªøµ¥«Ý¡A¥Ø¼Ð»ù²×©ó¹ê²{¡A¾ú¸g·Î¼õ¡A¹Lµ{§¢©VÁ}¨¯¡A­·­·«B«B¡A²×¦u±o¶³¶}¨£¤ë©ú¡C

¦^·Q¤§«e¡A­Ó¤H¥ç¨ü¼ÐÃD¡uªø´Á«ù¦³¡B¥Ø¼Ð»ù500¤¸¡v§l¤Þ¡A±q2015¦~12¤ë24¤é¶}©l¡A¥H¨H°g©óªÑ®ü¤p´²¤á¤ßºA²Ä1¦¸¶K¤å´£°Ýµo¨¥(²Ä223½g)¡C¦P®É¡A´Á¶¡¥ç¦sºÃ°Ý¥ý¶i¤j¤@­Ó°ÝÃD¡A¥ý¶i¤j¦^µª¦p¤U¡G

¡°¡°

¡·¡··|­û¡G¤p¥¿¥¿10141351 ¡B µoªí®É¶¡:2016/7/5 ¡B(²Ä362½g)

¥ý¶i¤j¡G¥i§_«_¨ý½Ð±Ð§A¡A§A©Ò»¡ªº{µ¥«ÝÃÄÃÒ¨ì¤âªÑ»ù¥ý¬Ý300¤¸¡Aµ¥«ÝÃľ¯¥Í²£ªÑ»ù¦ô­p¥i¤W¬Ý500¤¸¹ê¤O}ªº¥ß½×°ò¦¡AÁÂÁ¡C

¡·¡··|­û¡G¥ý¶i10000164 ¡B µoªí®É¶¡:2016/7/5¡B(²Ä363½g)

¥»¤H¹ïÃĵتº´Á³\¡A¹ïÃĵØÃĪ«¦³²`«pªº«H¤ß¡K¡K¡K¡C

¡°¡°

¥»¤é¡AÃĵØÃIJשó¨Ó¨ì500¤¸¡A¯uªº·PÁÂ¥ý¶i¤j¡A¯à¥ýª¾¥ýı¤À¨Éºô¤Í¡A°í«ù©ê¦íötªÑ¡A¤£Â÷¤£±ó¡A¥ô¨ä®i¯Í°ª­¸¡AÁÚ¦V°]´I¦Û¥Ñ¤§¸ô¡A¯u¬O¨ØªA¡C»¡¯uªº¡A­n©ê±o¦íÃĵØÃÄ¡A½T¹ê¤£®e©ö¡A¥²©w­n¦³±j¤jªº«H¥õ¡A§_«h´Á¶¡ªi§é¤£Â_¡A¶Õ¥²Ãø­@¾_Àú³Q­¢½æ¥X¡C©¯¦n¡A¥h¦~¬d¼t¤§«e¡A·Q»¡¦Aµ¹ÃĵØÃĤ@¦¸¾÷·|¡A¥ç¬Oµ¹¦Û¤v¤@¦¸¾÷·|¡A·í°µµ¹¦Û¤vªº±ÏÅ«¡A³£¤w­É¿úALL IN¡AÁÈ¿ú¨ä¦¸¡A¯à¦b¦Ñ±C¡B¨à¤l­±«e¡A¬~¨ê¶RªÑ²¼³£½ß¿úªº±J©R¡A³£¤w­È±o¡C³Ì«á¡A¦A¦¸·PÁÂ¥ý¶i¤j¡A¯¬¥­¦w³ß¼Ö¡C¥ç®¥ÁH°í«ù¨ì²{¦bªºµØ¤Í¡A¨É¨üÂ׺ӪºªG¹ê¡C

¤]§Æ±æ500¤¸¬O¥t¤@­Ó¶¥¬q°_º¦ªº¶}©l¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/6/22 ¤U¤È 10:11:16²Ä 10022 ½g¦^À³
Âà¸ü

¡i¬ã¨s³ø§i¡jÃĵØÃÄ(6446)µ²½×»P«Øij

¬Ý¦n ÃĵØÃÄ(6446) ¨ü´f©óBesremi¯Ç¤J¬ü°êÁp¨¹°·«Oµ¹¥I¡AÀ禬©ó²Ä¤G©u©úÅ㦨ªø¡A¥B¥¼¨ÓÂл\²v«ùÄò´£¤É¡A¥[¤W¤½¥q¦b°©Åè¼W¥Í©Ê¸~½F(MPNs)ªº»â°ìªø´Á³W¹º¡ACMoney¹w¦ô2022¦~¨CªÑ²b­È¤W¤É¦Ü20.5¤¸¡Aµ¹¤©25­¿ªÑ»ù²b­È¤ñ¡A±©ªñ´Á¾ãÅ饫³õªi°Ê¸û¤j¡A¥B¥Í§Þ±Ú¸s¥«³õ¸êª÷¼öµ¸¡A§ë¸ê«Øij¬°³{§C¶R¶i¡A¾A¦X¤¤ªø´Áí©w§G§½¡C

¥H¥xÆW¬°°ò¦aªº¥þ²y¥þ¤è¦ì¥Í§Þ»sÃĤ½¥q

ÃĵØÂåÃĪѥ÷¦³­­¤½¥q¦¨¥ß©ó2003¦~¡A¥H¥xÆW¬°°ò¦a¡A±q¨Æ·sÃijзs¦Û¥D¬ãµo¡BÁ{§É¸ÕÅç¡BcGMP¥Í²£»s³y¡B°Ó·~¤Æ¶q²£§¡¦b¥xÆW¶i¦æ¡A2017¦~©ó¤¤°ê¡B¤é¥»¡B¬ü°ê¦¨¥ß¤l¤½¥q¡A¥H MIT ¼Ò¦¡¦æ¾P¥þ¥@¬ÉªºÀç¹B¼Ò¦¡¡C

±qÃĪ«·§©À³]­p¶}©l¡A¨Ï¥Î­ì³Ð©Êªø®Ä«¬³J¥Õ½èÃĪ«¬ãµoPEG§Þ³N¥­¥x¤Î°ªÃø«×¤p¤À¤l¦X¦¨ÃĪ«§Þ³N¬°°ò¦¡A°t¦X¸ó°ê¬ãµo¦X§@ªº¼Ò¦¡¡A¦b°ê¤º¦¨¥\§¹¦¨²Ä¤@­Ó¥Íª«·sÃÄRopeg(P1101¡A°Ó«~¦WBesremi)¡AÀ°§U¯f±w¹ï§Ü¦å²G¸~½F¡BºC©Ê¨xª¢¡A¥H¤Î¬Y¨ÇÄY­«ªºÀù¯g¡C§¹¦¨¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)Á{§É¸ÕÅç«á¡ABesremi©ó2017¦~¦V¼Ú¬wÃĪ«ºÞ²z§½EMA»¼¥æ¤W¥«³\¥i¼f¬d¡A¨Ã©ó 2019¦~2¤ëÀò±o¼Ú·ùEMA·sÃĤW¥«³\¥i (marketing authorization application, MAA)¡A¬°§Ú°ê²Ä¤@­Ó¸g¼Ú·ù®Ö­ãªº³J¥Õ½è·sÃÄ¡C

www.cmoney.tw/notes/note-detail.aspx?nid=463278

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/6/22 ¤W¤È 10:34:08²Ä 10021 ½g¦^À³
¹ïÃĵØÃĪº«á¶Õ¤£®e¤pòó¡A500¤¸¥u¬O¤§«e³]ªº¤¤´Á¥Ø¼Ð»ù¡Aªø»·¨Ó»¡~ÃĵØÃĵ´¹ï¬O¥xÆW¤§¥ú¡A·|¦¨¬°¥xªÑªÑ¤ýªº......®É¶¡·|¥hÃÒ©ú¥»¤Hªº¦ô­p......¥[ªo
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GWalden10140608  µoªí®É¶¡:2022/6/22 ¤W¤È 10:25:34²Ä 10020 ½g¦^À³

³ÙÄÛÃøªø¤[¡A²Ó¤ô¤èªø¬y

¥ý¶i¤j¨¯­W¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2022/6/21 ¤U¤È 09:28:37²Ä 10019 ½g¦^À³
ªÑ»ù¤wÁÙ¥ý¶i¤j¤@­Ó¤½¹D¡A500¥H¥¼¨Ó5¦~¨Ó説¡AÀ³¸ÓÁÙ¤Ó«O¦u.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/6/21 ¤U¤È 06:16:37²Ä 10018 ½g¦^À³
¤½¥q¥Ø«e¥H¡u¥Í§ÞªÑ¤ý¡v¤§«º±U°_·í¤¤ ¦U¶µ¡]°ê¡^ÃÄÃÒ¨ú±o¥¿¦b³W¹º¸¨¹ê

±q¥Í²£»s³y¨ì°ª»ù­È¾P°â§V¤O³Ð³yM ITªº°{«G©ÛµP

¦^­º¦­´ÁªÑ»ù¤@«×³´¤JµL¤H°Ý¬zªº¹Ò¦a ¦A¬Ý¬Ý²{¥«³õª¥¤â¥i¼öªºµ{«× À³µ¹¥ý¶i¤j¤@­Ó¦w¼¢¼ú

´Á³\ÃĵØÂ\²æ§¾«ÄªºªÈÄñ µÛ¤O©ó¦U°ê¥«³õ¶}µo ³yºÖ¯f±w ¦¨¬°°ê»Ú¤Wµo¥úµo¼öªº¥xÆW«~µP

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/6/21 ¤U¤È 03:40:02²Ä 10017 ½g¦^À³
¬Ì±¡¡B³q¿±¡B¤É®§¸êª÷ªºÁ×­·´ä­º¿ïÃĵØÃÄ¡A¶}ªO·í®Éªº¼ÐÃD¡uªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W¡v¦p¤µªÑ»ù«ü¤é¥i«Ý

´N¬Ý©ú¤Ñ¦³¾÷·|¬ð¯}¥Ø¼Ð»ù500¤¸~¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/6/9 ¤U¤È 05:15:11²Ä 10016 ½g¦^À³
¤µ¤éÃĵØÃ妰±ªk¤H/§ë«H¦P¨B¤j¶R2006±i¡AªÑ»ù¬ð¯}¾ú¥v·s°ª«ü¤é¥i«Ý.......

¤§«e¬Ý°I¤pªº¡A¤]³£¸ú°_¨Ó¤F.......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnco10136449  µoªí®É¶¡:2022/6/8 ¤W¤È 09:10:15²Ä 10015 ½g¦^À³
ÁÂÁÂ¥ý¶i¤jªº¤À¨É¡AªÑ»ù¤Wº¦«á¡A¥¼¨Ó¦pªG¿ì²z¼W¸ê¡AÄw±¹¸êª÷ªº¿ú¥i¥H«Ü¦h
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2022/6/6 ¤U¤È 07:30:22²Ä 10014 ½g¦^À³
Åý¤H¿³¾ÄªºÀ禬¼Æ¦r¡I

Æg!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/6/6 ¤U¤È 05:23:39²Ä 10013 ½g¦^À³
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ÃĵØÃÄ¡@¤½¥q´£¨Ñ

¥Á°ê111¦~05¤ë ³æ¦ì¡G·s¥x¹ô¥a¤¸

¶µ¥Ø Àç·~¦¬¤J²bÃB

¥»¤ë 347,722

¥h¦~¦P´Á 32,168

¼W´îª÷ÃB 315,554

¼W´î¦Ê¤À¤ñ 980.96

¥»¦~²Ö­p 952,800

¥h¦~²Ö­p 159,820

¼W´îª÷ÃB 792,980

¼W´î¦Ê¤À¤ñ 496.17

³Æµù / À禬Åܤƭì¦]»¡©ú ¥»¤ë¤Î¥»¦~²Ö­pÀ禬¸û¥h¦~¦¨ªø¡A¥D­n¨Ó¦Û»{¦C¼Ú¬w¥X³f¤Î¬ü°ê¤l¤½¥qPharmaEssentia USA Corp. ¤§À禬¡C

¹Ú·Q¥¿¦b°_­¸¡B²{¦b¤£¶R¡H2~3¦~«á¦^ÀY¤ñ¸û¤w¤d¤¸¨­.......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/5/5 ¤U¤È 04:01:34²Ä 10012 ½g¦^À³
ÃĵØÃÄ¥|¤ëÀ禬¬ð¯}¾ú¥v·s°ª3.5»õ¡AªÑ»ùªø´Á¥Ø¼Ð»ù500¤¸«ü¤é¥i«Ý
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/4/20 ¤W¤È 07:58:38²Ä 10011 ½g¦^À³
¤@¼Ëªº¤ë¥ú ¤@¼Ëªº·ÓµÛ·s©±·Ë

¤@¼Ëªº³g¯T ¤@¼Ëªººò«r·s¥x¹ô

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDreamtiger10145627  µoªí®É¶¡:2022/2/25 ¤W¤È 03:04:44²Ä 10010 ½g¦^À³
13000¦h±i¦b³o¥«³õ·|³y¦¨¦h¤j½æÀ£?

¯S§O¬O¹ï¹L¥hAOP¥¼¤ä¥IÅv§Qª÷¤À¼í¡A¦ýÃĵØÃĤ´¨Ì·Ó¦X¬ù«ùÄò¨Ñ³fªºª¬ºA¡AÃĵØÃĦbµô©w³Ó¶D«á±N®i¶}°l°Q¡AÂǦ¹«O»ÙªÑªFÅv¯q¡C®Ú¾ÚÃĵØÃĪº¸ê®ÆÅã¥Ü¡A¦Ü¤µ¨Ñ³fµ¹AOPªºÃĪ«¤w¹O10¸U°w¡A¦ÓAOPªº¤í´Ú¤]¹F¨ì¼Æ¤d¸U¼Ú¤¸ªº³W¼Ò¡C¬°¤FÁקKAOP«ùÄò±Ä¦æ¤£¥æ¥I¤À¼íªºª¬ªp¡A¡u¥h¦~¦~©³¡A§Ú­Ì´N»¡­n¥Î²{ª÷¥æ©ö¡A¤£µM¤£¥X³f¡C¡vªL°êÄÁ»¡¹D¡C

¤W­±³o­Ó´N¬O¤§«e§Ú»¡ªº~«ç»ò¤@ª½³£¨S¦³Àç·~ÃBÀò§Q¸òµÛ½æÃĦӤW¤Éªº·Pı??

¨S¦³¤À¼í¦n¹³¤]¤@ª½¨S¤½¥¬?

¤£µM¤À¼íÀ³¸Ó¯àÅý¤½¥qEPSÅÜ¥¿¤~¹ï,©Ò¥H·íªì§Ú¨S¦³ºÃ°Ý¨S¯dªÑ...­ü~ÁÙ¦³¦nªøªº¶D³^¸ô­n¨«

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/2/23 ¤U¤È 04:56:40²Ä 10009 ½g¦^À³
¦p¤µ¤é·s»D:

»PAOP©x¥q§P¨M¤£¶·²z½ß¡A¤½¥q«e¤w¿ì²z177¤¸¤Î235¤¸¨p¶Ò®×1¸U3¥a¦h±i¡A¤½¥q¥Ø«e¤]µL«æ­¢©Ê¸êª÷»Ý¨D

«ØijÃĵØÃÄ¥ýµÛ¤â¿ì²z¥þÃB¥æ©ö¸Ñ°£«á¡A¦A¿ì²z¾lÃB3¸U6¥a¦h±iªº¤½¶}¶Ò¸ê¡A´À¥þÅé«ù¦³ÃĵØÃĤpªÑªFµÛ·Q¡A

¨p¶Ò©T©w¤HÆ[·P¤£¨Î¡A¬°¤F¤½¥qÃĵØÃĪº¦WÅA¡A§Æ±æ¤½¥q°ª¼h¯à°µ¨ì¬Ò¤jÅw³ß

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/2/23 ¤U¤È 04:31:19²Ä 10008 ½g¦^À³
¥xÆW¤§¥ú

ÃĵØÃÄ6446

©ó2022¦~2¤ë15¤é¡A¤½¥¬¼w°ê³Ì²×µô©wµ²ªG¡A§xÂZ¤½¥q1¦~¦hªº48»õ¤¸½ßÀv¡A½T©wµL¶·¤ä¥I¡C

¥u¤£¹L¡A¶D³^µo®iªº¹Lµ{¡A¹ï¤½¥qµo®i³y¦¨¤£¤Ö¼vÅT¡A¹ï¤pªÑªFªºÅv¯q¤]±a¨Ó½ÄÀ»¡C

±q¥h¦~11¤ë¤¤¨ú±o¬ü°êÃÄÃÒ¡Aªñ´Á¤S¤ÏÂà¸ó°ê¶D³^µ²ªG¡A§K½ß48»õ¤¸½ßÀvª÷¡AÃĵØÂåÃÄ¡]²ºÙÃĵØÃÄ¡^¥i»¡¬O¶i¤J¦¨¥ß22¦~¥H¨Ó¡Aµo®i«e´º³Ì¼ÖÆ[ªº®É¨è¡CµM¦Ó¡A»P¼Ú¬w¦X§@¹Ù¦ñAOPªº¯Éª§¨Ã¥¼ÀH½ßÀvª÷²×§P§i²×¡A¦Ó¥B¦]µu´Á¤º¦h¦¸µo°Ê¨p¶Ò¤]¤Þ°_¤pªÑªFªº¤£½Ì¸Ñ¡AÃĵØÃĪº¤U¤@¨B¨Ì¸ÜÃD©Ê¤Q¨¬¡C

2¤ë15¤é¡AÃĵØÃĤ½¥¬¼w°ê¶Ç¨Óªº®ø®§¡A¼w°êÁp¨¹³Ì°ªªk°|¥H²×§½½T©wµô©w¡AÃĵØÃļڬw¦X§@¹Ù¦ñAOP¤½¥q©Ò­n¨Dªº½ßÀv»P§Q®§¡AµL¶·¤ä¥I¡C³o­Óµ²ªG¡AÅýÃĵØÃÄ°õ¦æªøªL°êÄÁª½¨¥¡G¡u¥¿¸q°¸º¸¿ð¨ì¡A¦ý¤@©w·|¨ì¡C¡v¦¹¥~¡A¬°¤F¦P¨Bªï±µ¬ü°ê¥«³õªº¦¨ªø¡AªL°êÄÁ¤]µÛ¤â·Ç³Æ·s¤@½üªº¨p¶Ò¡F­Y¦¨¯u¡A³o±N¬OÃĵØÃÄ2019¦~©³¥H¨Óªº²Ä5¦¸¨p¶Ò¡C

¥u¤£¹L¡A¦h¦¸¹ê¬I¨p¶Òªº§@ªk¡A¤wÅý¥«³õ¼öij¡A¾á¼~·l¤Î¤pªÑªFÅv¯q¡C¤×¨ä¥h¦~11¤ë¤¤¡AÃĵØÃĨú±o¬ü°êÃÄÃÒ¡AÀH§Y¦b12¤ëµo°Ê¨â¦¸¨p¶Ò¡AÅý¬Ý¦n¤½¥q«e´ºªº¤pªÑªFµL½t°Ñ»P¡C¬Æ¦Ü¥h¦~12¤ë13¤é¡A¨p¶Ò»ù®æ177¤¸¡A·í®ÉªÑ»ù¬ù¦b390¤¸¡A¤¤¶¡»ù®t¤§¤j¡A§óÅý¤pªÑªF¤£½Ì¸Ñ¡C

¨üªÈ¯É©ì²Ö ¤´¦C¥þÃB¥æ³ÎªÑ

¦Û2019¦~¥H¨Ó¡AÃĵØÃÄ4¦¸¨p¶Ò¡AÁ`­p¼W¥[3.56»õ¤¸ªºªÑ¥»¡A¬O2019¦~©³¸ê¥»ÃB21.94»õ¤¸ªº16.24¢H¡C­±¹ïªÑªFªº¾á¼~¡AªL°êÄÁ©Z¨¥­I«á¦³µÛ¤½¥q¸gÀ窺Ãø³B¡A¯S§O¬OÃø¥H¨Ï¥Î¤½¶}¶Ò¸êªº¤è¦¡Äw¸ê¡C

ªL°êÄÁ¥H2019¦~¡B2020¦~¨â¦¸¨p¶Ò»¡©ú¡A¡u¨º®É­Ô¡A¤j®a³£Ä±±o§Ú­Ì­n­Ë±¼¤F¡C¡v¥«³õ¬ÝÃaÃĵØÃĵo®iªºª^³ò¡AÅý¤½¥q·Q³z¹L¤½¶ÒÄw¸ê¤]¬O§xÃø­«­«¡C¦Ü©ó¥h¦~12¤ëªº¨â¦¸¶Ò¸ê¡AªL°êÄÁ±j½Õ¡A¬O¬°¤Fºû«ù¨ì¤µ¦~¦~¤¤ªºÀç¹B©Ò»Ý¡A¡u¦]¬°¬ü°êÀ禬¡A¤j¬ù¦~¤¤´N·|¥X¨Ó¡C¡vµM¦Ó¡A¥h¦~³Q¥´¤J¥þÃB¥æ³ÎªÑ¡AÅýÃĵØÃÄ·Q­n¨«¤½¶Ò¤è¦¡Äw¸ê¡A½w¤£ÀÙ«æ¡C

½¾\ªk±ø¡A®Ú¾Ú¡mµo¦æ¤H¶Ò¶°»Pµo¦æ¦³»ùÃÒ¨é³B²z·Ç«h¡n¡]²ºÙ¡m¶Òµo·Ç«h¡n¡^²Ä¤K±ø¡A¦]¡u¤º³¡±±¨î¨î«×¡v°õ¦æ¦³¡u­«¤j¯Ê¥¢ªÌ¡v¡Aª÷ºÞ·|¹ï¤½¶Ò¥Ó½Ð¡u±o°h¦^¨ä®×¥ó¡v¡C¥h¦~³QÃÒ¨éÂdý^¶R½æ¤¤¤ß³B¤À¥´¬°¥þÃB¥æ³ÎªÑ«á¡AÃĵØÃÄ»{¬°¹ê°È¤WÃø¥H¨ú±o¥DºÞ¾÷Ãö³\¥i¡A¬°¤F§Ö³t¨ú±o¨¬°÷¸êª÷¡A¤~§ä¤W­ì©lªÑªF«ùÄò§ë¸ê¡C

¬Fªv¤j¾Çªk«ß¨t±Ð±Â¤è¹ÅÅï«ü¥X¡A¹ï©ó¤pªÑªF¡A¨p¶Ò¼vÅT³Ì¤jªº¬O»ù®æ¡AÁÙ¦³¹ïªÑÅvªºµ}ÄÀª¬ªp¡A¡u²z½×¤W¡A¤j³¡¤À¨p¶Ò¬O¦³µ¦²¤¥Ø¼Ð¡C¡v

¹ï©óÃĵØÃÄ¥´ºâ¦A¶i¦æ¨p¶Ò¡A¤@¦ìÃÒ¨é´Á³f§½©x­ûªí¥Ü¡A¤½¶Ò¥Ó½Ð®×¨Ì·Ó¡m¶Òµo·Ç«h¡n²Ä¤K±ø¡A¤º³¡±±¨î¨î«×ªº³]­p©Î°õ¦æ¦³­«¤j¯Ê¥¢¡A±o°h¦^®×¥ó¡CÁöµM¥Ø«eÃĵØÃĬ°¥þÃB¥æ³ÎªÑ¡A¦ý¤½¥q¤w¦b¥h¦~10¤ë¦VÂd¶R¤¤¤ß´£¥X¤º±±¯Ê¥¢§ïµ½­pµe¡A§Æ±æ«ì´_¥¿±`¥æ©ö¡C¡u¦pªG¤½¥q­n¤½¶}¶Ò¶°¸êª÷¡A§Ú­Ì·|µû¦ô¥¦ªº¹ê»Ú¤º±±ª¬ªp¡A³o¬O¦³°Q½×ªºªÅ¶¡¡C¡v

¡u§Ú­Ì²{¦b¬O¥þÃB¥æ³Îª¬ºA¡A­n¥Ó½Ð¤½¶}¶Ò¸ê¡A¤]·|Åý¥DºÞ¾÷Ãö¬°Ãø¡C¡vªL°êÄÁªí¥Ü¡C¦Ü©ó¸Ñ°£¥þÃB¥æ³Îª¬ºAªº¥i¯à¡A¥L±µµÛ»¡©ú¡G¡u¤´¦b´M¨D»PÂd¶R¤¤¤ß·¾³q¡A«ì´_¤@¯ë¥æ©ö¤è¦¡¡C¡v

¹ï¦¹¡AªL°êÄÁ»¡©ú¥òµôµ²ªG¥X¨Ó«e¡A¹L¥h5­Ó¦h¤ë¤w»PÂd¶R¤¤¤ß·|½Í3¦¸¡A§Æ±æª§¨ú«ì´_¥¿±`¥æ©ö¡C¦ý¥Ñ©ó¥òµôµ²ªG¥¼¥XÄl«e¡A©|Ãø§¹¦¨«DñÃÒ·|­p®vªº²Ä¤T¤è¬d®Ö¡A¾É­P«e´X¦¸¥Ó½Ð³£¥¼¦³¨ãÅ馨ªG¡C¦ýµô©wµ²ªG¥XÄl¡AÅýªL°êÄÁ«Ü¦³«H¤ß«ì´_¥¿±`¥æ©ö¡AÃöÁä¦b©ó¤£¦ý¨S¦³±M§Q³Q©ç½æªº±¡§Î¡A¦P®É¤]½T»{µL¶·½ßÀv48»õ¤¸ªº½ßÀvª÷¡A¡u§Ú­Ì·|ºÉ§Ö·Ç³Æ¡A3¤ë·|¦A·í­±·¾³q¡A§Æ±æ4¤ëªì¥i¥H¬Ò¤jÅw³ß¡C¡v

AOPÄò¿³³^ ©õ¤é¹Ù¦ñ¤¬«r

¨ú±o¨¬°÷¸êª÷ºû«ùÀç¹B¡A¯S§O¬O¬ü°ê¥«³õªº¦æ¾P»P·~°È±À¼s¡A±N·|¬O½T¥ßÃĵØÃÄÅ@«°ªeªºÃöÁä¡C¦Ü©ó¼Ú¬w»P¤¤ªF¦a°Ïªº¾P°â¡A¥Ñ©ó±ÂÅvAOPªº¦X¬ù¤º®e¤´Äݦ³®Ä¡A®É­­¨ì2039¦~¡A¦]¦¹¡A¦p¦ó»P¾P°âÅv²[»\¹F60­Ó°ê®aªºAOPºû«ù¦X§@Ãö«Y¡A¤]¦¨¬°ÃĵØÃĤ£¥i»´©¿ªº³¡¤À¡C

¦^ÅU·í®É»PAOPªº¦X§@¡AÂù¤è¦b2009¦~¥¿¦¡Ã±­q¦X§@«´¬ù¡A¥ÑAOP¶i¦æP1101¡]°Ó«~¦WBesremi¡^·sÃĪºÁ{§É¸ÕÅç¡A¨Ãµ¹¤©¼Ú¬w»P¤¤ªF¦a°Ïªº¾P°â±ÂÅv¡C¬Ý¦ü¬ü¦nªº¦X§@¡A«o¦b¤@¶}©l´N¥X¤F°ÝÃD¡C­ì¥»¹w´ÁÀ³¸Ó¦b2014¦~´N¥i¥H§¹¦¨ªº¤T´ÁÁ{§É¸ÕÅç¡A¶i«×¤£Â_©ì©µ¡Aª½¨ì2013¦~9¤ë¤~¶}©l¶i¤J¨ì¤T´Á¶¥¬q¡C

ªL°êÄÁ±µµÛ´£¨ì¡A¬ü°êÃÄÃҥӽФ]¨ü¨ì©ì©µ¡A­ì¦]¦b©óAOP¤@¶}©l¶È´£¨ÑÁ{§É¸ÕÅçÁ`µ²³ø§i¡A¦Ó«D§¹¾ãªºÁ{§É¼Æ¾Ú¡A¬Æ¦ÜÅý¬ü°ê­¹Ãħ½¡]FDA¡^¤@«×©Úµ´ÃĵØÃĪº¥Ó½Ð¡CÂù¤èªº¥Ù¬Þ¤£Â_¼W¥[¡A2018¦~4¤ë¡AAOP¤Ï¥HÃĵØÃĬG·N©µ¿ð·sÃĬãµo¶i«×¡A¾É­PAOP¹w´ÁÀò§Q¨ü·lªº²z¥Ñ¡A¦b¼w°ê´£°_¶D³^¡A­nÅýÃĵØÃÄ¥I¥X¼vÅTÀ禬ªº½ßÀvª÷¡C

2020¦~10¤ë¡A¼w°ê³Ì°ªªk°|§P¤U¤FÅýÃĵØÃÄ·N¥~ªºµ²ªG¡A¤]´N¬O¥²¶·½ßÀvAOP48»õ¤¸¡Cª½¨ì¤µ¦~2¤ë¡A¼w°ê³Ì°ªªk°|§ï§PÃĵØÃĵL»Ýµ¹¥I½ßÀvª÷¡A²×©óÅý¤½¥q¹Î¶¤¦Y¤F¤@°O©w¤ß¤Y¡C

¤ÏÀ»¶D³^¾Ô¶}¥´ Àç¹B²KÅܼÆ

µM¦Ó¡A¨Æ±¡¦ü¥GÁÙ¨S§¹¡C®Ú¾Ú¡m¦Û¥Ñ®É³ø¡n³ø¾É¡AAOP©x¤èÁn©ú¡u±NÄ~ÄòBesremiªº¾P°â¡A¨Ã­n¨D½ßÀv¬ÛÃö·l¥¢¡C¡vAOP·|¤£·|¥t¥ß·s®×¿³³^¡H¤´µM¥Rº¡¤£½T©wªº¦]¯À¡C

¬°¤F§áÂà¤@¸ô®Á¥´ªº±¡¶Õ¡AÃĵØÃĤ]±Nµo°Ê¤ÏÀ»¾Ô¨î¿Å¡CªL°êÄÁ´£¨ì¡A·|¥H¦¹¦¸ªºµô©wµ²ªG¡A¤]´N¬OÂù¤è¦X¬ùÃö«Y¤´¦bªº°ò¦¤W¡A¡u®Ú¾Ú¦X¬ù¥h±±§iAOP¡C¡v°w¹ïAOP©ì©µªºª¬ªp¡A¶i¤@¨B­n¨D½ßÀv¡C

¨ä¤¤¡A°w¹ïAOP¨S¦³°µ¨ì¥t¥~¤T¶µ¾AÀ³¯gªº¸q°È¡A¥H¤Î¾É­P¬ü°êÃÄÃҥӽЩµ¿ðªº³¡¤À¡AÃĵØÃĤw¸g¦b2020¦~11¤ë©ó¼w°ê´£§i¡C¦¹¥~¡A°w¹ïAOP¥ý«e¥H¡uÃĵØÃıM§Q³Q¦©©ã¡v¡B¡u±M§Q³Q©ç½æ¡vµ¥¤£¹ê°T®§¹ï°ÓÅAªº¼vÅT¡A¥H¤Î¥ý«eAOP¤í´Ú¤£ÁÙªº³¡¤À¡A¥t¥~·Ç³Æªk«ß¦æ°Ê¦^À»¡C

¯S§O¬O¹ï¹L¥hAOP¥¼¤ä¥IÅv§Qª÷¤À¼í¡A¦ýÃĵØÃĤ´¨Ì·Ó¦X¬ù«ùÄò¨Ñ³fªºª¬ºA¡AÃĵØÃĦbµô©w³Ó¶D«á±N®i¶}°l°Q¡AÂǦ¹«O»ÙªÑªFÅv¯q¡C®Ú¾ÚÃĵØÃĪº¸ê®ÆÅã¥Ü¡A¦Ü¤µ¨Ñ³fµ¹AOPªºÃĪ«¤w¹O10¸U°w¡A¦ÓAOPªº¤í´Ú¤]¹F¨ì¼Æ¤d¸U¼Ú¤¸ªº³W¼Ò¡C¬°¤FÁקKAOP«ùÄò±Ä¦æ¤£¥æ¥I¤À¼íªºª¬ªp¡A¡u¥h¦~¦~©³¡A§Ú­Ì´N»¡­n¥Î²{ª÷¥æ©ö¡A¤£µM¤£¥X³f¡C¡vªL°êÄÁ»¡¹D¡C

¥Î1¦~¦hªº®É¶¡¤ÏÂà¶D³^µ²ªG¡A¦p¤µ¡AÃĵØÃÄ®³¦b¤â¤Wªº¬ü°êÃÄÃÒ¡A¥i±æ¨«±o§óí¡B§ó»·¡C¦ýÃĵØÃÄ¥¼¨Ó¦b¥ú©ú¤¤¤´¦³³±¼v¡A»PAOPªºÄñ°«¯Éª§¡B¨p¶Òªºª§Ä³¡A³£¬O¸gÀç¹Î¶¤»P¥DºÞ¾÷Ãö¥²¶·¼f·VÀ³¹ïªº½ÒÃD¡C

©_Âݽ½L¡A¤@¥u§P¨M§K½ß48»õ¡K¥[¤W¥h¦~©³Àò±o¬ü°êÃÄÃÒ¡A³oÀÉ¡u¥þÃB¥æ³ÎªÑ¤ý¡v«e´º¯uÁŵM¶}®Ô¡C

ynews.page.link/82wE

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDreamtiger10145627  µoªí®É¶¡:2022/2/23 ¤U¤È 01:13:28²Ä 10007 ½g¦^À³
µM«á¤S¶}©l©T©w½æªѶR¼W¸êªÑ~À£§CªÑ»ù¦A¬~´Xªi....

ÁÙ¨S¶}©lÁÈ¿ú~­û¤u³£¦Y¹¡¹¡¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/2/21 ¤W¤È 09:55:29²Ä 10006 ½g¦^À³
m.youtube.com/watch?v=aQp8iSvr4hU

................................

ÃĵØÃÄ­Y¤½¥q¯Ê¿ú¡A²{¦b®É¶¡¦hªº¬O¡A¬°¦ó¤£»°§Ö¿ì²z¥þÅéªÑªF¼W¸ê®×©O¡H

´N«D±o¿ì²z¨p¶Ò¹Ï§Q¨º¸s©T©w¤H¡A¦Y¬Û¤ÓÃø¬Ý¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/2/17 ¤U¤È 09:07:02²Ä 10005 ½g¦^À³
¦U¦ì¤j¤j¦³ªÅ¶¢®É¥ç¥i«e©¹ YouTube Æ[¬Ý³o³¡¼v¤ù¡G

youtu.be/NG2A_eAhuUM

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/2/17 ¤U¤È 08:52:53²Ä 10004 ½g¦^À³
«D¤Z°]¸g¥x±M³X:

·sÃĬãµo¼t

<ÃĵØÃÄ6446>

¥h¦~¦]±M§QÅv¯Éª§¡A¾D°ê»Ú¥òµô48»õ¤¸½ß´Ú¡A¦ý¦b15¸¹ªº³Ì²×§P©w¬O½½L¬°³Ó¶D¡BµL¶·½ßÀv¡C¹ï¦¹¡AÃĵØÃĸ³¨Æªø<¸â«C¬h>¦b±µ¨ü§Ú­Ì±M³X®É¤]Â䣦í³ß®®¤ß±¡ ! ¦P®É³zÅS¡A¥h¦~©³¦b¬ü°ê¤W¥«ªº¨u¯f·sÃÄ¡A¥ÎÃÄ°jÅT°ª©ó¹w´Á¡AÅýÀç¹B®i±æ¥¿¦V¡C¦Ó¨Æ¹ê¤W°ê¤º¥Í§ÞÂåÃıڸs¡Aªñ¨Ó¸Ñª¼¡BÃÄÃÒ±¶³ø¤@¼Î¼Î¡Iªì¨B²Î­p¤µ¦~¥i±æ¦Aª§¨ú¦Ü¤Ö10±i°ê»ÚÃÄÃÒ¡C

ÃĵØÃĸ³¨Æªø ¸â«C¬h¡G¡uÁ`ºâµ¥¨ì¦b³Ì°ªªk°|ªº®É­Ô¡AÁ٧ڭ̲M¥Õ¡I«D±`¥O¤H³ß®®ªº¨Æ±¡¡A©Ò¥H§Ú»¡¤µ¦~¬O­Ó¦n¦~¡A¤@¶}©l§Ú­Ì´N¦³³o»ò¦nªºµ²ªG¡C¡v

¥òµôµ²ªG¤@Á|½½L¤Wºt¤j°fÂà¡I·sÃÄ¥x¼tÃĵØÃÄ»P¼Ú¬w¥N²z°ÓAOP±M§QÅv¥òµô®×Äñ³^4¦~¡A¥h¦~¤@«×¾D§P½ß48»õ¹dÃB¡AÅýÃĵØÃĦ¨¥«³õ¼öijªº¥þÃB¥æ³ÎªÑ¤ý¡A¦ý15¸¹Àò¼w°ê³Ì°ªªk°|µô©w³Ó¶D¡C¸³¨Æªø¸â«C¬hºZ§Öª½¨¥¡A¤µ¦~¦p­¸¾÷¥[º¡ªo¡A·Ç³Æ°_­¸¡A¦Ó­¼¸üªº¥¿¬O³Q°ê»Ú¶¡µø¬°­«½S·sÃĪº³o¶µ±M§Q¡C

ª½À»ÃĵØÃĥͪ«¦w¥þ¹êÅç«Ç¡A¾ã±Æµ¥¤ñÁY¤pªºµo»Ã¼Ñ¡A¥Ñ³Õ¤h¯Å¬ì¾Ç¹Î¶¤±Ò°Ê­ì®ÆÃÄ´ú¸Õ¡A´¦¯µ±q¬ãµo¨ì¥Í²£¡A¯Ó®É18¦~ªºªø®Ä«¬¤zÂZ¯À¡A¥Î©ó¨u¯f¯u©Ê¬õ¦å²y¼W¦h¯gPV¡Cªñ2¦~¶¶§Q®³¤U6°êÃÄÃÒ¡A¥h¦~11¤ë¦AÀò¬ü°êFDA®Ö¥i¡A¥H¥xÆW¦Û¦æ¬ãµo¤§«º¡A¦¨¬°¥þ²y²Ä¤@­Ó¤W¥«ªºPV¤@½u¥ÎÃÄ¡C

ÃĵØÃĸ³¨Æªø ¸â«C¬h¡G¡u©Ò¿×²Ä¤@½u´N¬O»¡ (PV)¯f¤H¤@¦³³o­Ó¯f §Ú´NÅý¥L¥Î¡A(FDA)¥¦¦³»¡§Ú­Ì³o­ÓÃĬOPVªº¯f¤H¡A¤£ºÞ§A¹L¥h¦³±µ¨ü¹L¤°»ò¼ËªºªvÀø¡A³£¬O¤@­Ó­º¿ïªº(ªvÀøPV)ÃÄ«~¡A©Ò¥H¥D­nªº¥«³õ¡A¤j·§¦b³o¤@¨â¦~¤§¤º³£¥i¥H¨ú±o(ÃÄÃÒ)¡C¡v

¤×¨äÂê©w¬ü°ê¥«³õ¬ù10¸U¦WPV±wªÌ¶·²×¨­´«ÃĪº»Ý¨D¡A¹w¦ô¨C¦~´«ÃÄ°Ó¾÷¦Ü¤Ö500»õ¤¸¡A¦Ó¥»¨­¨ãFDA­I´ºªº¸â«C¬h¤]¦³«H¤ß¡A¤µ¦~¦A©é¥X¤é¥»ÃÄÃÒ¡F¹Î¶¤¥t¤@¤j®Ö¤ß¤Hª« ¡AÂåÃĬãµo¥X¨­ªº³Ð¿ì¤HªL°êÄÁ«h«G¥X¼Æ¾Ú¡AÅã¥Ü¤W¥«¦Ü¤µ2­Ó¤ë¥ÎÃĤH¼Æ¤w°ª©ó¹w´Á¡C

ÃĵØÃijпì¤Hº[°õ¦æªø ªL°êÄÁ¡G¡u»s³y·|¦b¥xÆW¡A©Ò¥H·s¼t¤µ¦~·|°Ê¤u¡C¤µ¦~»Ý¨D¶q¤ñ¥h¦~¬O­¿¼Æ¡A¦Ó¥B¤£¬O¤@­¿¡A¬O´X­¿ªº¦¨ªø ¡C¨º³o­Ó¬O¦³¤@ÂIÂI¡A¤ñ§Ú­Ì¦ô­pªº­n´£¦­µo¥Í¡A¨º§Ú­Ì«Ü¼ÖÆ[¨ä¦¨¡C¡v

¬Ý¦n¤µ¦~·s°Ê¯àѺª`¡A¥u¬Oªñ¨Ó¥«³õ§ë¸êª^³ò¡A¹L«×±N¸Ñª¼¹LÃö©Î¨ú±oÃÄÃÒ¡Aµø¬°Ãļtªº¦¨±ÑÃöÁä¡A¨Æ¹ê¤W¤W¥«¨Ã«D³Ì«á¤@­ù¸ô¡C¹³°ê»Ú¤j¼tBiogen³QÅA¬°¥@¬ö¤§ÃĪºªü¯÷®üÀq¯g·sÃÄ¡A¥h¦~¶}³Ð©Ê¤W¥«¡A«o·N¥~º¢¾P¡A¦]¦¹¹ï·sÃĦӨ¥¡A«á­±ªº±ÂÅv¾P°â§ó·¥¨ã¥«³õ¦ÒÅç¡C

ÃĵØÃijпì¤Hº[°õ¦æªø ªL°êÄÁ¡G¡uBiogen¦n¥i±¤¡I¥¦Price wrong¥¦§â»ù¿ú­q¿ù¡Aµ¹§A³o»ò¦nªº(¤W¥«)¾÷·|¡A¦Ü¤Ö§Q¥Î³o­Ó°ò¦¥Ã»·»â¥ý¡A²Ä¤G¥N¡B²Ä¤T¥N·|¤@ª½¥X¨Ó¡C§Ú­Ì¤@¶}©l©w¦ì§Ú­Ì³o­ÓÃÄ¡A´N¬O»¡¤w¸g¦³ªºÃÄ¡A§Ú­n°µ±o§ó¦n¡C¥Íª«¬ì§Þ·|³Q³o»ò­«µø¡A¬O¤j®a¯uªº¬Û«H¥Íª«¬ì§Þªº¬ð¯}¡A½T¹ê·|¹ï¤HÃþ¯uªº«Ü¤jªº§ïµ½¡C¡v

¥xÆW¥Í§Þ²£·~¨I¼ç40¦~¡Aªñ3¦~¦b¬Ì±¡¤§¤U ¡A±À¤É¥«³õ±µ¨ü«×¡A¥x¼tÃÄÃÒ¡B¸Ñª¼±¶³ø¤@ªi±µ¤@ªi¡A¥]¬A·sÃļt¦X¤@¡B¤¤¸Î¡BÄ_ÄÖ¡A¥H¤Î¬Û¦üÃĪº®õºÖ¡B¥x±d¥Íµ¥ª§¨úÃÄÃÒ¡AÃzµo¤O±j«l¡Iªì¨B²Î­p2022¦~¥i±æ¦Aªï10±iÃÄÃÒ¤J³U¡A§ï¼g¥xÆW¥Í§Þ¥v¬ö¿ý¡C

ÃĵØÃijпì¤Hº[°õ¦æªø ªL°êÄÁ¡G¡u§A·|¬Ý¨ì³o¬O¥xÆW¯u¥¿¥i¥Hµo®i¡A¤p¦Ó¬ü¡A¦Ó¥B³opowerful «Ü¦³¼vÅT¤O¡C¡v

ÃĵØÃĸ³¨Æªø ¸â«C¬h¡G¡u§Ú¬Oı±o­n¥sÅ@°ê¸s¤s¡A§â³o­Ó°ò¦¥´¦n¤F¡A§Ú­Ì±N¨Ó¥i¥H¥h°µ§ó¦³¬D¾Ô©ÊªºÃÄ«~¡A¨º¥xÆWªº¥Í§Þ¬É´N¥i¥H¦b¥@¬É¤W¥e¦³¤@®u¤§¦a¡C¡v

¥xÆW¥Í§Þ¼tºë¶i¬ãµo¹ê¤O¡A±µ´Îªï±µ¦¨ªG¡A¤]¬°­«ªð¥ü¤¸¥«­Èªº¥Í§Þ²£·~¡A¥´¤U°í¼Ý½Y¥Û¡C¡]°OªÌ ½²¨Îªå¡B¤×±mËr¡þ¥x¥_±Ä³X³ø¾É¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/2/17 ¤U¤È 08:17:37²Ä 10003 ½g¦^À³
news.ustv.com.tw/newsdetail/20220217A122?type=103&listOnly=true
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/2/16 ¤W¤È 11:53:55²Ä 10002 ½g¦^À³
Ãĵإòµô¥´Ä¹Aop,¨DÀv48»õ¤¸³Q»é¦^

Âd¶R¤¤¤ß¥þÃB¥æ³Î³ÌªñÀ³¸Ó¥i¥H«Ü§Ö¸Ñ°£§a¡H

ÃĵØÃĦU°êÃÄÃÒ¥þ­±¬Ý¦n «ùÄò¦V¤W¤@¸ô«e¶i

¦p¦¹ÂX¤jÃĪ«Âл\²vªvÀø¯f±w ¤]º¡¨¬¤£Â÷±óªºªÑªFÅv¯q

¤@Á|¼Æ±o ¦n¨Æ¦h­« ®¥³ß¦U¦ì¤j¤j¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDreamtiger10145627  µoªí®É¶¡:2022/2/16 ¤W¤È 11:06:24²Ä 10001 ½g¦^À³
®¥³ß¦U¦ì¤F

ÁöµM¤½¥q¬£¤£¬O«Ü...

¦ý¬O³Ì¤jªº³±Åµ¤w¸g¹L¤F(³o¤]¬O§Ú·íªì³Ì¤jªººÃ¼{)

¯¬¦­¤é¨ì¹F¥ý¶i¤jªº¥Ø¼Ð ¥ý¤­«á¤d...¤£¹L¹ï¤½¥q¬£ªººÊ·þÁÙ¬O­nºò¨n,¦b260¥ª¥k®É·Q,¦ý¤]µL¤O¦^¸É

¥u¯à¬Ý¤j®aÄ~Äò½Ä¤Ñ~¥[ªo!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§_¨ì©³°Õ10148994  µoªí®É¶¡:2022/2/16 ¤W¤È 09:41:32²Ä 10000 ½g¦^À³
µ²ªG«Ü¦³½ì....¬O¦]¬°Ãĵش£¥Xªº·l®`½ßÀv·å²«¡A¶i¦Ó¥i¥H¥H¦¹ºM¾P¤F­ì¥»ªº§P©w....¤S¾Ç¨ì¤F¤@©Û
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§_¨ì©³°Õ10148994  µoªí®É¶¡:2022/2/16 ¤W¤È 09:24:52²Ä 9999 ½g¦^À³
­nÃz¤F¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/2/16 ¤W¤È 12:53:16²Ä 9998 ½g¦^À³
#ÃĵØÃÄ»PAOP¥òµô®× ¼w°ê³Ì°ªªk°|²×§½§P¨M¥XÄl¡GÃĵØÃijӶD§K½ß

ÃĵØÃÄ (6446-TW) 15¤é±ß¶¡µo¥¬­«°T¤½¥¬¡A±µÀò©e¥ô¤§¼w°ê«ß®v¥H¹q¶l§iª¾¡AAOP¥òµô®×Àò¼w°êÁp¨¹³Ì°ªªk°|µô©w¡AÃĵØÃĤ£»Ý¤ä¥I­ì¥òµô§PÂ_¤§ªñ45»õ·s¥x¹ô½ßÀv¤Î§Q®§µ¥¶O¥Î¡C

¦¹µô©w¬°ÃĵØÃÄ»PAOP¦Û2018¦~4¤ë¶}©l¥´°ê»Ú¥òµô®×Äñ³^ªñ4¦~ªº³Ì²×§½§P¨M¡A´Á¶¡ÃĵØÃľú¸g2020¦~10¤ë21¤éICC¥òµô§PÂ_»{©wÀ³¤ä¥IAOP¬ÛÃö½ßÀv¤Î§Q®§¡A¨ì¦V¼w°êªkÄõ§JºÖ°ªµ¥ªk°|´£ºM¥ò®×¦b2021¦~3¤ë25¤é¾D»é¦^¡A¦b¨â¦¸®À±Ñ«á¡A²×¦b¤W¶D¼w°êÁp¨¹³Ì°ªªk°|Àò±oÀ¸¼@¤Æªº°fÂà³Ó¡A¥]¬AÀ³¤ä¥IAOPªñ45»õ¤¸·s¥x¹ô¡]142,221,201¼Ú¤¸¡^¤Î¥H°ò¦§Q²v¥~¥[5%­pºâ¤§§Q®§ (°_ºâ¤é´Á¬°2019¦~8¤ë14¤é)¡A»P4¤d¦h¸U·s¥x¹ô¡]1,353,976.63¼Ú¤¸¡^¤§¥òµô¶O¥Î¡AÃĵØÃij£§K½ß¡C

¼ô±x°ê»Ú°Ó°È³^¶D®×ªºªk«ß±M®a«ü¥X¡A³q±`³Ì°ªªk°|³£°w¹ïµ{§Ç°µ¼f¬d¡A¦p¦³¤£¦P¨£¸Ñ«h¥Hµo¦^°ª°|­«¼fªº¤ñ¨Ò³Ì°ª¡A¦¹¦¸ÃĵØÃĺM¥ò®×¡A¼w°êÁp¨¹³Ì°ªªk°|¨u¨£§@¥X¦Û¬°§P¨M¡A¼o±ó°ª°|§P¨M¡A¤£³×¬°¥´¶i°ê»Ú¬×ªº¥xÆW¥ø·~¥¼¨Ó¦b°ê»Ú°Ó·~ªÈ¯Éµ¹¤©§ó¤jªº«H¤ß¾Ú²z¤Oª§¡C

¼w°ê³Ì°ª°|¦P®Éµô©w¡AÃĵØÃÄ»PAOPªº±ÂÅv¤Î»s³y¦X¬ù¤´¬°¦³®Ä¡A·N§YÃĵØÃļڬw¥«³õ¤´¥i»PAOPºû«ù¦X§@Ãö«Y¡A¦b§ð¤U¬ü°ê¥«³õ«á¡A­ì¥ý¼Ú¬w¥«³õ¤´¥X³fµL¸·¡Aºû«ùí©wªº¥«³õ¦¬¯q¡C

ÃĵØÃĦb³Ì·sªº¥òµô®×¶i«×­«°T¤¤¤]ªí¥Ü¡A­ìICC¥òµô§PÂ_»{©wÀ³¤ä¥I¤§¬ÛÃö½ßÀv¤Î§Q®§¡A·~¸g¼w°êÁp¨¹³Ì°ªªk°|µô©w½T»{¬°¤£¦s¦b¡A¹ï¤½¥q°]°È·~°È¦³¥¿­±¼vÅT¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/2/10 ¤U¤È 08:31:21²Ä 9997 ½g¦^À³
¤¤®É±ß³ø

­ÓªÑ·s»D:ÃĵØÃÄ

www.chinatimes.com/amp/realtimenews/20220210004142-260410

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/2/10 ¤W¤È 10:47:52²Ä 9996 ½g¦^À³
¼K§r¡I3000¤j¸s²Õ¤@¨¥°ó

¨ä¥L±}±}ªº¦b¬Ý¯º¸Ü

¥u¦³Àk³¾¤ßºAªº¤~¬Ý¤£¨£

²Õ¿ì³o¸s²Õªº¥u·|³Q§Q¥Î

¸s²Õ¦³¤H¦b»¡¤S¦b·d¨p¶Ò

ÃĵØÃĤ½¥q°ª¼h´N¬O³g

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/2/10 ¤W¤È 09:18:47²Ä 9995 ½g¦^À³
¨p¶Ò¤S¶}©l¤F¡HÁÙ¬O¤º³¡®ø®§¥ýª¾¹D¡H

°]´I¤H¤H·R ¤ß¦w²z±o¤~¬O¤]·|¥Ã»·

¤s¤W¤@¸s³g¯Tµu´ÁÀò§Q ²×¨s·|¥[­¿¦R¦^

¤j¸s²Õ®e¤£±o²§¤vµo¨¥ ¥u¯àºq¥\¹|¼wªþ¦X³Q¬~¸£

¤£¯à¦]¬°³o¨Ç¤Hªº¾Þ§@¤âªk¦Ó¹ïÃĪºµo®i»P§Q¯q¦Ó©ñ±ó ¤£¬O¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¹F10144219  µoªí®É¶¡:2022/2/9 ¤U¤È 10:13:51²Ä 9994 ½g¦^À³
¹ïªü.¬Ý¤£¹L¥h´N½æªü.....

¾{³½­ô¤]¬O¤j¸s²Õ¸Ìªº¤@­û.ÁÙ°¾¤£½æ.´N¯dµÛ¬ÝÀ¸

¤j¸s¸Ì´N¬O¨º´X­Ó¤H¦b°ÛÀ¸.¤µ¨à­Ó¤j¶^.´N¤£¨£¼v¤F

§A»¡¦n¯º¤£?¦b¤U°Ï°Ï«ùªÑ.¿é±o°_.

3¤d¤H¸s¥u¯à¦³¤@ºØÁn­µ.«¢

¬ÝµÛ´X¤d¤H³Qª±§ËªºÀ¸½X.±­±­²j

·Q¬Ý¶Ü?§Ú¥[§A°Ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/2/9 ¤W¤È 09:33:58²Ä 9993 ½g¦^À³
¦~°²¤w¹L~ÃĵØÃĪº¼W¸ê®×ÁÙ¦³3¸U6¥a±i¡A¬O¤£¬O¤S·d¨p¶Ò¡H¬ÝªÑ»ùµLºÝ¤j¶^¡A³o¨Ç³Q¨p¶Ò¹ï¶H¬O¤£¬O¦b½æ¦ÑªÑ¼W·sªÑ¡H

¨p¶Ò=§Q¹Ï¯S©w¤H¡AÃĵØÃijo¨Ç°ª¼h¨Mµ¦¤H¡A¤H®æ«D±`­«­n§O¯d¯ä¦W¡A§O³Q¸j¬[.........­n¹ï¥þÅé«ù¦³ÃĵØÃĪºªÑªFµÛ·Q

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/24 ¤W¤È 09:51:38²Ä 9992 ½g¦^À³
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) 6446 ÃĵØÃÄ ¡@¤½¥q´£¨Ñ

§Ç¸¹ 3 µo¨¥¤é´Á 111/01/22 µo¨¥®É¶¡ 20:39:48

µo¨¥¤H ªL°êÄÁ µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü (02)26557688

¥D¦®

»¡©ú¥»¤½¥q±M§Qª¬ºA

²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 111/01/21

»¡©ú

1.¨Æ¹êµo¥Í¤é:111/01/21

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q©ó2022¦~1¤ë21¤é¸g·ç¤h©e¥ô«ß®v³qª¾«á±oª¾¡A´N AOP¤½¥q©ó·ç¤h°w¹ï

¥»¤½¥q±M§Q©Ò¬°¤§±j¨î°õ¦æÁn½Ð®×¥ó¡A·ç¤hªk°|¤w¥¿¦¡µô©w¨ä±j¨î°õ¦æÁn½Ð

¤§µ{§Ç¨ã¦³­«¤jµ{§Ç·å²«¡A¬ÛÃö©R¥O¤§°e¹Fµ{§Ç§¡«D¦Xªk¡A¬G¥¿¦¡µô©w·ç¤h

debt collection office©Ò¬°¤ä¥I©R¥O¤Î¦©©ã©R¥Oµ¥°e¹Fµ{§Ç§¡µL®Ä¡A»Ý­«

¦æ¨Ìªk¶i¦æ¬ÛÃöµ{§Ç¨Ã¦Xªk°e¹F¤©¥»¤½¥q¡C°w¹ï¦¹µô©w¡AAOP¤½¥q¦p¦³ª§°õ¶·

©ó¤Q¤é¤º¦V·ç¤h³Ì°ªªk°|´£°_§Ü§i¡A¥¼¨Ó¬O§_´£°_§Ü§i¡A¥Ø«e©|«D¥iª¾¡C

°ò©ó«e­z·ç¤hªk°|µô©w¤§¥¿¦¡µ²ªG¡A¨¬»{¦¹«e´CÅé³ø¾É¦³Ãö¥»¤½¥q¤§±M§Q¤w

©ó·ç¤h¾D©ç½æ¤§±¡¨Æ¡AÅãÄÝÄY­«¤§»~¸Ñ¤Î¿ù»~¤§³ø¾É¡A¯S¦¹¤@¨Ö¼á²M¡C

6.¦]À³±¹¬I:

¥»¤½¥q¤w©e¥ô«ß®v«ùÄò±K¤Áª`·N¥»¤½¥q¦U°ê±M§Qª¬ºA¡A¨Ã·Ç³Æ¦]À³AOP¤½¥q«á

Äò¥i¯à±Ä¨ú¤§¦æ°Ê¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·

ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p§d10135724  µoªí®É¶¡:2022/1/16 ¤U¤È 07:04:11²Ä 9991 ½g¦^À³
ı±o¤½¥q¸gÀ綥¼h¦³°ÝÃD ¨º¤£´N½æ±¼ªÑ²¼´N¦n¶Ü¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/14 ¤W¤È 11:03:18²Ä 9990 ½g¦^À³
2950¤H¤£¬O¥þ¶Ì¤l¡A¬O¦b¬Ý¯º¸Ü¦Ó¤w¡A¨C¤@­Ó¸õ¥X¨Ó»¡¨£¤£±o¥úªº¨Æ¡A

°¨¤W´N½ð¥X¸s²Õ¡A¸s¸Ì¥þ¼Æ³£¤wª¾¹D¡A´N¬O¤@¨¥°óÐù¡A¨C¬Ý¯º¸Ü¤]¤£¿ù

¤ß±¡´r®®¡A¨º¨Ç³ò¦b®ÇÃ䪺°¼Ál¾m³¾¤ßºA¡A¬O¬Ý¤£¨£ªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/1/14 ¤W¤È 09:28:02²Ä 9989 ½g¦^À³
ÁÙ¦³ÁÙ¦³ÁÙ¦³

§Ñ¤FÁ¿

°¼Ál¦n¦h³á

Á¿¤£¤¤Å¥ªº·|³Q³ò¶Ï

³Q¬Ý¯º¸Üªº¸s²Õ

¨C¤H³£¦³·sÂA¨Æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/1/14 ¤W¤È 09:12:52²Ä 9988 ½g¦^À³
¦n¸Þ²§ªº¤j±Ú¸s

¥u­nÁ¿¨ì¨p¶Ò®×¸ò¤£¤¤Å¥ªº

´N·|³Q§R°£

©Î½ð¥X±Ú¸s

³o2950¤H¸s²Õ

¨C­Ó¤H³£¶Ì¶Ì¨S¬Ý¨£

§Ö°h¸s²Õ§a

¦b³o¸s²Õ¥u·|³Q½²§Û§Ë

¥i¼¦°Ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/13 ¤W¤È 09:58:04²Ä 9987 ½g¦^À³
®É¶¡ºâ¤@ºâ®t¤£¦h¤F¡A¤µ¤éªº¤U¶^¤S¬O¬°¨p¶Ò»ù®æ¦bÀ£§CªÑ»ù¡A¥»¤H¤@ª½±j½Õ¤½¥q¬£¤@ª½·d¨p¶Ò®×¡A

¤S¤@ª½¬¢¨º¨Ç©T©w¯S©w¤H¤h¡A¬O¦b§|±þ¨ä¥LªÑªF¡A§ë¸ê¤H¤£§{¯d·N¨p¶Ò¤½§i«e¤@¶g~10¤Ñ¥æ©ö¤éªÑ»ù

³£¬O¤j¶^¡A¤£¬O§|±þ§ë¸ê¤H¤Î¨ä¥LªÑªF¡A¬O¤°»ò¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/1/12 ¤U¤È 02:03:08²Ä 9986 ½g¦^À³
Anco¤j»¡ªº¬O

ªø´Á¥H¨Ó¤@ª½³£¦bªº¬O¦Ñ©d¡I

¥_³¡¬Y¤s°Ï­Ñ¼Ö³¡¦¨­û¬O¤pªº¡I¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnco10136449  µoªí®É¶¡:2022/1/12 ¤U¤È 01:28:09²Ä 9985 ½g¦^À³
³s¤µ¶g¥Z³£¬Ý¤£¤U¥h¤F⋯⋯¡A¹ï©óªø´Á¤ä«ù¤½¥qªºªÑªF¦p¦ó¥æ¥N¡H¡I³o·Pı´N¦n¤ñ¤@­Ó¤H¨Æ·~¦¨´Nµo¹F¤F¤§«á¡A±N©õ¤é¦@¦P§V¤OªºÁVÁR¤§©d±ó©ó¤£ÅU¡A«o·ÓÅU¥~­±ªº¤p?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/12 ¤U¤È 01:08:31²Ä 9984 ½g¦^À³
¸¹¥l30ªÑªF¬~·|³õ¡A¤Ó¥i´c¤F.....
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/1/12 ¤U¤È 01:03:39²Ä 9983 ½g¦^À³
²{¦bÅܦ¨¤@¨¥°ó

¦³2900¤H³£®¤¤£´±¨¥

§A°Ñ¥[¤]¨S¤°»ò§@¥Î

ÃĵØÃÄÅܦ¨¨p¶Ò®×¹Ï§QªºÅ]°­

ªÑªF·|¬~³õ¥d¹ê¦b

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GKilson10149103  µoªí®É¶¡:2022/1/12 ¤U¤È 12:02:01²Ä 9982 ½g¦^À³
½Ð°Ý¤j¸s²Õ±K½X¦h¤Ö¡H ·Q¶i¥h¬Ý¬Ý «¢
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/1/12 ¤W¤È 11:51:39²Ä 9981 ½g¦^À³
¤j¸s²Õ¥u­n°Q½×¨p¶Ò®×

¹Ï§Q©T©w¹ï¶H

Åܦ¨¤@¨¥°ó¤F

·|³Q©m½²©Î¤ý§R°£

¥i¨£¤ß¸Ì¦³°­

¤~·|¨£¤£±o¥ú

¤µ¦~ªÑªF·|ÃÙ¦¨±aÂû³J

¬~·|³õ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/12 ¤W¤È 11:22:16²Ä 9980 ½g¦^À³
AmerisourceBergen oncology supply

The latest product information

Now available BESREMi® (ropeginterferon alfa-2b-njft)

December 2021

³Ì·s²£«~«H®§

²{¤w¤W¥« BESREMi®¡]ropeginterferon alfa-2b-njft¡^

2021 ¦~ 12 ¤ë

³Æµù¡GAmerisourceBergen Corporation¬O¤@®a¬ü°êÃÄ«~§åµo¤½¥q¡A1996 Oncology Supply ¦¨¬° Bergen Brunswig ªº¤@³¡¤À¡A«áªÌ«á¨Ó¦¨¬° AmerisourceBergen¡AÂX¤j¤FÂл\½d³ò©M¤ä«ù¯à¤O¡C¥tBergen Brunswig ©M AmeriSource ©ó 2001 ¦~¦X¨Ö¦Ó¦¨¡C´£¨Ñ»PÂåÀø·~°È¹BÀç©M±wªÌªA°È¬ÛÃöªºÃÄ«~¤À¾P©M¿Ô¸ß¡CÁÙ¦V¬ü°ê¦U¦aªºÂåÀø«O°·´£¨ÑªÌ¡]¥]¬A«æ©ÊÅ@²zÂå°|©M½Ã¥Í¨t²Î¡^¡B¿W¥ß©M³sÂꪺÂåÀø«O°·´£¨ÑªÌ¤À¾P¤@¨t¦C«~µP¦WºÙ©M¥é»sÃÄ¡B«D³B¤è(OTC) «O°·²£«~©M®a®x«O°·¥Î«~©M³]³Æ¹s°âÃÄ©±¡B¶lÁʳ]¬I¡BÂå¥Í¡B¶E©Ò©M¨ä¥L³Æ¥Î³õ©Ò³]¬I¡A¥H¤ÎÅ@²z©M»²§U¥Í¬¡¤¤¤ß¡CÁÙ¬°ªø´ÁÅ@²z¡B¤u¤H½ßÀv©M¯S®íÃĪ«±wªÌ´£¨ÑÃÄ«~©MÃĩЪA°È¡C

°Ñ¦Ò¸ê®Æ¡G

www.oncologysupply.com/

en.wikipedia.org/wiki/AmerisourceBergen

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2022/1/12 ¤W¤È 10:24:10²Ä 9979 ½g¦^À³
Incyte IP Morgan ªº Presentation ¸ê®Æ: (To see 2016-2021 5¦~ªº¦~§¡½Æ¦X¦¨ªø²v>20% Page13 ¥D­n°^Äm¨Ó¦Û©óJakafi (¦~§¡½Æ¦X¦¨ªø>26% Page4) for PV and MF)......

s21.q4cdn.com/114423841/files/JPM-2022_vFINAL2.pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/1/10 ¤U¤È 04:09:46²Ä 9978 ½g¦^À³
¥¼¨Ó¦³¨S¦³¾÷·|·íªÑ¤ý®É¶¡·|ÃÒ©ú¤@¤Á

¥ý¶i¤j©Ò»¡¬O´£¨Ñ¥t¤@ºØ«ä¦Ò¤è¦¡

·íµM·ÓÅU¤Î¿EÀy¦Û¤v­û¤u¬O³Ì¦n¤F ¦Ó¥B§C»ù­û¤u»{Áʤ]¤£¬O²Ä¤@¦¸

¦b¥¼Àò§Qªº±¡ªp¤U¬O¤£¬O¤]¦Ò¼{ªø´Á¤ä«ùªºªÑªF­ÌªºÅv¯q

¦]¬°¤j®a³£ª¾¹D¦b¤£¤[ªº±N¨ÓÀ禬¼Wªø³t«×¥[§Ö

¦³eps®É½×¥\¦æ½àÀ³¸Ó´N¨S¦³¤H·|¼L¤F§a¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªø½u10139882  µoªí®É¶¡:2022/1/10 ¤U¤È 01:11:39²Ä 9977 ½g¦^À³
¤½¥q¦p³o¼Ëªv²z¡A§A·Q¥L·|¦¨ªÑ¤ý¶Ü¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/10 ¤U¤È 12:29:33²Ä 9976 ½g¦^À³
¦pªG¯à½|¿ô¬OÃĵØÃĪѪF¤§ºÖ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G±Û«a10139522  µoªí®É¶¡:2022/1/10 ¤U¤È 12:24:52²Ä 9975 ½g¦^À³
³o­Óª©§ÖµL¥i¬Ý©Ê¤F¡A²_¬°¤£º¡¨p¶Òðã½|ª©¡A§Ú¥u¦b·NÃĵط|¤£·|¬O¥¼¨ÓªºªÑ¤ý¡K
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/10 ¤W¤È 11:54:38²Ä 9974 ½g¦^À³
§ë¸êªÑ²¼ª±¤F40¦~±q¥¼¬Ý¹L³o»ò³g¡A¦ÛªÎªº¤½¥q¡A¯d¤Uªº¬O¯ä¦W......
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/1/10 ¤W¤È 10:32:51²Ä 9973 ½g¦^À³
¶ýªº

¨p¶ÒµL¼Æ¦¸

®³§ë¸ê¤Hªº¿ú¶RªÑÁÈ¿ú¤Fµ¹¦Û¤v­û¤u

Á«¿ú¤F´NÂk§ë¸ê¤Hªº

³g°]

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/1/10 ¤W¤È 09:46:46²Ä 9972 ½g¦^À³
¥ý¶i¤j»¡ªº¨S¿ù

¤µ¦~ªÑªF·|³J¬~·|³õ

¤z¤@¸s½Þ¦b·m­¹

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/10 ¤W¤È 09:44:29²Ä 9971 ½g¦^À³

§A¬ÝÃĵØÃĤ½¥q¤º³¡ªº¦æ®|¦h¥i´c¡A¤½¥q©Ò¦³¤W¦Ü¤U³£¬O³g§Qªº¡A¤W¦¸90¤¸¼W¸êªº¸êª÷¦b87¤¸Å@½L¡A·í®É¤½¥qÁÙ¥¼®³¨ìFDAÃÄÃÒ¡A

¤½¥q¤í¯ÊÀç¹B¸êª÷¦V©Ò¦³¤pªÑªF¼W¸ê¡A®¿¥Î¸êª÷¨ÓÅ@½L(Á¿ªº¦nÅ¥)¡AúҹϦۤvªº§Q¡A¤½¥q·í®ÉÁÙ¦b­·«BÄÆ·n¤¤«×¤é¡A®³¨ìÃÄÃÒ

«á»ù¤Wº¦¡A´N»°§Ö§â¤§«e©Ò§C»ù¶R¤Jªº»ù®æµ¹¬ù©Ò¦³­û¤u¡A¦h¥i´c°Ú~¤µ¦~ÃĵØÃĪºªÑªF·|¡A«Øij±z¶}½|³o¨Ç¤½¥q¬£³g§Q¦æ®|

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/10 ¤W¤È 09:31:37²Ä 9970 ½g¦^À³
www.businesstoday.com.tw/article/category/80392/post/202201060041?utm_source=LINE&utm_medium=text&utm_campaign=2201061900

....,..................................

§A¬ÝÃĵØÃĤ½¥q¤º³¡ªº¦æ®|¦h¥i´c¡A¤½¥q©Ò¦³¤W¦Ü¤U³£¬O³g§Qªº¡A¤W¦¸90¤¸¼W¸êªº¸êª÷¦b87¤¸Å@½L¡A·í®É¤½¥qÁÙ·|®³¨ìFDAÃÄÃÒ¡A

¤½¥q¤í¯ÊÀç¹B¸êª÷¦V©Ò¦³¤pªÑªF¼W¸ê¡A®¿¥Î¸êª÷¨ÓÅ@½L(Á¿ªº¦nÅ¥)¡AúҹϦۤvªº§Q¡A¤½¥q·í®ÉÁÙ¦b­·«BÄÆ·n¤¤«×¤é¡A®³¨ìÃÄÃÒ

«á»ù¤Wº¦¡A´N»°§Ö§â¤§«e©Ò§C»ù¶R¤Jªº»ù®æµ¹¬ù©Ò¦³­û¤u¡A¦h¥i´c°Ú~¤µ¦~ÃĵØÃĪºªÑªF·|¡A«Øij±z¶}½|³o¨Ç¤½¥q¬£³g§Q¦æ®|

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/10 ¤W¤È 08:52:29²Ä 9969 ½g¦^À³
¤@¡B¬ü°ê¦³¸É§UªvÀøPVÃÄ«~¸g¶O¥Á¶¡«DÀç§Q²Õ´­p¦³¡G

(¤@)PAN Foundation¡GBESREMI¡BJAKAFIV¡BPEGASYS¡C

(¤G)good days¡GBESREMI¡BJakafi¡C

(¤T)GENENTECH PATIENT FOUNDATION¡GPegasy(peginterferon alfa-2a)¡C

¤G¡B±q¬ÛÃöMPNªÀ¸s°Q½×PAN Foundation¸É§UBesremi±¡§Î¡G

(¤@)PAN Foundation has approved Besremi!

PAN °òª÷·|¤w§å­ã Besremi!

(¤G) Today I learned the PAN Foundation is already up to speed about Besremi and is already awarding big annual grants ($8,000+) to eligible patients to help cover copayments for Besremi¡C

¤µ¤Ñ§Ú¤F¸Ñ¨ì PAN °òª÷·|¤w¸g¥[§Ö³t«×¸É§U Besremi ¡A¨Ã¥B¤w¸g¦V²Å¦X±ø¥óªº±wªÌ´£¨Ñ¤jµ§¦~«×ÃØ´Ú¡]8,000 ¬ü¤¸¥H¤W¡^¡A¥HÀ°§U¤ä¥I Besremi ªº¦@¥IÃB¡C

(¥|)If you get approval from your Medicare Part D plan to cover Besremi then I think

you¡¦d have to call the PAN foundation to cancel your existing grant for Pegasys copayments and apply for a new grant to cover Besremi copayments. If I were in your shoes I¡¦d call PAN next week to inquire about whether it will be possible to do this switch in February.

¦pªG±zÀò±o Medicare D ³¡¤À­p¹ºªº§å­ã¥H²[»\ Besremi¡A¨º»ò§Ú»{¬°±z¥²¶·­P¹q PAN °òª÷·|¨ú®ø±z²{¦³ªº Pegasys ¦@¥IÃBÃشڨ֥ӽзsªºÃØ´Ú¥H²[»\ Besremi ¦@¥IÃB¡C¦pªG§Ú³B©ó§Aªº¦ì¸m¡A§Ú·|¦b¤U¶g¥´¹q¸Üµ¹ PAN¡A¸ß°Ý¬O§_¥i¥H¦b 2 ¤ë¥÷¶i¦æ¦¹Âà´«¡C

(¤­)Dr. Mesa is prescribing Besremi. Hoping it is in my UHC Medicare Part D formulary. is saying PAN is writing grants for it now.

Mesa³Õ¤h¥¿¦bµ¹ Besremi ¶}³B¤è¡C§Æ±æ¥¦¦b§Úªº UHC Medicare D ³¡¤À³B¤è¤W¡C¾Ú»¡ PAN ²{¦b¦³¸É§U¤F¡C

¤T¡B¤pµ²¡GPAN Foundation¤Îgood daysµ¥²Õ´¤w±NBesremi¦C¤J¸É§UÃÄ«~²M³æ¡A¬Û«H­ì¥»¦bPAN ¥Ó½Ð¸É§U¨Ï¥ÎJAKAFIV¡BPEGASYS©Î¬O¦bGENENTECH ¥Ó½ÐPegasy¸É§U¨Ï¥ÎªºPV±wªÌ¡AÀ³¸Ó·|¶V¨Ó¶V¦hÂà¦VPAN ©Îgood days¥Ó½Ð¸É§U¨Ï¥ÎBESREMI¡C¦P®É¡A¥¼¥Ó½Ð¸É§UPV±wªÌ¡A¥ç¬O·|¶V¨Ó¶V¦hª½±µ¦VPAN ©Îgood days¥Ó½Ð¸É§U¨Ï¥ÎBESREMI¡C

°Ñ¦Ò¸ê®Æ¡G

¤@¡Bwww.panfoundation.org/

¤G¡Bwww.mygooddays.org/patients/diseases-covered/myeloproliferative- diseases

¤T¡Bwww.gene.com/patients/patient-foundation

¥|¡BMPN¬ÛÃöªÀ¸s

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/9 ¤W¤È 09:40:35²Ä 9968 ½g¦^À³
½Ã¥Í³¡ (VM) ¤w¹ïªk°|µô¨M´£¥X¤W¶D¡A¸Óµô¨M¤ä«ù¤@¦W¸~½F±wªÌ­n¨D±q°ê®a¹wºâ¤¤¤ä¥I²{¥NÃĪ«¶O¥Î¡C

¸Ó³¡¦b¦V·s»Dªù¤áºô¯¸ LSM.lv ¸ÑÄÀ¹ï§P¨M´£¥X¤W¶Dªº¨M©w®Éªí¥Ü¡Aªk°|±o¥X¤F¿ù»~ªºµ²½×¡A³o»P¾Ëªkªk°|ªº½Õ¬dµ²ªG¬Û¥Ù¬Þ¡Cªk°|ÁÙ¦±¸Ñ¤Fªk³W¤¤Ãö©ó¥i³ø¾PÃÄ«~»s«×©Ê½èªº³W©w¡C

½Ã¥Í³¡ªí¥Ü¡A³ø¾P¨î«×¦³¨âºØ³ø¾P¾÷¨î¡G¤@¯ë³ø¾P©M­Ó¤H³ø¾P¡C¸Ó³¡»{¬°¡A¦a°Ï¦æ¬Fªk°|¦b¨ä§P¨M¤¤¨S¦³¦Ò¼{³o¨âºØ¾÷¨îªº©Ê½è¡A¦]¦¹¦bÂåÃIJ£«~ªº¤@¯ë³ø¾P¾÷¨î¥²¶·±Ä¨ú­Ó§O³ø¾Pµ{§Çªº±¡ªp¤U¡A¥¦¬O¿ù»~ªº¡C³QÀ³¥Î¡C

¥i³ø¾PÃĪ«²M³æ¥]¬A¨Ã¥]¬A¾A¥Î©óªvÀø¥Ó½Ð¤H¯S©w¶EÂ_ªº Hydrea¡C¬°¥Ó½Ð¤H½T©wªº¶EÂ_¥H¤Î¸Ó¯f¨Òªº©Ò¦³¨ä¥L±¡ªp¤£¯à³Qµû¦ô¬°¿W¯Sªº¡A¦]¬°¦b©Ô²æºû¨ÈÁ`¦@¦³¤j¬ù 600 ¦W±wªÌ­Ñ¦³¬Û¦Pªº¶EÂ_¡C

¬°¤F«OÃÒ©Ò¦³±wªÌ¥u¨Ï¥Î¤@ºØÃĪ« Besremi ªvÀøªºÅv§Q¡A»Ý­n 4320 ¸U¼Ú¤¸¨Ó³ø¾P¸ÓÃĪ«¡A

¦pªG¦b½Ã¥Í³¡­pºâªºÃÄ«~¤@¯ë³ø¾P½d³ò¤º³ø¾P¡C2021¦~ÃÄ«~³ø¾P¨t²ÎªºÁ`¹wºâ¬°1.7»õ¼Ú¤¸¡C

¡§³o·N¨ýµÛ 600 ¦W³Q¶EÂ_¬°¯u©Ê¬õ²Ó­M¼W¦h¯gªº±wªÌ±N¤£±o¤£ªá¶O¤j¬ù¥|¤À¤§¤@ªº°ê®a¹wºâ¥Î©óÃĪ«³ø¾P¨t²Î¡A¨Ã¥B¤£±o¤£©ñ±ó¥þ³¡©Î³¡¤ÀÃĪ«¡A¨Ò¦p¤ßż¯f±wªÌ©Î¿}§¿¯f±wªÌ¡A ¡§¸Ó³¡¦b¤@¥÷Án©ú¤¤»¡¡C

§Y¨Ï³o¨ÇÃĪ««ö­Ó¤H³ø¾P¡A³o 600 ¦W±wªÌ¤]»Ý­n 850 ¸U¼Ú¤¸¡C³o¤ñ­Ó¤HÃÄ«~³ø¾Pªº©Ò¦³¸êª÷°ª¥X 2.5 ­¿¡C

»y¹Ò¡G

¦@¦³ 7 ¦W¸~½F±wªÌµ´±æ¦a°_¶D¸Ó¦{¡A­n¨DÀò±oªvÀø¬õ²Ó­M¼W¦h¯g©Ò»ÝªºÃĪ«¡C°ê®a¥u¬°¥i³ø¾PÃĪ«²M³æ¤WªºÃĪ«¥I¶O¡A¦ý¥¦­Ì¨Ã¤£Á`¬O¾A¦X±wªÌ¡CLīga Pumpuriņa »P°ê®aªº°«ª§¬O¦³¥Øªºªº¡A¦b¤W¶D®×¥ó¤¤¡A¦æ¬F°Ï°ìªk°|µô©w½Ã¥Í³¡¤£³ø¾P¥²­nÃÄ«~ªº ¨M©w¬O«Dªkªº¡C

www.lsm.lv/raksts/zinas/latvija/vm-parsudz-tiesas-spriedumu-par-musdienigu-onkologijas-zalu-apmaksu.a437965/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/7 ¤W¤È 11:13:09²Ä 9967 ½g¦^À³
¤@¡BÃĵØÃĦ۱q2021¦~11¤ë13¤é¨ú±o¬ü°êFDAÃÄÃÒ«á¡A¬ü°êPVº¯³z²v¸Û¦p¤½¥q©Ò¨¥¡APV±wªÌªº«OÀIÂл\°·¥þ¡AP1101®Ö­ã²Ä¤@¤Ñ¶}©l´N¥i¥H«OÀIµ¹¥I¡AÃĵØÃĹw­p¦b6­Ó¤ë¤º¦³80%ªº«OÀIÂл\²v¡C¥Ø«e¬ü°êÂåÀø«OÀI¤½¥q±NBesremi¯Ç¤JÃÄ«~²M³æ¡A­p¦³AlaskaCare Retiree DC Plan ¡BWestern Health ¡BUnitedHealthcare Oxford ¡BCoordinated Care¡BKaiser Permanente¡BHealthPartners¡BAnthem BlueCross¡BHealth Alliance¡BBlueCross BlueShield

TUFTS HEALTHµ¥(ÁÙ¦³¨ä¥L, ¸ê®ÆµLªk¤U¸ü)¡A·PıÃĵØÃĹw­p¦b6­Ó¤ë¤º¦³80%ªº«OÀIÂл\²v¡A¦n¹³¦³¥i¯à¹F¼Ð¡C

¤G¡B¨C¤éMPN¯f¤ÍªÀ¸s¡A°Q½×©Î¨Ï¥ÎBesremi¤H¼Æ¦³¤éº¥¼W¥[¡A¨C¤ëÀ禬¼W¥[¥i´Á«Ý¡A¦ý·|¼W¥[¦h¤Ö¡A©|«ÝÆ[¹î¡C

¤T¡B«Øij¤½¥q¨p¶Ò®×¡A±N¤í¯Ê¸êª÷¡A¤@¦¸¸Ñ¨M´M§ä«D­ì¦³ªÑªF¡A§äµ¦²¤¦X§@§ë¸ê¤H¡A¡u±j±jÁp¤â¡v¦p¤¤¥~¥Í§Þ§ë¸ê°òª÷¡B¤j«¬ªk¤H¡B¥~°êÂåÃĤ½¥qµ¥¤JªÑ¡A¦³§U©óÄw½Xí©w¡AªÑ»ù¤Wº¦¡B±j¤Æ¥«³õ«H¤ß¡A¾¨§Ö¤Æ¸Ñ¥«³õ¹ï¨p¶ÒªººÃ¼{¤ÎÂø­µ¡C

¥|¡BBesremi¦b¬ü°êÂåÀø«OÀI¤½¥q¤ÎPV¨Ï¥Îº¯³z²v¤é¯q¼W¥[¡A¦ý¥Ø«e¤£«OÃÒÃĵØÃĤ½¥qªÑ»ù·|¤Wº¦¡A§ë¸ê§PÂ_¶R½æ½Ð¦Û¦æ­t³d¡C

¤­¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¡¯¡¯¡¯¬ü°êÂåÀø«OÀI¤½¥q²¤¶

¤@¡BUnitedHealth Group¡]Áp¦X°·±d«OÀI¡^

1977¦~³Ð¥ß¡AÁ`³¡³]©ó©ú¥§Ä¬¹F¦{¡A¬O¬ü°ê³Ì¤jªº°·±d«OÀI¤Î½Ã¥Í¸ê°T¬ì§Þ¤½¥q¡AºX¤U¥]§tUnitedHealthcare¡BOvations¡BAmeriChoice¡BUniprise¡BSpecialized Care Services ©MIngenix¡C2012¦~³QFORTUNÂø»xµû¿ï¬°¬ü°ê«OÀI©MºÞ²z¦¡·ÓÅ@¤½¥q¤¤³Ì¨ü·q­«ªº°·±d«OÀI¤½¥q²Ä¤@¦W¡C¥Ø«e¬ù¦³7500¸U¦W§ë«O¤H¡AªA°È¦a°Ï²[»\¥þ¬ü50­Ó¦{¤Î50¦h­Ó°ê®a¡C

¤G¡BKaiser Permanente¡]³ÍÂÄÂåÀø¾÷ºc¡^

¦¨¥ß©ó1945¦~¡AÁ`³¡¦ì©ó¥[¦{¶ø§JÄõ¡A²[»\Kaiser Foundation Health Plans («DÀç§Q¤½¦@ÂåÀø²Õ´)¡BKaiser Foundation Hospitals («DÀç§Q¤½¦@ÂåÀø²Õ´) »PPermanente Medical Groups (Àç§QÂåÀø²Õ´)¡A¾Ö¦³910¸U¦W§ë«OªÌ¡B17,425¦ìÂå¥Í¡B48,285¦ìÅ@¤h¡B38­ÓÂåÀø¤¤¤ß©M608­ÓÂåÀø¿ì¤½«Ç¡C¦b«X°Ç©£¦{¡B¥[§QºÖ¥§¨È¦{¡B¬ìù©Ô¦h¦{¡B°¨¨½Äõ¦{¡BµØ²±¹y¦{¡B¥±¦N¥§¨È¦{©M«n¤j¦è¬v¦a°ÏÀò±o³Ì°ª¾ãÅéÅéÅç¡A¤]¬O°ß¤@¤@®a¦b¦h­Ó¦a°Ïűo³Ì°ª¾ãÅéÅéÅ窺¤½¥q¡C

¤T¡BBlue Cross Blue Shield

Á`³¡¦ì©óªÛ¥[­ô¡ABlue Cross Blue Shield½Ï¥Í©ó1930¦~¥N¤j¿½±ø®É´Á¡A±q¼w¦{¹F©Ô´µ¥«¶}©l¡A·í®É·í¦a±Ð®v¨C¤ë¦V¨©°ÇÂå°|¤ä¥I50¬ü¤À«O¶O¡A¥iÀò±o21¤ÑÂå°|Å@²zªA°È¡F¦P¤@®É´Á¡A¬ü°ê¦è¥_ªu©¤¦a°Ïªº¥ï¤ì©M±ÄÄq¤u¤H¶}©l¦V·í¦aÂå¥Í¤ä¥I¤pÃB¤ë¶O¥HÀò±o´NÂåªA°È¡ABlue Cross Blue ShieldÂå«O­p¹º¥¿¦¡½Ï¥Í¡C§@¬°¬ü°ê³W¼Ò³Ì¤jÂåÀø«OÀI¾÷ºc¡ABlue Cross Blue Shield´£¨Ñªñ1»õ¦W§ë«O¤H(¬ù1/3¬ü°ê¤H¤f)¡AªA°È¦a°ìÂл\¥þ¬ü50¦{¡B­ô­Û¤ñ¨È¯S°Ï¤Îªi¦h¾¤¦U°UºÞ¦a¡C

¥|¡BIndependence Health Group

§@¬°Blue Cross Blue Shield¡A¦b¦h­Ó¦{´£¨ÑªA°È¡AAmeriHealth©MTandigm¤]¬OIHG®a±Ú¥ø·~ªº¤@³¡¤À¡A¬°¶W¹L830¸U¤H´£¨Ñ«OÀIªA°È¡A¨ä¤¤¥]¬A¶W¹L19000¦WÀ¦¨à¡A¾Ö¦³¶W¹L42000¦W°·±d±M·~¤H¤h¡AIndependence Blue Cross«ù¥d¤H¥i¥H¦b¶O«°ªºBlue Cross RiverRink§K¶O·Æ¦B¡C

¤­¡BAnthem

³Ð¥ß©ó1940¦~¥N¡A«e¨­¬OWellPoint, Inc.¡A©ó2014¦~12¤ë§ó§ï¬°²{¦W¡A¬O¬ü°ê²Ä¤G¤j°·±dÂåÀø«OÀI¤½¥q¡A¬ù¦³3750¸U«O¤á¡A¦b¥[¦{«h¦³830¸U¦W«O¤á¡A¦b¥[¦{¥sAnthem Bluecross ¬°¥[¦{¥«¦û²v³Ì°ªªºÂåÀø«OÀI¤½¥q¡CAetna ³Ð«Ø©ó1850¦~ªº±d¤D¨f§J¦{Hartford¡A¾ú¸g¥@¬É¤j¾Ô»P¸gÀÙ¤j¿½±ø¡A¬°¥þ¬ü¾ú¥v³Ì±y¤[ªºÂåÀø«OÀI¤½¥q¡C°£¤F´£¨Ñ¦h¤¸ÂåÀø«OÀI¤è®×¡B¼u©Ê¤º®e»P¥i­t¾áªº«O¶O¿ï¾Ü¡AAetnaªº¥þ¬üÂåÀøºôµ¸¦³¶W¹L458,000¦WÂå®v¡B4,681¶¡Âå°|¡CªA°È¦a°Ï²[»\¥þ¬ü50¦{¡C

¤»¡BHumana¡]«¢ªù¨º¤½¥q¡^

¤£³q¹LACA¡]±wªÌ«OÅ@»P¥­»ùÂåÀøªk®×¡^¥X°â­Ó¤H°·±d«OÀI­p¹º¡A¥u¦³¦ì©ó«n³¡ªº¥D­n°·±d«OÀI¤½¥q¡]ªÖ¶ð°ò¦{ªº¸ô©ö´µºûº¸¡^¤½¶}¤ä«ù­t³d¥ôªºÂåÀø¤ä¥I¼Ò¦¡¡AÂå¥Í¦b«O»Ù±wªÌ°·±d¤è­±°µ±o«Ü¦n¡A¾¨ºÞÀ²¼Ð¦rÅé¬Ý°_¨Ó¦³ÂI©_©Ç¡A¦ý¤´µM«Ü®e©öÃѧO¡A¼w§JÂÄ´µ¦{³Ì¦nªº¾ãÅéÅéÅç¡F«X¥è«X¦{³Ì¦nªº«O»Ù©MºÖ§Q¡F¥ì§Q¿Õ¥ì¦{©M¦L²Ä¦w¯Ç¦{³Ì¦nªº¥æ¬y³q°T¡C

¤C¡BHealth Care Service Corporation

Health Care Service Corporation¬O¥ì§Q¿Õ¥ì¦{¡B»X¤j®³¦{¡B·s¾¥¦è­ô¦{¡B«X§J©Ô²ü°¨¦{¡A¥H¤Î¼w§JÂÄ´µ¦{ªºBlue Cross Blue Shield¡]ÂŤQ¦rÂŬިó·|¡^´£¨Ñ°Ó¡A¾Ö¦³¶W¹L233000¦WÂåÀøªA°È´£¨ÑªÌ¡AÀò±oEthisphere Institute¹{µoªº¥þ²y³Ì¨ã°Ó·~¹D¼w¥ø·~¼ú¾Ö¦³ªñ1500¸U¦W·|­û¡A¬O³Ì¤jªº«D§ë¸êªÌ±±¨îªº°·±d«OÀI¤½¥q¡A¥ì§Q¿Õ¥ì¦{³Ì°ª¾ãÅéÅéÅçµû¤À¡F¦òù¨½¹F¦{³Ì°ª«È¤áªA°Èµû¯Å¡C

¤K¡BCentene

¾Ö¦³Ambetter¡BHealth Net©MFidelis CareÂåÀø«OÀI¤½¥q¡A·|­û¼Æ¶q¶W¹L1200¸U¡ACentAccount­p¹º¦V²Å¦X±ø¥óªº·|­û´£¨Ñ¤pÃB¤ä¥I¡A¥HÀò±o§K¶O°·±dÀˬd©ÎªÌÀù¯gÀˬd¡A¦b¤ºµØ¹F¦{¡BµØ²±¹y¦{µ¥«Ü¦h¦a°Ï¡A¥H¤Î¨ä¥L«OÀI¤½¥q°±¤î¾P°â­Ó¤H¶ø¤Ú°¨Âå§ï­p¹ºªº¦a°Ï´£¨Ñ°·±d­p¹º¡C

¤E¡BCigna¡]«H¿Õ¶°¹Î¡^

³Ð¥ß©ó1792¦~©ó»«¦{¡A¦P¼Ë¬°¬ü°ê³Ì±y¤[°·±d«O¤½¥q¤§¤@¡A¬O¥ÑInsurance Company of North America©MComnecticut Gcncral Life¦X¨Ö¦Ó¦¨¡CCignaªº«e¨­Insurance Company of North America¬O²Ä¤@®aÀò­ã¦b¤¤°ê¸gÀç«OÀI·~°Èªº¬ü°ê«OÀI¤½¥q(1897¦~)¡CAnthem©ó2015¦~7¤ë±ý¥H¶W¹L480»õ¬ü¤¸¦¬ÁÊCigna¡A¦¨¬°¬ü°êÂåÀø«O°·¦æ·~¨ÖÁʼ餤³Ì¤jªº¤@µ§¥æ©ö¡CµM2017¦~2¤ë¬ü°êºÊºÞ¾÷ºc¨Ã¥¼§å­ã¨ÖÁʮסC

¸ê®Æ¨Ó·½¡G

www.tigerless.com/american-health-insurance/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/7 ¤W¤È 08:00:38²Ä 9966 ½g¦^À³
¤@¡B¸É¥R¸ê®Æ¡G(­Y¦³¿ù»~¡A¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç)¡C

(¤@)AlaskaCare Retiree DC Plan Prescription Drug Formulary

BESREMI

Drug Tier¡G3(Highest-cost)

Requirements/Limits¡GSP(Specialty Medication)

mail.google.com/mail/u/0/?tab=rm&ogbl#inbox?projector=1

(¤G)Your 2021 Western Health Advantage 3-Tier Preferred Drug List

BESREMI SUBCUTANEOUS SOLUTION PREFILLED

SYRINGE 500 MCG/ML (ropeginterferon alfa-2b-njft)

Coverage Requirements &Limits: PA

doc-0o-4k-apps-viewer.googleusercontent.com/viewer/secure/pdf/bbsdnmudv7bk969gc31mekr52aesn5oi/apjrku632c63tghvktkd0okad5ipshcs/1641513225000/gmail/10341448784053036

¤G¡B¸ê®Æ¨Ó·½¡GMPN¬ÛÃöªÀ¸s

(¤@)I just got approved for Besremi! For those who have started on it recently, how is it going? Are side effects better on it as opposed to Peg? I¡¦ve been taking 27 mcg of Peg a week-not as effect as 45 but trying to keep the side effects to a tolerable level. How does that translate into the dosage of Besremi?

§Ú­è­èÀò±o Besremi ªº§å­ã¡I¹ï©ó¨º¨Ç³Ìªñ¶}©l¨Ï¥Î¥¦ªº¤H¨Ó»¡¡A¶i®i¦p¦ó¡H»P Peg ¬Û¤ñ¡A¥¦ªº°Æ§@¥Î¬O§_§ó¦n¡H§Ú¨C¶gªA¥Î 27 ·L§J Peg¡X¡X®ÄªG¤£¦p 45¡A¦ý¸Õ¹Ï±N°Æ§@¥Î«O«ù¦b¥i¥H§Ô¨üªº¤ô¥­¡C³o¦p¦óÂà¤Æ¬° Besremi ªº¾¯¶q¡H

(¤G)Me too! First dose tomorrow!

§Ú¤]¬O¡I©ú¤Ñ²Ä¤@¾¯¡I

(¤T)Does anyone know what the CIGNA ¡¨J-code¡¨ for BESREMi is? I¡¦ve an appointment with my doctor tomorrow for my first dose but they still don¡¦t know what the code or cost will be.

¦³½Öª¾¹D BESREMi ªº CIGNA ¡§J-code¡¨ ¬O¤°»ò¡H§Ú©ú¤Ñ©M§ÚªºÂå¥Í¹w¬ù¤F§Úªº²Ä¤@¾¯¡A¦ý¥L­Ì¤´µM¤£ª¾¹D¥N½X©Î¶O¥Î¬O¦h¤Ö¡C

(¥|)Feeling concerned¡K I¡¦m setting up to start Besremi (excited!)

·P¨ìÃö¤ß......§Ú¥¿¦b·Ç³Æ¶}©l Besremi¡]¿³¾Ä¡I¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/6 ¤U¤È 12:47:50²Ä 9965 ½g¦^À³
¤ß¬O©Z¿º¿ºªº«ç»ò·|©È¤H»¡©O¡H¤j¸s²Õ¤@¨¥°ó.....¤ß¸Ì¦³°­
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/1/6 ¤U¤È 12:44:23²Ä 9964 ½g¦^À³
Ãĵؤj¸s²Õ¦³285O¤H

¦³¤HÂà¶K¥ý¶i¤jªºµo¨¥

µ²ªG¬O³Q¬í§R

¨S³o¦^¬O?

¬°¤°»ò¦³¤Hı±o«Ü¨ë²´©O?

´N¤U­±³o½g

¤µ¤éÃĵØÃÄ12¤ëÀ禬Áٺ⤤¤W¡A¶i¨B¤¤.....³ºµM§Ë¥X¤@­Ó¶^°±

¬O¤£¬OÀ£»ù¤S·d¨p¶Òªº¤âªk¡A¯uªºÅý¥»¤H«ÜÃhºÃ¡A¨p¶Ò¬O§|±þ¤@¯ë§ë

¸ê¤H¹Ï§Q¥L¤Hªº¤âªk¡A³oÃĵØÃĤº³¡¸ò°­¨S¨â¼Ë¡AÄ~Äò¬Ý¤U¥h......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/1/6 ¤U¤È 12:28:18²Ä 9963 ½g¦^À³
¥ý¶i¤j¡ã§Ö¹L¦~¤F ¬O¦b»°¶i«×°Õ⋯⋯
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/6 ¤W¤È 10:46:58²Ä 9962 ½g¦^À³
¤µ¤éÃĵØÃÄ12¤ëÀ禬Áٺ⤤¤W¡A¶i¨B¤¤.....³ºµM§Ë¥X¤@­Ó¶^°±

¬O¤£¬OÀ£»ù¤S·d¨p¶Òªº¤âªk¡A¯uªºÅý¥»¤H«ÜÃhºÃ¡A¨p¶Ò¬O§|±þ¤@¯ë§ë

¸ê¤H¹Ï§Q¥L¤Hªº¤âªk¡A³oÃĵØÃĤº³¡¸ò°­¨S¨â¼Ë¡AÄ~Äò¬Ý¤U¥h......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/6 ¤W¤È 07:58:46²Ä 9961 ½g¦^À³
¸É¥R¸ê®Æ¡G(­Y¦³¿ù»~¡A¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç)¡C

¤@¡BUnitedHealthcare Oxford Policy Update Bulletin: January 2022

Policy Title¡GDrug Coverage Guidelines¡GBesremi (Ropeginterferon-Alfa-2b-Njft)

Status¡GRevised¡C

Effective Date¡GFeb. 1, 2022

UnitedHealthcare Oxford ¬Fµ¦§ó·s¤½§i¡G2022 ¦~ 1 ¤ë

¬Fµ¦¼ÐÃD¡GÃĪ«Âл\«ü«n¡GBesremi (Ropeginterferon-Alfa-2b-Njft)

ª¬ºA ¡G ­×­q¡C

¥Í®Ä¤é´Á¡G2022¦~2¤ë1¤é

mail.google.com/mail/u/0/?tab=rm&ogbl#inbox?projector=1

¤G¡BNALC Health Benefit Plan Specialty Drug List

Medication Name¡GBesremi

Prior Approval Required: YES

Medication Obtained through CVS Specialty *:µL¡C

Step Therapy ¡GµL¡C

NALC°·±dºÖ§Q­p¹º±M¬ìÃÄ«~¥Ø¿ý

ÃĪ«¦WºÙ ¡G Besremi

»Ý­n¨Æ¥ý§å­ã¡G¬O

³q¹L CVS ±M¬ìÀò±oªºÃĪ« *¡GµL¡C

¶¥±èÀøªk¡GµL¡C

doc-10-4k-apps-viewer.googleusercontent.com/viewer/secure/pdf/bbsdnmudv7bk969gc31mekr52aesn5oi/gr7vjqi33vj4v5sgoo6e8336op4hja7p/1641425850000/gmail/10341448784053036761/ACFrOgAiDb-4S8-_utVSWcGVm-zPaQJhNVtCDujjvtLIwJ62u2m7RJXWHomNEJSynAIvddoC9TOTRpkEiXH4dx2nN_kQTZ7PLHDWkISFva9seu2r0X93BIGTKo39DGc=?print=true&nonce=and2skjq49frm&user=10341448784053036761&hash=urt4v4nbeauuv9anhoej9frj7pdo7iak

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/6 ¤W¤È 06:52:24²Ä 9960 ½g¦^À³
¸ê®Æ¨Ó·½¡GMPN¬ÛÃöªÀ¸s

¤@¡BBESREMI UPDATE:

My hematologist sent my prescription to a pharmacy in Louisville, KY called Onco360. There, the pharmacists applied a grant to cover the entire cost of Besremi with a $0 co-pay. I received my first two vials in the mail yesterday, and it came with a large welcome packet, and some goodies from the pharmacy (lip balm, hand sanitizer, sunscreen, and lotion). I¡¦m waiting to begin injections until after I receive an eye exam (per instructions from my hematologist), but am so thankful I have this in my possession. If anyone with private insurance is waiting on coverage, PLEASE advocate with your pharmacy to see if you qualify for grant coverage like I apparently did. The pharmacy did not verify my income to make this available to me.

BESREMI §ó·s¡G§Úªº¦å²G¬ìÂå¥Í±N§Úªº³B¤è±Hµ¹¦ì©óªÖ¶ð°ò¦{¸ô©ö´µºûº¸ªº¤@®a¦W¬° Onco360 ªºÃĩСC¦b¨º¸Ì¡AÃľ¯®v¥Ó½Ð¤F¤@µ§ÃØ´Ú¡A¥H¤ä¥I 0 ¬ü¤¸ªº¦@¥IÃB¨Ó¤ä¥I Besremi ªº¥þ³¡¶O¥Î¡C¬Q¤Ñ§Ú¦¬¨ì¤F§Úªº«e¨â²~¶l¥ó¡A¸Ì­±¦³¤@­Ó«Ü¤jªºÅwªï¥]¡AÁÙ¦³¤@¨ÇÃĩЪº¦nªF¦è¡]¼í®B»I¡B¬~¤â²G¡B¨¾ÅÎÁ÷©M¨Å²G¡^¡C§Ú¥¿¦bµ¥«Ý±µ¨ü²´¬ìÀˬd¡]®Ú¾Ú§Úªº¦å²G¬ìÂå¥Íªº«ü¥Ü¡^¤§«á¤~¶}©lª`®g¡A¦ý§Ú«D±`·PÁ§ھ֦³³o­Ó¡C¦pªG¦³¨p¤H«OÀIªº¤H¥¿¦bµ¥«Ý©Ó«O¡A½Ð¦V±zªºÃĩЫŶǡA¬Ý¬Ý±z¬O§_¦³¸ê®æ¹³§Ú¤@¼ËÀò±o¸É§Uª÷©Ó«O½d³ò¡CÃĩШS¦³®Ö¹ê§Úªº¦¬¤J¨Ó´£¨Ñµ¹§Ú¡C

I just sent out my prescription yesterday. I¡¦m waiting on the approvals. Dr. Said it should take 2 weeks

§Ú¬Q¤Ñ­è±H¥X§Úªº³B¤è¡C§Ú¥¿¦bµ¥«Ý§å­ã¡CÂå¥Í»¡À³¸Ó»Ý­n 2 ¶g

Mine took two weeks as well. Good luck!¡¦

§Úªº¤]ªá¤F¨â¶g¡C¯¬§A¦n¹B¡I

¤G¡BBesremi Approval Saga - SUCCESS!

I am very pleased to report success in getting Besremi authorized by my Cigna Medicare Rx - Medicare Part D plan. The original denial contained the statement There are no conditions under which this request would be approved under Medicare part D. It took about 6 hours of repeated phone calls to various Cigna Departments but persistence overcame resistance.

For those is a similar circumstance, there are two things that seem to have worked to get past the initial denial and first level appeal denial.

1. I filed a formal Medicare Grievance due to Cigna not providing a copy of the Plan Rules on which the denial was based and denying access to Besremi.

2. I kept calling back to the Cigna Appeals division seeking the information needed to file an appeal. In my last call, the customer service representative identified that Cigna had made a mistake. They originally referred the appeal to an Administrative Review when this should have been a Medical Coverage Review. This should have been handled as a Formulary Coverage Review requesting authorization for a medication not on the formulary.

Cigna faxed a new appeal form to the doctor who prescribed the Besremi. When he contacted Cigna they told him it had already been approved. The doc called me to tell me and said the approval was not the result of anything they had done. Cigna contacted me moments later to notify me of the authorization.

The next step is for Biologics to contact me to arrange shipping. I have three doses of Pegasys left, which I will use up before starting the Besremi. I am planning to follow Dr. Mesa¡¦s recommendation for the starting dose for someone stable on 45mcg/week of Pegasys - 63mcg/every-other-week of Besremi. We will see how that goes. As it turns out the switch from Pegasys to Besremi was not researched so it really is going to be trial-and-error. I am fine with being a Beta-tester for doing the switch. It is the only way we will learn.

To all those who encounter denials of Besremi or any other medication needed to treat their MPN or other condition - do not give up! We may not always succeed due to persistence, but we will always fail when we do not persist. We must be our own best advocates.

All the best to all of you and continued success in accessing the care we all need and deserve.

Besremi §å­ã¶Ç©_ - ¦¨¥\¡I

§Ú«Ü°ª¿³¦a³ø§i Besremi ¤wÀò±o§Úªº Cigna Medicare Rx - Medicare Part D ­p¹ºªº±ÂÅv¡C³Ìªìªº©Úµ´¥]§t³o¼ËªºÁn©ú¡G¡§®Ú¾ÚÂåÀø«OÀI D ³¡¤À¡A¨S¦³¥ô¦ó±ø¥ó¥i¥H§å­ã¦¹½Ð¨D¡C¡¨ ªá¤F¤j¬ù 6 ­Ó¤p®É¤ÏÎ`¼·¥´ Cigna ¦U­Ó³¡ªùªº¹q¸Ü¡A¦ý°í«ù§JªA¤Fªý¤O¡C

¹ï©ó¨º¨ÇÃþ¦üªº±¡ªp¡A¦ü¥G¦³¨â¥ó¨Æ¥i¥H§JªAªì©l©Úµ´©M¤@¯Å¤W¶D©Úµ´¡C

1. ¥Ñ©ó Cigna ¥¼´£¨Ñ©Úµ´©Ò¨Ì¾Úªº­p¹º³W«h°Æ¥»¨Ã©Úµ´³X°Ý Besremi¡A§Ú´£¥æ¤F¥¿¦¡ªº Medicare ¥Ó¶D¡C

2. §Ú¤@ª½µ¹ Cigna ¤W¶D³¡ªù¥´¹q¸Ü¡A´M¨D´£¥X¤W¶D©Ò»Ýªº«H®§¡C¦b§Ú³Ì«á¤@¦¸³q¸Ü¤¤¡A«È¤áªA°È¥Nªíµo²{ Cigna ¥Ç¤F¤@­Ó¿ù»~¡C¥L­Ì³Ìªì±N¤W¶D´£¥æµ¹¦æ¬F¼f¬d¡A¦Ó³o¥»À³¬OÂåÀø«OÀI¼f¬d¡C³oÀ³¸Ó§@¬°³B¤èÃÄÂл\²v¼f¬d¨Ó³B²z¡A­n¨D¹ï¤£¦b³B¤èÃĮѤ¤ªºÃĪ«¶i¦æ±ÂÅv¡C

Cigna ¦V¶} Besremi ³B¤èªºÂå¥Í¶Ç¯u¤F¤@¥÷·sªº¤W¶Dªí¡C·í¥LÁpô Cigna ®É¡A¥L­Ì§i¶D¥L¥¦¤w¸gÀò±o§å­ã¡CÂå¥Í¥´¹q¸Ü§i¶D§Ú¡A¨Ã»¡§å­ã¤£¬O¥L­Ì©Ò°µªº¥ô¦ó¨Æ±¡ªºµ²ªG¡C¤£¤[¤§«á¡ACigna Ápô¤F§Ú¡A³qª¾§Ú±ÂÅv¡C

¤U¤@¨B¬O Biologics »P§ÚÁpô¥H¦w±Æ¹B¿é¡C§ÚÁٳѤT¾¯ Pegasys¡A§Ú±N¦b¶}©l Besremi ¤§«e¥Î§¹¡C§Ú­p¹º¿í´` Mesa ³Õ¤hªº«Øij¡A¹ï©ó 45 ·L§J/¶g Pegasys - 63 ·L§J/¹j¶g Besremi í©wªº¤Hªº°_©l¾¯¶q¡C§Ú­Ì±N¬Ý¨ì±¡ªp¦p¦ó¡C¨Æ¹êÃÒ©ú¡A±q Pegasys ¨ì Besremi ªºÂà´«¨Ã¥¼¸g¹L¬ã¨s¡A¦]¦¹½T¹ê»Ý­n¤Ï½Æ¸ÕÅç¡C§Ú«Ü°ª¿³¦¨¬°¶i¦æÂà´«ªº¡§Beta ´ú¸Õ¤H­û¡¨¡C³o¬O§Ú­Ì¾Ç²ßªº°ß¤@³~®|¡C

¹ï©ó©Ò¦³©Úµ´±µ¨ü Besremi ©ÎªvÀø MPN ©Î¨ä¥L¯e¯f©Ò»Ýªº¥ô¦ó¨ä¥LÃĪ«ªº¤H - ¤£­n©ñ±ó¡I§Ú­Ì¤£¤@©w·|¦]¬°°í«ù¦Ó¦¨¥\¡A¦ý¦pªG§Ú­Ì¤£°í«ù¡A§Ú­Ì±N¥Ã»·¥¢±Ñ¡C§Ú­Ì¥²¶·¦¨¬°¦Û¤v³Ì¦nªº¾ÖÅ@ªÌ¡C

¯¬¤j®a¤@¤Á¶¶§Q¡A¨Ã¦bÀò±o§Ú­Ì©Ò¦³¤H³£»Ý­n©MÀ³±oªºÅ@²z¤è­±Ä~Äò¨ú±o¦¨¥\¡C

Good luck and God bless you ! I¡¦m waiting to begin it very soon myself, it¡¦s been approved for me as well I have United Healthcare. My doctor appointment is 1/11. Hopefully I will get it soon after that . I¡¦m praying it helps me because I¡¦m on three hydrox. a day and my platelets are still 1.2 million.

¯¬§A¦n¹B¡A¤W«Ò«O¦ö§A¡I§Ú¥¿¦bµ¥«Ý¦Û¤v«Ü§Ö¶}©l¡A¥¦¤]¤w¬°§Ú§å­ã¡A§Ú¦³ United Healthcare¡C§ÚªºÂå¥Í¹w¬ù¬O 1/11¡C§Æ±æ¦b¨º¤§«á§Ú·|«Ü§Ö±o¨ì¥¦¡C§Ú¬è륦¹ï§Ú¦³À°§U¡A¦]¬°§Ú¥¿¦bªA¥Î¤Tßm¦âÓi¡C¤@¤Ñ§Úªº¦å¤pªOÁÙ¬O120¸U¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/5 ¤U¤È 05:28:47²Ä 9959 ½g¦^À³
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Type : Bid Notification

Due : 03 Jan, 2022 (1 day ago)

Posted : 1 month ago

Started : 14 Dec, 2021 (21 days ago)

P&T COMMITTEE MEETING: February 2022: The following drug classes/subclass will be reviewed: Besremi ¡V Oncological Agents ¡V Subclass

From: Federal Government (Federal)

°ê¨¾³¡ÃĩвΤ@³B¤è¤@Åó¤lÁʶR¨óij/²Î¤@³B¤èªþ¥[§é¦©­p¹º

Ãþ«¬¡G§ë¼Ð³qª¾

ºI¤î¤é´Á¡G 2022 ¦~ 1 ¤ë 3 ¤é¡]1 ¤Ñ«e¡^

µoªí¡G 1 ­Ó¤ë«e

¶}©l®É¶¡¡G 2021 ¦~ 12 ¤ë 14 ¤é¡]21 ¤Ñ«e¡^

P&T ©e­û·|·|ij¡G2022 ¦~ 2 ¤ë¡G±N¼f¬d¥H¤UÃĪ«Ãþ§O/¨ÈÃþ¡G Besremi ¡V ¸~½FÃĪ« ¡V ¨ÈÃþ¡G

¨Ó¦Û¡GÁp¨¹¬F©²¡]Áp¨¹¡^

www.instantmarkets.com/q/besremi?ot=Bid%20Notification,Pre-Bid%20Notification,Award,Contract&pg=1&c=us&os=Active,Archived&defaultSearch=true

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õÁ`²Î10135593  µoªí®É¶¡:2022/1/5 ¤U¤È 02:39:35²Ä 9958 ½g¦^À³
¤£¬O¨C­Ó¤H³£¬OÁo©ú¤H

¬Ý¦nÃĵØÂåÃĪº§ë¸ê¤H ©w¬O±M·~¤¤ªº±M·~

Àç·~ÃB©w¤ñ incy ¦n

¦h¤Ö©O °Ñ¦Ò¤W¦¸¬ü°ê¤ÀªR®v¹ï PTGX ªº¹w¦ô ¦Ó¥B P1101 ©w¯à¤ñ³oª÷ÃB°ª

¦]¬° PTGX¬O 1½u¥ÎÃÄ INCY¬O2½u ¦Ó P1101 ¬O¥þ½u¥ÎÃÄ

³o¼ËÀ´¤F»ò¶Ü ¦pªGÁÙ¤£À´´N¥h°Ý¶ý¶ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAronHsiao10139924  µoªí®É¶¡:2022/1/5 ¤U¤È 01:24:05²Ä 9957 ½g¦^À³
The scoop: PharmaEssentia¡¦s Besremi in November won approval to treat polycythemia vera, a rare disorder that slows blood flow and can cause clotting, heart attack and stroke. Besremi, which was co-developed by AOP Orphan of Austria and approved in Europe in 2019, is the first interferon treatment for the disease and the only drug that can be used for it regardless of treatment history. While Incyte¡¦s Jakafi is a second-line therapy, Besremi can be applied upon initial diagnosis. The drug, which was launched on Dec. 6, is injected every two weeks and if effective, injections can be reduced. The Taiwan-based company has priced it at $180,000 for an annual regimen. Yuanta projects Besremi will add 800 patients each year in the U.S. and increase sales each year by $100 million. PharmaEssentia has more in mind for Besremi as it is investigating its effectiveness against essential thrombocythemia, myelofibrosis and chronic hepatitis.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAronHsiao10139924  µoªí®É¶¡:2022/1/5 ¤U¤È 12:23:24²Ä 9956 ½g¦^À³
¦­¤W¬Ý¨ì¡A¦n¹³¬O°ê¤º¤¸¤jµoªíªº¡A°ê¤ºªk¤H¤@°ï²´¥úµu²L¤§¤H¡A±`±`¤£ª¾©Ò¤ª¡I

Ãĵجü°ê¹Î¶¤¬O·~¬Éµ×­^¡A¥[¤W¦³7.5¦~ªºÁ{§É¸ê®Æ¸òfda¥þ½u¥ÎÃĪº­I®Ñ¡A

Áٽ檺¤ñ¤G½uÃÄÁÙ®t¡H§Aı±o¥i¯à¶Ü¡H1­Ó¦h¤ëªº®É¶¡¡A«OÀI¤½¥q³°Äò¥[¤J²[»\¡A

³o2¤Ñ±qÀ禬´N¥i¥H¤@¿s¤@¤G¤F¡I¤£¾å±o§A¦p¦ó¬Ýªk

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/5 ¤W¤È 11:34:37²Ä 9955 ½g¦^À³
¸É¥R«OÀI¡G(¸ê®Æ­Y¦³»~¡A½Ð¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç)

¤@¡BCoordinated Care

BESREMI

Requirements/Limits ¡GPA

FORMULARY-CoordinatedCare_Washington.pdf

¤G¡BÃĵØÃľP°âÃB(«O¦u¬Ýªk?)

2021¡¦s NDA list includes some extraordinary accomplishments. Hitting a new record on approvals was just one

½âª÷ÄÝ2021 ¦~ªº NDA ²M³æ¥]¬A¤@¨Ç«D¤Zªº¦¨´N¡C³Ð¤U¼f§å·s¬ö¿ý¥u¬O¨ä¤¤¤§¤@

2022 ¦~ 1 ¤ë 4 ¤é

(ºK¿ý)

Company: PharmaEssentia Corporation

Price: $180,000 per year

Peak sales estimate: $900 million by 2030

Approval date: 11/12/2021

¤½¥q¡GPharmaEssentia Corporation

»ù®æ¡G¨C¦~ 180,000 ¬ü¤¸

³Ì°ª¾P°âÃB¦ô­p¡G¨ì 2030 ¦~¹F¨ì 9 »õ¬ü¤¸

§å­ã¤é´Á¡G11/12/2021

PharmaEssentia faces an entrenched competitor in the space, Incyte¡¦s Jakafi in the US, approved in 2014. Its second-line treatment status though may give Besremi an edge in the $1.1 billion PV market. Besremi does come with a black box warning though with risk of serious disorders from interferon alfa products including fatal or life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders. ¡X Beth Snyder Bulik¡C

PharmaEssentia ¦b¸Ó»â°ì­±Á{µÛ¤@­Ó®Ú²`¸¦©TªºÄvª§¹ï¤â¡A§Y¬ü°ê Incyte ªº Jakafi¡A¸Ó²£«~©ó 2014 ¦~Àò±o§å­ã¡C¤£¹L¡A¨ä¤G½uªvÀø¦a¦ì¥i¯à·|Åý Besremi ¦b»ù­È 11 »õ¬ü¤¸ªºPV¥«³õ¤¤¦û¾ÚÀu¶Õ¡CBesremi ½T¹ê±a¦³¶Â®Øĵ§i¡A¾¨ºÞ¤zÂZ¯À alfa ²£«~¦³¾É­PÄY­«¯e¯fªº­·ÀI¡A¥]¬A­P©R©Î¦M¤Î¥Í©Rªº¯«¸gºë¯«¯e¯f¡B¦Û¨­§K¬Ì©Ê¯e¯f¡B¯Ê¦å©Ê©M¶Ç¬V©Ê¯e¯f¡C¡X¨©µ·•´µ©`¼w•¥¬§Q§J

www.nxtmine.com/news/articles/base-metals/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/1/4 ¤U¤È 10:35:28²Ä 9954 ½g¦^À³
ÃĵØÃħä¤F´X­Ó¦W¤H´N·Q»´»´±a¹L¡H

±q90¤¸ªº¨p¶Ò¦Ü177¤¸³o¦¸ªº235¤¸¥h¬d¤@¤U¦W³æ

¦Ê¤À¤§¤»¤Q³£¬O¥_³¡¬Y¤W¤s­Ñ¼Ö³¡ªº¤H­û

«D¬O¬F°Ó¦W¬y©Î¥Í§Þ¬É¤H¤h©Î¥ø·~ ¦p¬O³o¼Ë¹ï¤½¥qªø»·µo®i¼ç¤O¦³À°§U

¦ý¬O´N¬O¤@¯ëªº°h¥ð¤H­û¡A¹ï¤½¥qÀç¹B¼vÅT¦³¦h¤jÀ°§U©M·N¸q¡H

µo­Ó¼s§i¤å¦w¼­¤pªÑªF´N·Q¥i¥H¦A¨Ó¤@¦¸¡H

Âû³J¦A±K¤]¬O¦³Á_¡A¤½¥q¬£§O¦Ñ·QµÛ¹Ï§Q©T©w¯S©w¤H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2022/1/4 ¤U¤È 09:58:16²Ä 9953 ½g¦^À³
ÃĵØÃÄ2¦¸¨p¶Ò¤j¦¨¥\ ¤k¯«±i¶vÚ¬¡B¥x¥_101¸³®y±i¾ÇµÏ³£°Ñ¥[

2022/01/04 19:27:48

¸gÀÙ¤é³ø °OªÌ¦ó¨q¬Â¡þ¥x¥_³ø¾É

·sÃĤWÂd¤½¥qÃĵØÃÄ¡]6446¡^¥h¦~12¤ë¡A¦b¤ëÀY¸ò¤ë§À¦U¿ì¤F¤@¦¸¨p¶Ò¡A¨â¦¸¨p¶Ò¤@¦@¶Ò¶°¨ì27.3»õ¦h¤¸ªº¸êª÷¡A¬Ý¦b¤£¤Ö±Mªù¨ó§U¥ø·~Äw¸êªº·|­p®v¡B«ß®v²´¤¤¡A°µ±o¬Û·íº}«G¡A¡uÃĵØÃÄ11¤ë¦b¬ü°ê¨ú±oÃÄÃÒ¡Aºò±µµÛ¦b12¤ë´N¦³¨â³õ¨p¶Ò¡A®É¶¡ÂI§ì±o«ê¨ì¦n³B¡Aºâ¬O¶Ò±o«Ü¦¨¥\¡I¡v

ÃĵØÃĦb¬ü°ê¨ú±oªºÃÄÃÒ¡A¬O±MªùªvÀø¡u¯u©Ê¬õ¦å²y¼W¦h¯g¡v¡]PV¡^·sÃÄRopeginterferon alfa-2b¡]P1101¡^¡A¥h¦~11¤ë13¤éÀò¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^®Ö¥i¤W¥«¡A¦¨¬°²Ä¤@­ÓÀòFDA®Ö­ãªºPV¤@½u¥ÎÃÄ¡C

ÃĵØÃĪñ¨ÓªÑ»ù¥i»¡¤Wºt¤jÅå©_¡A¥h(2021)¦~10¤ë7¤é¡AÃĵØÃĪѻù±q³Ì§C»ù69¤¸°_º¦¡A12¤ë14¤é´¿¨Ó¨ì422¤¸·s°ª»ù¡Aªñ¤T­Ó¤ë¨Ó¡AªÑ»ùº¦´T¤w¹F204%¡C¤µ¦~1¤ë3¤é³s°²«áªº¶}¤u­º¤é¡AªÑ»ù¥H264¤¸¶^°±§@¦¬¡A»á¦³¦^Àɸñ¶H¡A¦ý¬O¤´¦³¤£¤Ö¤H¬Ý¦nÃĵØÃĪº¥¼¨Ó¡C

2¦¸¨p¶Ò §l¤Þ¤£¤Ö¬F°Ó¦W¬y

®Ú¾Ú¤½¶}¸ê°TÆ[´ú¯¸¸ê®Æ¡A¤ñ¸ûÃĵØÃĪº¨â¦¸¨p¶Ò¡A¦³¤£¤Ö¬F°Ó¦W¬y°Ñ»P¨ä¤¤¡C²Ä¤@¦¸°Ñ»P¨p¶ÒªÌ¡A¥D­n¦³ÃĵØÃĸ³¨Æ»PªÑªF¡AÁÙ¦³ª¾¦WªA¸Ë³]­p®v½²©s®L»â­xªºÀs²Ã¹ê·~¡C

²Ä¤G¦¸¨p¶Ò¡A§ó¥i¬Ý¨ì¡A¥H­Ó¤H¦W¸q°ÑªÑªº¥x¥_101²{¥ô¸³¨Æªø±i¾ÇµÏ¡AÁÙ¦³¤k¯«¯Åºt­û±i¶vÚ¬¡A«e¹ü¤Æ¿¤ªø¨ô§B·½¡A¥H¤ÎÁé¤s§ë¸êªÑ¥÷¦³­­¤½¥q¡A³£°Ñ¥[¨p¶Ò¡CÁé¤sªº­t³d¤H¡A«h¬OµØ©T«Ø³]¡]2548¡^¸³®yÁéºa©÷¤§¤lÁé¨ô§g¡C

´¿¦h¦¸¨ó§U¥ø·~¨p¶Òªº«ß®vªí¥Ü¡A¤@¯ë¥ø·~¿ì¨p¶Ò¡A¦h·|¦hºÞ»ô¤UÁܬù§ë¸ê¤H¡A¦³¦W¤H¥[«ù¡A¹ï¤½¥q¨Ó»¡¡A¥i¥H³Ð³y¥úÀô®ÄÀ³¡C

¦Ü©óÃĵØÃÄ«h»¡¡A¸Ó¤½¥q¤£±Ä¤½¶}¶Ò¶°¡A¦Ó¬O¥Ñ¨p¶Ò¶Ò¸ê¡A¥D­n¬O¦Ò¶q¨p¶Ò¨ã®É®Ä©Ê»P«K§Q©Ê¡A¥B¨p¶Ò¦³»ùÃÒ¨é¤T¦~¤º¤£±o¦Û¥ÑÂàÅý¡A¯à½T«O¤½¥q»PÀ³¶Ò¤H¶¡ªºªø´ÁÃö«Y¡C

©È³QK¡H°êµo°òª÷°û©Ú°Ñ¥[¨p¶Ò

­È±oª`·Nªº¬O¡A­ì¥»ÃĵØÃÄÄÝ·N¤jªÑªF¤§¤@ªº°êµo°òª÷¡A¤]¨Ó°Ñ¥[¨p¶Ò¡A¦ý¬O´¿¸g¦n´X¦¸³Q¥ß©e®üK¡u¶Ã§ë¸ê¡vªº°êµo°òª÷¡A³o¦¸«o¬O«Ü§C½Õ¡A°û©Ú¤F³o¦¸¨p¶Ò¡C

°êµo°òª÷°õ¦æ¯µ®ÑĬ¨Ó¦u¦b±µ¨ü¡m¸gÀÙ¤é³ø¡n¬dÃҮɪí¥Ü¡A°êµo°òª÷¤w§ë¸êÃĵØÃij\¦h¦~¡A¥i»¡¡u¤½¥q¦¨¥ß´X¦~¡A°êµo°òª÷´N§ë¸ê´X¦~¡v¡A¦ý¦]¬°ÃĵØÃĤw¸g¤WÂd¡A¥i¥H¦Û¤v¤Þ¤J¥~³¡§ë¸ê¤H¡A¤£»Ý­n¬F©²¨ó§U¡A¨p¶Ò¦ÛµM¤]¯à§ä¨ì¯S©w§ë¸ê¤H¡A¬F©²À³¸ÓÀ°§U§ó»Ý­nªº¤½¥q¡A©Ò¥H°êµo°òª÷¥h¦~¨Ã¨S¦³°Ñ»PÃĵØÃĪº¨p¶Ò®×¡C

¦Ü©ó±i¾ÇµÏ¡A¦³ª¾±¡¤H¤hªí¥Ü¡A±i¾ÇµÏ¤j¤âµ§»{ªÑªñ1,000±i¡A­Y¥HÃĵØÃĪñ´ÁªÑ»ù¨Ó¬Ý¡A¤â¤WªÑ²¼¥«­È¯}»õ¡C¤£¹L¡A°Ñ»P¨p¶ÒªºªÑÅv¡A¤T¦~¤º¤£±o¶R½æ¡A±i¾ÇµÏºâ¬O§ë¸ê¤FÃĵØÃĤT¦~ªº¥¼¨Ó©Ê¡C

°]¬F³¡ªí¥Ü¡A±i¾ÇµÏÁö¬O¥H©xªÑ¥Nªí¨­¤À¾á¥ô¥x¥_101¸³®y¡A¦ý¥L¥H­Ó¤H¨­¤À°Ñ»P¨p¶Ò¡A¨Ã¤£¹Hªk¡C¡m¸gÀÙ¤é³ø¡n³z¹L¥x¥_101ªºµ¡¤f¡A¸ß°Ý±i¾ÇµÏ¬°¦ó­n°Ñ»PÃĵØÃĨp¶Ò¡AºI¦ÜºI½Z«e¡A³£¥¼¨ú±o±i¾ÇµÏ¦^À³¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õÁ`²Î10135593  µoªí®É¶¡:2022/1/4 ¤U¤È 02:09:52²Ä 9952 ½g¦^À³
¦pªG§A¦³¥Î¤ßÃö¤ß¹L¤½¥q ©Î³\§Aªº°ÝÃD´N¤£¬O°ÝÃD
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/4 ¤W¤È 11:46:55²Ä 9951 ½g¦^À³
Dreamtiger¤È¦w~¹ï©ó±zµL°í«ùÄ~Äò«ù¦³·P¨ì¥i±¤¡Aªø»·¨Ó¬ÝÃĵØÃīᥫÁÙ¬O²`¨ã«H¤ß¡A¦ý¤½¥q¬£¹ï¨p¶Ò¤@®×¤w¤Ó¦h¦¸ªº¬¢©T©w¤H¤h

¹ï©óªø´Á«ù¦³ªº­ì©lªÑªF¬O¶Ë®`¡A¤µ¤Ñ³o¿´¤j²î¤w±NÁÚ¤J¥¿­y¡AÀ³¦P¦à¦@ÀÙ¦³ºÖ¦@¨É¡AÃĵØÃÄ­Y¤z¦~«á¦³¬Õ¾l¡A¦AÀÀ¼·¤À¼í¼úª÷º¹½à

©Ò¦³¤½¥q­û¤u¡A©Ò¦³«ù¦³ÃĵØÃĪºªÑªF¤]¼Ö¨£¨ä¦¨¡A¦Ó«D¦b¨p¶Ò®×¤¤¹Ï§Q¡A«ØijÃĵØÃĤ½¥q¹ï©Ò¦³«ù¦³ªºªÑªF¤½¥­¹ï«Ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDreamtiger10145627  µoªí®É¶¡:2022/1/4 ¤W¤È 11:11:34²Ä 9950 ½g¦^À³
¸ò¤F³oª©5¦~¦h~µ²ªGÁÙ¬O§Ô¤£¦í·Q°µªi¬q¦Ó¤U¨®(½æ¨ì180-160¨º¬q¯}¤­¤é«æ±þ)...

µ²ªGªi¬q¨S°µ¨ì´N¦^¸É¤£¤F¡A¤j·§¬O¯d¤F¨º»ò¤[ÁÙ¨SÁȨ쪺¤Ö¼Æ¤H§a(­ú..

»¡»¡¬°¤°»ò·Q°µªi¬q

1.¦]¬°¸g¾ú¹L´X¦¸º¦¤W¨Ó,µM«á§é¥b»ù¡A¤W¦¸¦³µo¨¥°Ý¬°¤°»ò¼Ú¬w½æ¤@¦~¤F¡AÁÙ¬O¤@©uÁ«3¤¸ªºª¬ºA¡A¨S¿ìªkª¾¹D¾ã­Ó¤½¥qÀç¹B¬O§_ÁÈ¿ú¡A¯uªºÅý§Ú¹ï¤½¥q¤@ª½µo¥¬¦n®ø®§«o¤@ª½Á«¿ú²£¥ÍÃhºÃ¡Aµ²ªG½æ±¼¤F¹j¤Ñ´N¶]¥X¨Ó»¡¤S¥X³f¤F2»õ ORZ

2.¸òanderson¤j¤@¼Ë¡A¬Ý¦n³o¤äÃÄ¡A«o¤£¬Û«H°ª¼hªº¡A¤pªÑªF¹ê¦b·í­´µæ³Î

3.¨C¦¸§Q¦hº¦¤@ÂI´N·|¶^»ù«Ü²`¡A¨C¦¸¬Ý½u«¬ªi¬q«oÁÙ¬O©ê¨c¡A¶Ë®`«Ü¤j(¥u¦³³o¦¸ÃÄÃÒ¦³ª£°_¨Ó)~µ²ªG³o¦¸§Ú«o³Q¬~¤F¥X¥h

4.ÁÙ¦³¬Y¨Ç­ì¦]Åý§Ú§ó°í«H³Î­´µæªº¦s¦b

¹ï©ó³o¦¸³s¥ý¶i¤j³£§Ô¤£¦íªº©ê«è¡A¹ê¦b·PIJ«Ü²`¡A¦pªG¬Y¨Ç¤H¯à±Mª`¦bÃľ¯¬ãµo¸ò±À¾P¡A¤£­n¦Ñ¬O·QºÉ¿ìªk³Î­´µæ¡A

À³¸Ó¤£·|µo¥ÍAOPªº¨Æ¥ó¡A¤]¤£·|Åý¬Û«H¥LªºªÑªF³Ì«á³£¤j½|¦Ó¥h

³Ì«áÁÙ¬O¯¬¤j®a¯àÁȱo¤¤ªø§Q¯q~¤p§ÌµL¤O¦^¸É´N¯¬ºÖ§A­Ì..ÃÄ«e´º«Ü¦n¡A«o¬O°¦§¯ªÑ..

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/4 ¤W¤È 10:55:35²Ä 9949 ½g¦^À³
Besremi¥Ø«e¬ü°ê«OÀI±¡§Î¡G(¸ê®Æ­Y¦³»~¡A½Ð¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç)¡C

¤@¡BKaiser Permanente

BESREMI¡C

NOTE:µL¡C

wa.kaiserpermanente.org/static/pdf/public/formulary/largegroup-tier3-formulary.pdf

¤G¡BHealthPartners

BESREMI

LIMITS&RESTRICTIONS:PA

www.healthpartners.com/ucm/groups/public/@hp/@public/documents/documents/entry_218240.pdf

¤T¡BAnthem BlueCross

Besremi

NOTES&RESTRICTIONS: PA

client.formularynavigator.com/Search.aspx?siteCode=1227528522&targetScreen=3&drugBrandListBaseKey=besremi%2Bsubcutaneous%2Bsolution%2Bprefilled%2Bsyringe%2B500%2Bmcg%252fml&drugId=217171

¥|¡BHealth Alliance

BESREMI

NOTES:PA

www.healthalliance.org/documents/formulary/666/2022

¤­¡BBlueCross BlueShield

BESREMI

Additional Information: PA

fm.formularynavigator.com/FBO/68/BCBS_AZ_2022_Coinsurance_Member_.pdf

¤»¡BTUFTS HEALTH Plan

Besremi

Tier¡GNTM(New-to-Market)

Pharmacy Program¡GµL¡C

formularysearch.caremark.com/formularypdf/TuftsByTier_3.pdf

³Æµù¡G

PA(Prior Authorization):

You may need to get benefits approved before certain prescriptions can be filled.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gpete591410145259  µoªí®É¶¡:2022/1/3 ¤U¤È 11:10:18²Ä 9948 ½g¦^À³
ÃĵØÂåÃÄ

ÃĵØÃĨu¯f·sÃÄ ¯Ç¤J¬ü°ê³Ì¤j³sÂêÂå°|³Í·æÂåÀøµ¹¥I

money.udn.com/money/story/5613/6006945?from=edn_newestlist_rank

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gpete591410145259  µoªí®É¶¡:2022/1/3 ¤U¤È 10:51:28²Ä 9947 ½g¦^À³
ÃĵØÃĨu¯f·sÃÄ ¯Ç¤J¬ü°ê³Ì¤j³sÂêÂå°|³Í·æÂåÀøµ¹¥I

ÃĵØÃÄ¡]6446¡^¤µ¡]3¡^¤é±ß¶¡«Å¥¬¡AºX¤U·sÃÄRopeginterferon alfa-2b¡]©ÎP1101¡A¥H¤U²ºÙRopeg¡^¯Ç¤J¬ü°ê³Ì¤j³sÂêÂå°|³Í·æÂåÀø¶°¹Îµ¹¥I¡C

ÃĵØÂåÃĪí¥Ü¡A³Í·æÂåÀø¶°¹Î¡]Kaiser Permanente¡^¬O¬ü°ê³Ì¤jªº°]¹Îªk¤H³sÂêÂå°|¡A¾Ö¦³39¶¡Âå°|¤Î700¦h¶¡ÂåÀø¾÷ºc¡B¶W¹L30¸U¦W­û¤u¡A¨ä¤¤Âå®v¶W¹L2¸U¦W¡AÅ@²z®v¶W¹L6¸U¤H¡C³Í·æÂåÀø¶°¹Î¦b¬ü°êªºÀç¹B¾î¸ó¤K­Ó¦{¡]¥]¬A¥[¦{¡BµØ²±¹y¦{¡B¶ø°Ç©£¦{¡B¬ìù©Ô¦h¦{¡B®L«Â¦i¦{¡B³ìªv¨È¦{¡B°¨¨½Äõ¦{¤Îºû¦N¥§¨È¦{¡^¥H¤ÎµØ²±¹y¯S°Ï¡A¦b¥þ¬ü¾Ö¦³¶W¹L1,200¸U¦W·|­û¡C³o¨Ç¦{¦b¬ü°êÄÝ©ó¬Û¹ï´I¸Î¥B¦Ñ¦~¤H¤f¶°¤¤ªº¦{¡A³Í·æÂåÀø¶°¹Î¦b³o´X­Ó­«­nªº¦{¾Ö¦³«D±`¤j¼vÅT¤O¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/3 ¤U¤È 02:21:18²Ä 9946 ½g¦^À³
zh.wikipedia.org/wiki/%E7%BE%8E%E5%9C%8B%E8%99%95%E6%96%B9%E8%97%A5%E5%83%B9%E6%A0%BC#%E5%AD%A4%E5%85%92%E8%97%A5

©t¨àÃÄ

ÃÄ«~¤½¥q¥i¬°·sÃÄ¡A¯S§O¬O©t¨àÃÄ¡]¬ü°ê¹ï³oºØÃĪº©w¸q¬O¼vÅT¤£¨ì200,000¦W¨u¨£¯e¯f±wªÌ¨Ï¥ÎªºÃĪ«¡^©w»ù¡A»ù®æ°ª¨ì¤@¯ë­Ó¤HµL¤O¤ä¥I¡A¦Ó¥Ñ«OÀI¤½¥q©Î¬F©²¨Ó§@¥I´Ú¤H¡C°ê·|³q¹Lªº¡m1983¦~©t¨àÃĪk®×¡n¡]ODA¡^¡A¥Øªº¬O¿EÀyÃļt¬ã¨s¨u¨£¯e¯f¡A¶}µoªvÀø¨Ò¦p«á¤Ñ©ÊA«¬¦å¤Í¯f©M½¦½è¥À²Ó­M½FªºÃÄ«~¡C¦bODA¥ßªk¤§«e¡AFDA¦@§å­ã34ºØ©t¨àÃÄ¡C¦bODA³q¹L¤§«á¡AFDA¦bÀH«áªº¤Q¦~¤¤§å­ã500¦hºØ©t¨àÃÄ¡C¦¨¥\¹ê²{¼W¥[©t¨àÃĪº¥Ø¼Ð¡C©t¨àÃĤ@¦~ªº¨Ï¥Î¶O¥Î¥i¯à°ª¹F40¸U¬ü¤¸¡C¨Æ¹êÃÒ©ú¡AÃbÂ_©t¨àÃĬOÃļt¬Û·í¦³§Q¥i¹Ïªºµ¦²¤¡C¨u¨£¯e¯fªº±wªÌ¼Æ¥Ø¤£¤j¡A¦]¦¹µL»Ý¦bÀç¾P¤W§ë¤J¤jµ§¸êª÷¡A±wªÌ¤Ö¦³¨ä¥L¿ï¾Ü¡C¦¹¥~¡A¤j¦h¼Æ©t¨àÃÄ¡]93¢H¡^³£¥Ñ«OÀI¤½¥q¤ä¥I¡C­±¹ï¤£Â_ªº§åµû¡AÃļtªº°ªºÞ¬°³oºØ°µªkÅGÅ@¡A«ü¥X¥Ñ©ó°ª¦¨¥»¡A¥L­Ì¤½¥q¤~¯à°÷¬°·¥¤Ö¼Æ»Ý­n³oºØÃĪ«ªº±wªÌ¥Í²£ÃÄ«~¡A¦ý¤j¦h¼Æ¿©±w¨u¨£¯e¯fªº±wªÌ´X¥G¬O¤£»Ý­n±µ¨ü¥ô¦óªvÀø¡C

±Mª`¦b©t¨àÃĪº¬ãµo¡A¦³®É¤]·|¥H¥¢±Ñ¦¬³õ¡C¨Ò¦p¡AAlipogene tiparvovec¡]°Ó«~¦WGlybera¡^¬O¥Î©óªvÀø¨u¨£ªº¯×³J¥Õ¯×酶¯Ê¥F¿ò¶Ç¯fªºªºÃĪ«¡Aª`®g¤@¦¸»Ý­nªá¶O100¸U¬ü¤¸¡A¦ý¥Ñ©ó»Ý¨D¤£¨¬¦Ó³Q¤U¬[¡C¦ý¬O¡A¦³«Ü¦h°w¹ï©t¨àÃĪ«¶}µoªº¹ê¨Ò¡AÃÒ©ú¹ïÃļt¨Ó»¡¬OÀò§Q»áÂתº¼Ò¦¡¡C¨Ò¦p¡A¨È¤O¥S»sÃÄ©ó2007¦~±À¥XEculizumab¡]°Ó«~¦WSoliris¡]µÎ¥ß·ç¡^¡^¡A³o¶µÃÄ«~¥Î©óªvÀø¨u¨£ªº¦å²G¯fÅÜ¡C¨C¦W±wªÌ¨Ï¥ÎSolirisªº¶O¥Î¨C¦~¬ù¬°41¸U¬ü¤¸¡A§Y¨Ï±wªÌ¥u¦³9,000¤H¡A2016¦~ªºÁ`¾P°âÃB¤]¥i¹F¨ì28»õ¬ü¤¸¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2022/1/3 ¤W¤È 10:59:47²Ä 9945 ½g¦^À³
¬Ý©x¤j~ÀR«Ý¤½¥q¦p¦ó¿ì²z¡A§O«æ¡A»¡¤£©w°ª¼h¦ò¤ß¨Óªº¥Ñ¥þÅéªÑªF¼W¸ê»{ÁÊ¡A²q´ú·|¦b¹A¾ä¦~«e¤½¥¬§a
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2022/1/3 ¤W¤È 09:38:33²Ä 9944 ½g¦^À³
¤µ¦­¶^°±

¤½¥q«ç»ò¿ì²z¼W¸ê®×¡H¨p¶Ò¡H¥þÅéªÑªF¼W¸ê¡H

§Ú­ÌÀR«Ý¬Ý¤½¥q¾lÃB3¸U6¥a¦h±i¦p¦ó³B²z

°²³]ÁÙ¬O¥Î¨p¶Ò¤S¬O¦P¨º¤@²¼¤Hª«

¦b³ø½ÐÃÒºÞ·|¬d©ú¨º¨Ç¤H­û¬O§_¦³¹Ï§Q²{¶H¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2022/1/1 ¤U¤È 09:30:28²Ä 9943 ½g¦^À³
ÃĵجO¦nªÑ²¼¡A

ªø´Á¦b³o¸Ì¯Ñ¯Ð³£ª¾¹D¥¦ªº¦n¡A

«Ü©¯¹B¦³³o¨Ç¦P¦n¤À¨É¸ê®Æ¡C

¯¬¤j®a¥¼¨Ó´X¦~³£¯à¤~´I¦Û¥Ñ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/1 ¤U¤È 05:48:32²Ä 9942 ½g¦^À³
3 Reasons to Add McKesson (MCK) Stock to Your Portfolio

±N McKesson (MCK) ªÑ²¼²K¥[¨ì±zªº§ë¸ê²Õ¦Xªº 3 ­Ó²z¥Ñ

By Zacks Equity Research December 31, 2021

(¸`¿ý)

Strength in Biologics: Investors are optimistic about McKesson¡¦s robust Biologics business. Independent specialty pharmacy, Biologics by McKesson, has been making impressive progress of late. This month, the pharmacy was selected by PharmaEssentia USA Corporation as a specialty pharmacy provider of BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera.

¥Íª«»s¾¯ªºÀu¶Õ¡G§ë¸êªÌ¹ï McKesson ±j«lªº¥Íª«»s¾¯·~°È«ù¼ÖÆ[ºA«×¡C¿W¥ß±M·~ÃÄ©Ð Biologics by McKesson ³Ìªñ¨ú±o¤F¥O¤HÆf¥Øªº¶i®i¡C¥»¤ë¡A¸ÓÃĩгQ PharmaEssentia USA Corporation ¿ï¬° BESREMi¡]ropeginterferon alfa-2b-njft¡^ªº±M·~ÃĩШÑÀ³°Ó¡A¥Î©óªvÀø¦¨¤H¯u©Ê¬õ²Ó­M¼W¦h¯g¡C

www.entrepreneur.com/article/410999

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­¸¯T10148959  µoªí®É¶¡:2022/1/1 ¤U¤È 03:17:40²Ä 9941 ½g¦^À³
ÁÂÁ¤p¥¿¥¿¤j¤À¨É

¸ê®ÆÅã¥Ü¥Ñ©ó¬Ì±¡ FDA¥Ø«e¹ï©ó°ê¥~¬d¼t°ò¥»¤W¬O°±Â\ªº

ÃĵØÃįà¦b2021¦~¤´¯àÀòFDA­u¥~°ê¬d¼t¡A¨Ã¨ú±oÃÄÃÒ¡AÀ³¸Ó¬O¹ï­«¤j¯e¯f¤@½u¥Î·sÃĪº¯S§O«Ý¹J

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2022/1/1 ¤U¤È 01:45:15²Ä 9940 ½g¦^À³
¡¯¡¯¸ê®Æ­Y¦³¤Þ­z¿ù»~¡A½Ð¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç¡C

¡¯¡¯½g´T¹Lªø¡A½Ð¿ï¾Ü¬O§_¾\Ū¡A¥H§K®ö¶OÄ_¶Q®É¶¡¡C

¡¯¡¯¤U­z¸ê®Æ¡A¶È¨Ñ°Ñ¦Ò¡A­YµL°Ñ¦Ò»ù­È©Î½×­z¿ù»~¡A½Ð·í¯º¸Ü¤@1«h¡C

ÁÂÁÂ!!

¡¯¡¯°ÝÃD¡G·s»D¸ê®Æ¦^ÅU

¤@¡BÃĵØÃĦ۱q2021¦~11¤ë13¤é¨ú±o¬ü°êFDAÃÄÃÒ«á¡A¬ü°êPVº¯³z²v¸Û¦p

¤½¥q©Ò¨¥¡APV±wªÌªº«OÀIÂл\°·¥þ¡AP1101®Ö­ã²Ä¤@¤Ñ¶}©l´N¥i¥H«OÀIµ¹¥I¡AÃĵØÃĹw­p¦b6­Ó¤ë¤º¦³80%ªº«OÀIÂл\²v¡C¥B¥iªvÀø¹O8¸U¦W¯f±w¡C¼ÖÆ[ªº¸Ü¥i¹F10¸U¤H¡C

(°ÝÃD¡G6­Ó¤ë¤º¦³80%ªº«OÀIÂл\²v¡A¯f±w¼Æ¬O´X¤H?¡F¥BªvÀø¹O8¸U¦W¯f±w¡A¬ù´X¦~¹F¦¨?¡F¼ÖÆ[ªº¸Ü¥i¹F10¸U¤H¡A´X¦~¹F¦¨?)

¤G¡BÃĵØÃĬݦn¡A¸Ó·sÃĬü°ê FDA ®Ö­ãªº¥é³æ¨Ï¥Î½d³ò¸û¼Ú·ù¼s¡A©Ò¦³¯u©Ê¬õ¦å²y¼W¦h¯g (PV) ¦¨¤H¯f±w§¡¥i¨Ï¥Î¡A¥B»ù®æ¤ñ³Ì¤jÄvª§ÃÄ«~ jakafi §ó¨ãÄvª§¤O¡Aº¯³z²v±NÀu©óÄvª§¹ï¤â¡C¬ü°êÃļt Incyte ¶}µoªº jakafi¡A¸ÓÃÄ«~¬° PV ¤G½u¥ÎÃÄ¡A¤W¥«­º¦~ªvÀø 800 ¦W¯f±w¡A¤W¥««á²Ä 7 ¦~¬ü°ê¾P°âÃB¹F¨ì 10 »õ¬ü¤¸¡A¨ÃªvÀø¶W¹L¸U¤H¡AÃĵØÃÄ»{¬°¡ABESREMi ©ó¬ü°ê¤W¥«­º¦~ªº¯f±w¼Æ¡A±N¶W¹L jakafi¡C

(°ÝÃD¡G²Ä¤@¦~¯f±w¼Æ¡A¥i¹F´X¤H?¡F¦ó®É¥i¹F10 »õ¬ü¤¸?)

¤T¡B¥H¤W°ÝÃD¡A¥i¯à¦³¿àÃĵØÃĬü°ê¤½¥q¹Î¶¤§V¤O¡A¾¨¦­§V¤O¹F¦¨¡C

(¬ü°ê·~°ÈÁ`¸g²z±ö¹p­}«ä•°Ò¹ç (Meredith Manning) ²¦·~©óªÛ¥[­ô¤j¾Ç¥¬´µ°Ó¾Ç°|¡A¾Ö¦³¤G¤Q¦~¦b¬ü°ê³»¯Å»sÃĤ½¥q¾á¥ô²£«~¾Ô²¤±M®aªº¸gÅç¡C¦o­t³d¼Æ¤Q»õ¬ü¤¸ªº²£«~½u¡A¨Ã´¿¦b¤K­Ó¤ë¤º¦¨¥\¹ê²{¤@¶µ·sÃĸ겣ªº¾P°âÃB¹F 10 »õ¬ü¤¸¡C)

¡¯¡¯°ÝÃD¡GBesremi¬ü°êº¯³z²v?

­Ó¤H¹ï¬ü°êº¯³z²v«ù¼ÖÆ[ºA«×¡A¤£¹L¶È¬O­Ó¤H«H¥õ»PÁr´ú¡A¨ÃµL¥ô¦ó§â

´¤¡A¤U¦C½×­z¡A¶È¨Ñ°Ñ¦Ò¡A­YµL°Ñ¦Ò»ù­È©Î½×­z¿ù»~¡A½Ð·í¯º¸Ü¤@«h:

¤@¡B±q¬ÛÃöMPNªÀ¸sºô¯¸¡APV¯f±w¨Ï¥ÎBesremi·NÄ@°ª¡A«OÀI°ÝÃD¤´¦b§V¤O¤¤©Î³°ÄòÀò±o¸Ñ¨M¡C¸`¿ýªñ¤G¤ÑPV¯f±wªº½Í¸Ü¡G

(±©MPN¬ÛÃöªÀ¸sºô¯¸¥À¸sÅé¼Æ¶È¬O­Ó®×¡A¬O§_¦³¥Nªí©Ê?)

(¤@)Wow! I hope I can get my insurance to approve it! But I will still have to come up with the first $10,000 for my yearly deductible.

«z¡I§Ú§Æ±æ§Ú¯à±o¨ì§Úªº«OÀI§å­ã¡I¦ý¬O§Ú¤´µM»Ý­n¬°§Úªº¦~«×§K½ßÃB®³¥X²Ä¤@µ§ 10,000 ¬ü¤¸¡C

(¤G)My insurance approved Besremi for PV. (I know not everyone has been able to get it approved and I hope they can.)

§Úªº«OÀI¤½¥q§å­ã Besremi ¥Î©ó PV¡C¡]§Úª¾¹D¤£¬O¨C­Ó¤H³£¯àÀò±o§å­ã¡A§Ú§Æ±æ¥L­Ì¥i¥H¡C¡^

(¤T)PAN Foundation has approved Besremi¡Cjust had to share that my grant was accepted and will be starting BESREMI in January! My oncologist is as thrilled as me!

PAN °òª÷·|¤w§å­ã Besremi¡C­è­è¤À¨É§Úªº¸ê§U¤w³Q±µ¨ü¡A¨Ã±N¦b 1 ¤ë¥÷±Ò°Ê BESREMI¡I§Úªº¸~½F¬ìÂå¥Í©M§Ú¤@¼Ë¿E°Ê¡I

So PAN is now covering Besremi?

©Ò¥HPAN²{¦bÂл\Besremi¡H

Yes.

¬Oªº¡C

(¥|)My Besremi was approved and being delivered next week. I¡¦m so nervous! Has anyone else starting it?

§Úªº Besremi ¤wÀò§å¨Ã©ó¤U¶g¥æ¥I¡C§Ú¦nºò±i¡I¦³¨ä¥L¤H¶}©l¶Ü¡H

(¤­)Mine¡¦s still stuck at $6k per month. I need to work quickly with my hematologist to get the price down considerably before I can access it. Good luck to you!!

§Úªº¤´µM°±¯d¦b¨C¤ë 6,000 ¬ü¤¸¡C§Ú»Ý­n»P§Úªº¦å²G¬ìÂå¥Í¨³³t¦X§@¡A¦b§ÚÀò±o¥¦¤§«e¤j´T­°§C»ù®æ¡C¯¬§A¦n¹B ¡I¡I

(¤»)I¡¦m still waiting¡K good luck!¡C

§ÚÁÙ¦bµ¥¡K¡K¯¬§A¦n¹B¡I

(¤C)Hoping to have that myself soon.

§Æ±æ¦Û¤v¦­¤é¾Ö¦³¡C

(¤K)I just got the phone call I¡¦m being switched

§Ú­è±µ¨ì¹q¸Ü§Ú¥i¥HÂà´«¤F¡C

(¤E)I¡¦m hoping to get it soon.

§Ú§Æ±æºÉ§Ö±o¨ì¥¦¡C

¤G¡BBesremi V.S. Pegasys®

(¤@) Pegasys®¬ü°ê¦ó®É°±²£©Î°±¤î¨ÑÀ³¡A­Ó¤H¬dµL½T¤Á¤é´Á¡A±©Pegasys®§Y©Ò¿×off label ¨Ï¥Î¡AÂå¥Í¥²¶·¥ý¼x±o¯f¤H©MÂå«Oªº¦P·N¤~¯à¤UÃÄ¡A¦P®ÉÂå¥Í¦Û¤v¤]¥²¶·©Ó¾á¦h¤@¼hªº¹D¼w©MÂåÀø³d¥ô¡C¦P®É¡A¨Ã¥B¦b¬ü°ê¡AÂå¥Í§A毎¤Ñ¹ï¯f¤H©Ò»¡¨C¥y¸Ü¡A©Ò°µªº¨C¥ó¨Æ¡A³£¥²¶·°µ¦n¦³¤@¤Ñ¦bªk®x¤W¬°¦Û¤vªº¦æ¬°©M«áªGÅGÅ@ªº·Ç³Æ¡C¬ü°ê¦³¥@¬É¤W³Ì¦hªº«ß®v¡A¥L­ÌµL¤Õ¤£¤J¡A¬JÄ@·N¬°´I¤H¥´©x¥q¡A¤]¼Ö·N¬°½a¤H¥´©x¥q¡C¥I¤£°_«ß®v¶O¨SÃö«Y¡A©x¥q¿é¤F¤£­n¿ú¡A©x¥qŤF¦A¤À¦¨¡CÂå¥Í¥i¿×À£¤O¤j¡C

(¤G) Ruben Mesa©ó10 facts MPN patients need to know about FDA approval of Ropegylated interferon alpha2b (Besremi)¼v¤ù°ÝÃD8´£¤Î¡A­Y¨Ï¥Î¥½ÀòFDA®Ö­ãªº¤zÂZ¯ÀªvÀø®ÄªG¤£¨Î¡A±j¯P¦Ò¼{¡ustronger consideration¡vÂà´«¦Ü(Besremi)¡CPegasys®¨ÃµL¨ú±oFDAÃÄÃÒ¡AÂå¥Í¨Ï¥Î¤zÂZ¯ÀªvÀøPV­º¿ï¡AÀ³¬O¦³ÃÄÃÒBesremi¡ABesremi¨ú¥NPegasys®¬O¦­±ßªº°ÝÃD¡C

¤T¡BBesremi V.S. jakafi

(¤@)Besremi »Pjakafi»ù®æ¬Û¦ü¡A±©Besremi¬O¤@½u¥ÎÃÄ¡Bjakafi¬O¤G½u¥Î

ÃÄ¡ABesremi¦ÛµM¨ã¦³§¹¥þÄvª§¤O¡C

(¤G)ªp¥B¡AFDA«ü¥XBesremi¦b¨Ï¥Î¤@¦~«á¥i¥H´î¤Ö¦h¾lªº¦å²Ó­M¨Ã«O«ù¥¿±`

¤ô¥­¦Ü¤Ö¤@¦~¡A¨º»òµ¹ÃÄÀW²v¥i¯à·|´î¤Ö¨ì¨C¥|­Ó¬P´Á¤@¦¸¡A²Ä2¦~°_¨C¤ë1

°w¡A¬ù13°w¡A»ù®æ¦ÛµM´î¥b¡A¥B¦³ªv¡¥i¯à¡A´N«OÀI¤½¥q¸gÀÙ¦¨¥»®Ä¯q¦Ò¶q¡A

·íµM¿ï¾ÜBesremi¡C

¥|¡BBesremi V.S. HU

°Ñ·Ó¡G(QIC¼e¶q°ê»Ú»PCEO¹ï½Í²Ä¤G¤Q¤­´Á¡GMeredith Manning¤k¤h)

Q¡G¥Ø«e HU ³Q¼sªx¥Î©óªvÀø¤@½u PV¡A¨Ã¥B¤ñ BESREMi® «K©y¡C¬°¤°»ò«OÀI¤½¥q­n¤ä«ù BESREMi®¡H

M¡GÁöµM¦¨¥»¬O¤@­Ó­«­n°Ñ¼Æ¡A¦ý«OÀI¤½¥q¤]©ú¥ÕÀ³¸Ó©Ó«O¨ã¦³©ú½TÁ{§É¯q³Bªº²£«~¡C¥I´Ú¤H§Æ±æ½T«O¥L­Ì§ë¸êªº²£«~¹ï¥L­Ìªº±wªÌ¸sÅ馳¯q¡C§Ú­Ìªº¤u§@¬O¦V¥I´Ú¤H¶Ç¹F BESREMi® ±N¬°¥L­Ìªº±wªÌ¸sÅé±a¨Ó¤°»ò¦n³B¡C³o¬O¤@ºØªø´Á¯e¯f¡A¦]¦¹¥I´Ú¤H§óÄ@·N¬°¥i¥Hªø´Á±±¨î¯e¯fªº²£«~¥I´Ú¡CHU ¹ê»Ú¤W¤£¬O FDA §å­ãªº PV ÃĪ«¡AÁöµM¥¦«Ü«K©y¡A¦ý±q²{¹ê¥@¬Éªº¼Æ¾Ú¤¤¥i¥H²M·¡¦a¬Ý¥X¡A±wªÌªº¦å²Ó­M­p¼Æ¤£¨ü±±¨î¡C§Y¨Ï¥¦«Ü«K©y¡A¦pªG¥¦¤£°_§@¥Î¡A¬°¤°»ò¦³¤H­n¥I¶O©O¡H

¤­¡Bºî¤W¡GBesremi¦³¥i¯à³q¦YPV¥«³õ¡A­È±o´Á«Ý¡A¦ý§Æ±æ¾¨¦­¹F¦¨¡C¦P®É¡AªÑ»ù¾¨¦­¹F¨ì¥ý¶i¤j¤§«e¼ÐÃDªº¥Ø¼Ð»ù¡A¦­¤é¹F¦¨°]°È¦Û¥Ñ¡C

¡¯¡¯³Æµù¡G

·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2021/12/31 ¤U¤È 02:50:20²Ä 9939 ½g¦^À³
3 Top Growth Stocks to Consider Buying in January

¤¸¤ë¥÷¦Ò¼{ÁʶRªº 3 ¤äº¦¶Õ³Ì¨ÎªºªÑ²¼

By Priyanka Mandal

Dec 29, 2021

(ºK¿ý)

ÁöµM³q¼ê¤W¤É©M omicron «aª¬¯f¬rÅܺتº«ùÄò¶Ç¼½¡A¹w­p·|Åý§ë¸êªÌ·P¨ì¾á¼~¡A¦ý°²¤é¾P°â³Ð¬ö¿ýªº¼Wªø©M±j«lªº®ø¶OªÌ«H¤ßÀ³¸Ó·|¤ä¼µ°ò·Ç«ü¼Æ¡C¦]¦¹¡A¾Ö¦³Ã­°·¼WªøÄݩʪº S&P Global (SPGI)¡BSynopsys (SNPS) ©M Veeva Systems (VEEV) ²{¦b¥i¯à¬O²z·Qªº§ë¸ê¡C

Veeva Systems Inc. ( VEEV -Àò±oµû¯Å)

VEEV ¦¨¥ß©ó 2007 ¦~¡A¬°¥_¬ü¡B¼Ú¬w¡B¨È¤Ó¦a°Ï¡B¤¤ªF¡B«D¬w©M©Ô¤B¬ü¬wªº¥Í©R¬ì¾Ç¦æ·~´£¨Ñ°ò©ó¶³ªº³n¥ó¡C¸Ó¤½¥qªº¸Ñ¨M¤è®×¥]¬A¶³³n¥ó¡B¼Æ¾Ú©M·~°È¿Ô¸ß¡CVEEV ¬°¥Í©R¬ì¾Ç¦æ·~´£¨Ñªº¦æ·~¶³¸Ñ¨M¤è®×¤À¬°¨â­Ó²£«~»â°ì¡GVeeva Commercial Cloud ©M Veeva Vault¡C

¥»¤ë¡A¥Íª«§Þ³N¤½¥q PharmaEssentia ±Ä¥Î VEEV ªº¼Æ¾Ú¤ª¨Ó¤ä«ù BESREMi ªº±À¥X¡A³o¬O¤@ºØªvÀø¨u¨£¦åÀù¯u©Ê¬õ²Ó­M¼W¦h¯g (PV) ªº·sÀøªk¡C­É§U¼Æ¾Ú¤ª¡AVEEV À³³q¹L¦hºØ°Ó·~¤ÀªR©M¹BÀç¤u§@¬yµ{¤ä«ù PharmaEssentia¡A¥H«K¤½¥q¥i¥H§ó¦n¦a´N¨ä­«­nªº·sªvÀø¤è®×¹ïÃöÁä HCP ¶i¦æ±Ð¨|¡C

stocknews.com/news/spgi-snps-veev-3-top-growth-stocks-to-consider-buying-in-january/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2021/12/29 ¤W¤È 11:28:15²Ä 9938 ½g¦^À³
§Ú¤]¬O¦]¥ý¶i¤j¹ïÃĵز£«~ªºÁA¸Ñ»P«H¤ß¤~¤ä«ù¨ì²{¦b

µM¦Ó¹ï³o2¦¸¡]«e´X¦¸¤]¬O¡^¨p¶Ò¹ï¶H¨Ã«D§¹¥þ¬O¤½¥q¬£ ¦³¨Ç¤H¨Ã¤£¬O¡I

¾Ú§ÚªB¤ÍÁA¸Ñ§iª¾±¡ªp¬O³o¨Ç«D¤½¥q¬£¯S©w¤H¥u¬O¦b¥_³¡¬Y¤s°Ï­Ñ¼Ö³¡¦¨­ûªÑªF¦Ó¤w

¦p¦¹³o¯ë¨p¤ß¾Þ§@¯àÅý¤H¤£·P¨ì¿ò¾Ñ¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/29 ¤W¤È 10:15:35²Ä 9937 ½g¦^À³
¹ï©óÃĵØÃĨp¶Ò®×§ä©T©w¯S©w¤H¡A¹Ï§Q©~¦h§@·~¬yµ{¤]¤j·§³£¤F¸Ñ¡A»·¤ñ§A­Ì·Q¹³¤¤ªº¦h¡A¤£·QÁ¿¤Ó¦h¤Ó©ú¥Õ

²³æ»¡¨p¶Ò®×§ä­ì¨º¨Ç©T©w¯S©w¤H¡A¹ïªÑ»ù¼vÅT«Ü¤j¡A¸T¤î¦A¨p¶ÒºûÅ@¥þÅé¤pªÑªFÅv¯q´N¹ï¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/29 ¤W¤È 10:00:34²Ä 9936 ½g¦^À³
¹ï©óÃĵØÃĨp¶Ò®×§ä©T©w¯S©w¤H¡A¹Ï§Q©~¦h§@·~¬yµ{¤]¤j·§³£¤F¸Ñ¡A»·¤ñ§A­Ì·Q¹³¤¤ªº¦h¡A¤£·QÁ¿¤Ó¦h¤Ó©ú¥Õ

²³æ»¡¨p¶Ò®×§ä­ì¨º¨Ç©T©w¯S©w¤H¡A¹ïªÑ»ù¼vÅT«Ü¤j¡A¸T¤î¦A¨p¶ÒºûÅ@¥þÅé¤pªÑÅv¯q´N¹ï¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GYiHong10143518  µoªí®É¶¡:2021/12/29 ¤W¤È 09:12:57²Ä 9935 ½g¦^À³
¹ï©ó¥ý¶i»P¬Ý©x¤j¨p¶Òªº¬Ýªk¡A¤p§Ì·Qµoªí¤@¤U¦Û¤vªº¬Ýªk¡C

¦Û¤v¤»¦~«e¶}©l§ë¸ê¡A¤]¬O¬ÝµÛ¥ý¶i¤j¸ê°T»P¤ä«ù¨«¹L¨Ó¡Aª¾¹D¥ý¶i¤j¬O¬°¤F§Ú­Ì³o¨Ç¦ÑªÑªF³]·Q¡C

¦ý¹ï©ó³o¦¸¨p¶Ò¨ä¹êı±oÁÙ¥i¥H±µ¨ü¡A­ì¦]¦³¤TÂI:

1. ¦Û¤v»P®a¤H¨ä¹ê¦b¦­´Á70 - 209´Á¶¡³£¦³¶R¤J¡A§Ú­Ì³oºØ´²¤á¥i¥H¶R­Ó¤@¤G¤Q±i¸êª÷¤]®t¤£¦h¡A´N³s¤§«eªº¼W¸ê802ªÑ¤]¬O¬Ù¦Y»ü¥Î´ê¥X¨Óªº¡A¥»¨­¨S¦³¤°»ò¦h¾l¸êª÷¡A¦]¦¹¥H²{¦bªºªÑ»ù¼W¸ê177©ÎªÌ235»ù®æ¹ï§Ú­Ì¨Ó»¡°Ñ¥[·NÄ@¤£°ª¡A¦¹¥~¤½¶}¼W¸ê¬O¤£¬O©Òªáªº®É¶¡·|¤ñ¸ûªø¡A¥Ø«e­Ó¤H·Pı¤½¥q»Ý­n¤@µ§¸êª÷¬O¥¼¨ÓºÉ§Ö¶i¤J¤U­Ó¶¥¬q¡A¨Ò¦p:¸Ñ°£¥þÃB¥æ³Î...¤§Ãþ(±À´ú)¡C

2. ¨p¶Ò¹ï¶HÁöµM¤j³¡¤À³£¬O¤½¥q¤º³¡¤H¡A¹Ï§Q¨ì¤½¥q¬£¤H­û¡A¦ý¦³¨Ç°Q½×ª©¦³¤@­Ó»¡ªk¦Û¤v¥»¨­Ä±±o¥i¯à©Ê¬Û·í°ª¡A¬°¤F¾d©T¤½¥q¬£ªºªÑÅv¡C¦Û¤v«á¨Ó·Q¤F¤@¤U¡A¦pªG³o¤­¸U±i¨p¶Ò³£¬Oµ¹¥~¤H¡A©¹«áÁÙ¦³¬F©²ªÑ²¼·|ÄÀ¥X¬ù¨â¤T¸U±i¡A³o¼Ë¤½¥q¬£ªº¤H­ûªÑÅv¥²µM·|¨ü¨ì¤@©wªº«Â¯Ù¡A¤@­Ó¤½¥qªº¤j¤áªÑªF³£Ä@·N¤ä«ù¡A¤Ï¦Ó¹ï§Ú­Ì¨Ó»¡¬O¤@ºØ«ü¼Ð¡A½T©w¤½¥q¤w¸g©¹§ó¦nªº¤è¦Vµo®i¡C

3. ²Ä¤TÂI¬O°w¹ï¬O§_¦³Â´«·sªº¶ûºÃ¡A­Ó¤H¦³°µ¤F¤@¨ÇÄw½X¤ÀªR¡A²Ä¤@¦¸¨p¶Ò®Éªº½T¦³Â´«·sªº¶ûºÃ¡A¦ý²Ä¤G¦¸¬Ý¨ìªº²{¶H¤Ï¦Ó¬O§l¦¬¥~¸êªºÄw½X¡A¦Û¤vªº¤ÀªR¤W¨ÃµL´«·sªº¼x¥ü»P²Ä¤GÂI©IÀ³¡C

¥H¤W¤TÂI¬O§Ú³o¨â­Ó¤ë¬Ý¤F³\¦h¸ê°T»P¦Û¤vªº¤@¨Ç¤ÀªR±o¨ìªº¤ß±o¡C

¦³¤°»ò¤£¦Pªº¬Ýªk³£Åwªï´£¥X¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10148182  µoªí®É¶¡:2021/12/29 ¤W¤È 09:02:43²Ä 9934 ½g¦^À³
¤jªÑªF.¬F©²..°êµo·|- 22,066±i... 8.36%

³£¦P·N..ÃÒºÞ·|·|¬d¶Ü

¤½¶}¦VªÑªF¼W¸ê...°êµo·|©ñ±ó..¬¢¯S©w¤H

µ²ªG¤@¼Ë

¦n³B..¨p¶Ò..º¡¤T¦~«á©l±o¦Û¥ÑÂàÅý

¤T¦~¥«³õ...Äw½X¤£¼W¥[

¨p¶Ò..²Ä1¦¸177¤¸..²Ä2¦¸...235¤¸

¥Nªí¤jªÑªF..¹ïÃĵØÃĪº«á¶Õ...ªø¦h¬Ýªk

¦@«j¤§

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2021/12/29 ¤W¤È 08:44:03²Ä 9933 ½g¦^À³
¦³Ãö¨p¶Ò®×¡A­Ó¤H·M¨£¡A¬O§_¥i¥H±q¦³§U©óªÑ»ù¤Wº¦¡A±j¤Æ¥«³õ§ë¸ê¤H«H¤ß»P°l»ù·NÄ@¬°³Ì¤j¦Ò¶q­ì«h¡G

¦pÁÞÁp(4168)2013¦~8¤ë«Å¥¬¡AÂǥѨp¶Ò¤Þ¶i¤é¥»¤j¶ï»sÃÄ°µ¬°µ¦²¤§ë¸ê¤H¡A¤j¶ï»sÃħë¤J2.76»õ¤¸¡F¥x±d¥Í(6589)2021¦~10¤ë¨p¶Ò®×50»õ¤¸¡A¥Ñ³¢¥x»Ê¥D¾Éªº¥x±d¥Í¨p¶Ò§ë¸ê®×¡A¤À§O¥HÂE®üºë±K¡B¥ÃÄָꥻ±±ªÑ¤Î³¢¥x»Ê­Ó¤H§ë¸êªºèbºû¤½¥q¤JªÑ¡C¤W­z2¥ó¨p¶Ò®×¡A¬Ò¹ï·í®É¤½¥qªÑ»ù³y¦¨¤Wº¦¡A±j¤Æ¥«³õ§ë¸ê¤H«H¤ß»P°l»ù·NÄ@¡C

¦]¦¹¡AÃĵØÃĤ½¥q­Y­nÄ~Äò¿ì²z¨p¶Ò®×¡A¬O§_À³ÁקK§ä­ì¦³ªÑªF°Ñ»P¨p¶Ò¡A¦Ó³y¦¨¥«³õ¦³¡u½æ¦ÑªÑ¡A´«·sªÑ¡v¼ç¦b½æÀ£¡AªÑ»ù¤£©ö¤Wº¦¡A¬Æ¦Ü¹Ï§Q¯S©wªÑªF¡A¦³¹HªÑªF¥­µ¥­ì«h¤§ºÃ¼{¡C

«Øij¨p¶Ò®×¡AÀ³¤Þ¶i¡uµ¦²¤§ë¸ê¤H¡v¡A¥[±j¦X§@Ãö«Y¡F¦P®É¡A¯à¤Þ°_¥~¸ê¾÷ºc°ª«×§ë¸ê·NÄ@¡A¦p¤Þ¶i»PÃĵØÃĤ½¥q¦³·~°ÈÃö«Yªº¬ü°ê¤½¥q¡G

¤@¡BOnco360 ®¸~½FÃĩСG(¬ü°ê³Ì¤jªº¿W¥ß¸~½FÃÄ©Ð)

¤G¡BMcKesson Corporation(MCK)(¥_¬ü³Ì¤jÂåÃħåµo°Ó)¡C(ªÑ»ù246¤¸)

¤T¡BVeeva systems(VEEV)¡C(Veeva ¬O³Ð·s©Êªº¶³³n¥ó¤½¥q¡AÀ°§U 1,000 ¦h®a¥Í©R¬ì¾Ç¤½¥q§ó§Ö¦a¬°±wªÌ´£¨Ñ·sÃÄ©M·sÀøªk¡C)(ªÑ»ù258¤¸)

¥H¤W²L¨£¡A¤£ª¾¬O§_¥i¦æ?­Y¤£¥i¦æ¡A½Ð·í¯º¸Ü¤@«h!ÁÂÁ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2021/12/29 ¤W¤È 07:48:40²Ä 9932 ½g¦^À³
¸ê®Æ¨Ó·½¡Ghealthunlocked.com/mpnvoice/posts/private/147344831/besremi

Typically MPN specialists are experienced at handling the insurance appeal process. This should not have to fall on the shoulders of the patient. I have been to 3 different specialists over the past 4 years and they were all able to appeal and very quickly resolve any issue with obtaining my Pegasys. This was with private insurers however, and I understand medicaid/medicare is another matter. With FDA approval for Besremi I¡¦m not sure what grounds any of them would have to deny it on, unless it¡¦s just too soon and their documentation hasn¡¦t been updated or something. Due to life circumstances I am temporarily on Medicaid and my specialist told me that they can start prescribing Besremi as of today actually. I¡¦ll try and post back what my experience is with that. My next appt with the specialist is next week.

³q±`¡AMPN ±M¬ìÂå¥Í¦b³B²z«OÀI¤W¶D¹Lµ{¤è­±¸gÅçÂ×´I¡C³o¤£À³¸Ó¸¨¦b±wªÌªºªÓ¤W¡C¦b¹L¥hªº 4 ¦~¸Ì¡A§Ú¸g¾ú¹L 3 ¦ì¤£¦Pªº±M®a¡A¥L­Ì³£¯à°÷¤W¶D¨Ã«Ü§Ö¸Ñ¨M¤FÀò±o§Úªº Pegasys ªº¥ô¦ó°ÝÃD¡CµM¦Ó¡A³o¬O»P¨p¤H«OÀI¤½¥q¦X§@ªº¡A§Úª¾¹DÂåÀø¸É§U/ÂåÀø«OÀI¬O¥t¤@¦^¨Æ¡CÀHµÛ FDA ¹ï Besremi ªº§å­ã¡A§Ú¤£½T©w¥L­Ì¤¤ªº¥ô¦ó¤@­Ó¤H¦³¤°»ò²z¥Ñ¥²¶·§_¨M¥¦¡A°£«D¥¦¤Ó¦­¤F¡A©Î¬O¥L­Ìªº¤å¥óÁÙ¨S¦³§ó·s¤Î¦³¨ä¥L°ÝÃD¡C¥Ñ©ó¥Í¬¡±¡ªp¡A§Ú¼È®É±µ¨ü¤FÂåÀø¸É§U¡A§Úªº±M¬ìÂå¥Í§i¶D§Ú¡A¥L­Ì¹ê»Ú¤W¥i¥H±q¤µ¤Ñ¶}©l¶}¥X Besremi ³B¤è¡C§Ú·|¸ÕµÛµo¥¬§Úªº¸gÅç¡C§Ú»P±M¬ìÂå¥Í¤U¦¸ªº¬ù·|¬O¦b¤U©P¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/28 ¤U¤È 09:16:10²Ä 9931 ½g¦^À³
¬Ý©x¤j§â¨p¶Ò®×¹Ï§Q¯S©w¤H»¡ªº«Ü¸Ô²Ó

¨Ò¦p:¤½¥q­n¦b1¤ë23¤é¦Ü1¤ë29¤éú´Ú¡A¨º»ò¨p¶Ò¹ï¶H¤Î±i¼Æ¦b1¤ë12¤é«e«á¤w½T©w

¨p¶Ò¤H¡u¼ôÃÑ­ìªÑªF¡v¦¬³qª¾«á¡A¥þ³¡ªº¯S©w¤H¶}©l¤j½æ¤â¤W«ùªÑ¡A¶i¦æÀ£»ù~1.¥i¥H½æ¨ì°ª»ù2.À£§CªÑ»ù«á¥´¤K§é¤S¥i¥H¼W¨ì³Ì§CªºªÑ»ù

¤@Á|¨â±oªº¤âªk¡A§|±þ­ì¥»ªÑªFÅv¯q¡A¯S©w¤H¨Ó¦^ì§Q®t»ù³Ì¤Ö120¤¸¥H¤W¡A¥»¤H´£«e¹w§iªñ´ÁÁÙ·|¦³²Ä¤T¦¸¨p¶Ò¡A¦]¾lÃB±i¼ÆÁÙ¦³3¸U6¥a¦h±i

ÃĵØÃĤ½§iú´Ú¤é´Á·í¤Ñ¡A©¹«e¬Ý¤Q¤ÑªºªÑ»ù¥²©w¨«¶^¡A¥L­Ì·Q¼W§C»ù®æ¥²©w­n¤j½æÀ£»ù¡A©Ò¥H¤pªÑªF­Ì­n¥h§Üij¡AÃĵØÃĤ£­n¤@¦Ó¦A¤T¨p¶Ò

­nµ¹¥þÅé§ë¸ê«ù¦³ÃĵØÃĪºªÑªFÀ³¦³ªºÅv¯q

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2021/12/28 ¤U¤È 06:02:19²Ä 9930 ½g¦^À³
Æg¦¨¥ý¶i¤j»¡ªk ¦bªÑ¥«¸Ì·í±þ¤â©Î­´µæ³£¥i¯à

¥D­n¬O¤½¥­¥¿¸q »¡¤F¦h¦¸¦³«ÜÃøÀ´¶Ü

ÁÙ¬O¼Ö¦b¨ä¤¤

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/28 ¤U¤È 05:22:20²Ä 9929 ½g¦^À³
­Y¬O¤½¥i¦³¸êª÷¯Ê¤f´£«e¤½¶}¦VªÑªF¼W¸ê¡A¬°¤°»ò¤£»°§Ö¶i¦æ¡A¹³¤W¦¸90¤¸¨p¶Ò®×¤@¼Ë¡A

¨p¶Ò¤F¤G~¤T¦¸³Ì«á¤@¦¸¤~¥Ñ¥þÅéªÑªF¼W¸ê·í®É»{ÁÊ»ù¬O90¤¸¤W¤U¡A¦A»¡¤F~ÃĵØÃijo¦¸5¸U±i

¬O¤£¬O¹³¤W¦¸¤@¼Ë¡Aµ¹¯S©w¤H3~4¦¸¨p¶Ò«á¡A³Ì«á¤@¦¸¤~¥þ³¡ªÑªF¼W¸ê©O¡H³o¦¸5¸U±i¨p¶Ò²Ä¤@

¦¸11¤ë23¤éú´Ú¦Ü11¤ë©³¡B²Ä¤G¦¸12¤ë23¤éú´Ú¦Ü¤ë©³¡A¨º»ò¦X²z·Q¹³1¤ë23¤é¤S¨Ó¤@¦¸¡H

¤@­Ó¨p¶Ò¤]·d´X­Ó¤ë¡A¸ò¤½¶}¼W¸ê¨ì©³®É¶¡®t¦h¤Ö¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pÃC10147871  µoªí®É¶¡:2021/12/28 ¤U¤È 04:53:41²Ä 9928 ½g¦^À³
¨p¶Ò©Î²{¼W¥u­n¯à¦b¦³®Ä²vªº®É¶¡¤º¨ú±o¤½¥qªº¸êª÷»Ý¨D §Ú³£ÃÙ¦¨¡C ¦ý²{ª÷¼W¸ê »Ý­n¸g¹LÂd¶Rªº ¦Ó¥B§@·~®É¶¡­n´X­Ó¤ë¡C À³¸Ó®É¶¡¤W¨Ó¤£«æ¡C ©Ò¥H§Ú¿ï¾Ü¬Û«H¤½¥qªº¦w±Æ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/28 ¤U¤È 04:39:57²Ä 9927 ½g¦^À³
ÃĵØÃĦ^¨ìÀ³¦³ªº»ù­È¡A¬OªÑªFªø´Á°í«ù«ù¦³ªºªG¹ê¡A¤]¦]³q¹L¤FFDAªºÃÄÃҪѻù¤~¦³ªí²{¡A¸ò¨p¶Ò®×¬O¤G½X¨Æ¡A¤£¯à²V¬°¤@½Í
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gandytom10148211  µoªí®É¶¡:2021/12/28 ¤U¤È 04:24:49²Ä 9926 ½g¦^À³
¦n¤[¨S¤W¨Ó¤F¡A¨S·Q¨ìªÑ»ùºCºC¦^¨ìÀ³¦³»ù­Èªº®É«á¡A¬°¤F¨p¶Ò¥i¥H³o¼Ë§n¡A§Ú¬O¤ä«ù¤pÃC¤jªº¡A¥u­n¡§À´ºÊ«ùªÑ¡¨¨S¦³²§±`¡A³o¦Xªkªº¶Ò¸ê§Úµ´¹ï¤ä«ù¡A§Ú¥ý©Ó»{°£¤F¨p¶Ò¥~¡A¨C¦¸ªº²{ª÷¼W¸ê§Ú³£¦³°Ñ»P¡A¦Ó¨C¦¸§Ú¤]½æ´X±i¦ÑªÑÁÈÂI¹s¥Î¿ú¡A¦n¯ºªº¬O¨C¦¸¼W¸êú´Ú«áªÑ»ù³£·|¤U±þ¶^¯}¼W¸ê»ù¡A§Ú¬O¤£¬O¤]¬O¥û¤â¤§¤@¡A§Ú¹ê¦b«Ü³Y²§¡§¤½¥q¸Û«H¡¨³o¦Ñ®C¥i¥H±qÃĵح·«BÄÆ·nªº®É«á¤@¦Aªº....¡A¥u¯à»¡Besremi³oÃĪº«e¡]¿ú¡^´º¤Ó°g¤H¤F
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/28 ¤U¤È 03:20:20²Ä 9925 ½g¦^À³
¥»¤H¦b¦¹±j½Õ¤@¤U¡A¹ïÃĵØÃĪº«á¶Õªø¦h¬Ýªk¤£ÅÜ¡A¦ý±j¯P¤Ï¹ï¨p¶Ò®×¡A¤½¥q¯Ê¿ú¥i¦V­ì©lªÑªF¥þÅé¼W¸ê¡A

­Y¤£Ãº´Úªº³¡¥÷¦A¥Ñ¸³¨Æªø¬¢¯S©w¤H¤h¡AÃĵØÃij̤֭n°µ¨ìÁ׶û¡A¨p¶Ò®×¤@¦Ó¦A¤T¦h¤Ö¦¸¤F¡H§Ö¯}°O¿ý¤F§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2021/12/28 ¤U¤È 03:18:25²Ä 9924 ½g¦^À³
§Ú«ù¦³ÃĵتѲ¼¤w¦³¦h¦~ ´Á¶¡ªÑ»ù¾ú¸gº¦¶^¦h¦¸ ¯à®³¨ìÃÄÃÒ§ó¬O´¶¤ÑÅw¼y¡I

µM¦Ó¥u¹ï¤½¥q¨p¶Ò®×°µªk´£¥XºÃ°Ý©M«Øij¤]¬O¦X²z°Ú ¤£¦æ¶Ü¡H³o¼Ë´N²Ö¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/28 ¤U¤È 02:59:47²Ä 9923 ½g¦^À³
³o»ò¬Ý¨Ó³o¦ì¬Ý©x¤j¬O¤º¦æ¤H¡A§â²Ó¸`³£»¡ªº¤@²M¤G·¡¡A¤½¥q¯Ê¿ú¬°¤°»ò¤£¤½¶}¼W¸êµ¹­ì©lªÑªF¡A¦Ó¨p¶Ò¦A¤Tµ¹©T©w¨º´X­Ó­ì¯Z¤H°¨

®Ú¥»´N¬O¹Ï§Q¡A½ÐÃÒºÞ·|¥h¹î©ú´N¤@¥Ø¤FµM

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pÃC10147871  µoªí®É¶¡:2021/12/28 ¤U¤È 02:50:19²Ä 9922 ½g¦^À³
§Ú¬O¤@­ÓªÑªF¡A§Æ±æ¬Ý¨£Ãĵغ¦¨ì¸Ó¦³ªº»ù­È¡C¤½¥q¯Ê¿ú§ä¿ú¡A¥u­n¦X¥G³W©w ¡C ªÑ»ù¶^®É¤½¥q³Q駡¸Û«H ¸gÀç¯à¤O¤£¨¬¡A²{¦b®³¨ìÃÄÃÒ ªÑ»ùº¦¤F ¤]³Q駡¡A¤]³Q½èºÃ¸Û«H¦³°ÝÃD¡C §Ú¬OªÑªF ¥u­n¬Ý¨£ªÑ»ù´£¤É ´N¬O³Ì ¦nªº¦^³ø¡C ªÑ»ù¥»´N·|º¦º¦¶^¶^ ¨º¨Ó¨º»ò¦hªºÃhºÃ¡A¤£²Ö¶Ü¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2021/12/28 ¤U¤È 12:03:40²Ä 9921 ½g¦^À³
¬Ý©x¤j

¥ý¶i¤jÁ¿ªºÃĵØÃĨp¶ÒªÑ»ù´N¶^

³o¤]¤Ó¦h¦¸¥©¦X¤F

ÃÒ©ú¨p¶Ò¦W³æ¤H½æ¦ÑªÑ¼W·sªÑ

¥sÃÒºÞ·|¥h¬d¤W¦¸90¤¸¨p¶Òªº

¸ò177¤¸¨p¶Òªº¦W³æ¦³¨S¦³Ãº´Ú«e½æªÑ

¨p¶ÒªºªÑ²¼¦³¨S¦³¹ý©³°õ¦æÂê¤T¦~

ÃĵØÃĸ۫H¨ü¨ìÃhºÃ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2021/12/28 ¤W¤È 11:39:27²Ä 9920 ½g¦^À³
ªÑ»ù¤Ï¼uÀ³Åç¤F¥ý¶i¤j¹w´ú §ë¸ê¤H³£·QÀò¨ú§Q¼í

¥u¬OÁȦh¤Ö©Î¬OÁ«·l°ÝÃD¦Ó¤w

¦ý¬O±`¨¥¹D¦³Ãö«Y´N¨SÃö«Y¤@¸ôÁȦnÁȺ¡¡H

¸Û¦p¦Ì¤j©Ò¨¥2¤d¦h¤Hªº¸s¥u¯àºq¥\¹|¼w¶¶µÛ¤òºN

µy¦³¤£·V°Q½×¨p¶Ò®×´N¸s°_³ò¶Ï§ðÀ»µM«á³Q°h¸s

¶°¦XªÑªF«Ø¥ßªÀ¸s¤£´N¬O¥i¥H°Q½×µM«á¤ÏÀ³µ¹¤½¥q¤W¼hªº¶Ü¡H

¦p¦¹£¸¬N¦a¦P·Å¼h¨ú·x¬O¥i¥H¾®»E¦@ÃÑ

°ÝÃD´N¬O¦b©¿²¤¤Fªø´Á¤ä«ùªº¤pªÑªF Åý³o¸s©¾Ãį»±¡¦ó¥H³ô°Ú¡I

§g¤l·R°] ¨ú¤§¦³¹D ³o«ÜÃøÀ´¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/27 ¤U¤È 02:39:46²Ä 9919 ½g¦^À³
¨p¶Òú´Ú´Á12¤ë23¤é~12¤ë29¤é¡A¤]´N¬O»¡¸êª÷¤£¨¬½æ¦ÑªÑ¼W·sªÑªº¤H¡A¦b¤µ¤Ñ27¤é­n½æ¥X¡A¤G¤Ñ29¤é«á¤J´Úú»{ÁÊ´Ú

©Ò¥H¤µ¤éªÑ»ù¶^¬O·N®Æ¤¤ªº¨Æ¡A©ú¤ÑÃĵØÃĪºªÑ»ù¤Ö¤F½æÀ£¡A½¬õªº¾÷²v¸û¤j..........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/27 ¤U¤È 12:17:52²Ä 9918 ½g¦^À³
¦b¦¹©IÆ~ÃĵØÃÄ°ª¼h¨Mµ¦¤H¡A¤H®æ³Q¸j¬[¤F¶Ü¡H«D±o¨p¶Ò¨º¨Ç©T©w¤H¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G´Iª¨ª¨10024083  µoªí®É¶¡:2021/12/27 ¤U¤È 12:05:53²Ä 9917 ½g¦^À³
¥i¥H¨p¶Ò¡A¦ý¤w¤Ó¦h¦¸¤F¡AÆ[·P¤£¨Î. ¨p......¨p......¨p......
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10148182  µoªí®É¶¡:2021/12/27 ¤W¤È 09:20:49²Ä 9916 ½g¦^À³
ÃĵØÃĪvET·sÃÄ ¤T´ÁÁ{§ÉÀò¥¿­±¦^À³

22:452021/12/26 ¤u°Ó §ù¿·»T

ÃĵØÃÄ¡]6446¡^«Å¥¬¡ARopeginterferon alfa-2b¡]P1101¡^¥Î©óªvÀø­ìµo©Ê¦å¤pªO¼W¦h¯g¡]ET¡^ªº²Ä¤T´ÁÁ{§É¸ÕÅç¡AÀò¬ü°ê¡u¼Æ¾Ú¦w¥þºÊ·þ©e­û·|¡v¡]DSMB¡^¥¿­±¦^À³¡A½T©w¦w¥þ©ÊµL¸·¡A¨Ã«Øij¥i¨Ì·Ó­ìÁ{§É­pµeÄ~Äò¶i¦æ¡A±N¤O©é2022¦~©³§¹¦¨¦¬®×¡C

Ropeginterferon alfa-2b¡]P1101¡^¤ë«e¤w¨ú¬ü°êÃÄÃÒ¡A¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^¤@½u¥ÎÃÄ¡A¥t¥~¡A¤]±Ò°Ê¥þ²y¦h°ê¦h¤¤¤ßªvET²Ä¤T´ÁÀu¶V©ÊÁ{§É¸ÕÅç¡A¦¬®×½d³ò§t¬A¬ü°ê¡B¤é¥»¡B¥xÆW¡BÁú°ê¡B­»´ä¡B¤¤°ê¡B·s¥[©Y»P¥[®³¤j¡C

ÃĵØÃĪí¥Ü¡A¬ü°êFDA¤w¦³20¦h¦~¥¼§å­ãET·sÃĤW¥«¡A§å­ãRopeginterferon alfa-2b¶i¦æET¤T´ÁÁ{§É¸ÕÅç¥O¤H®¶¾Ä¡C¥Ø«eETªº²Ä¤@½u¥ÎÃĬO¥é³æ¼Ð¥Ü¥~ªº·Rªv¡]Hydroxyurea HU¡^¡A²Ä¤G½u¥ÎÃÄ«h¬O1997¦~®Ö­ãªº¦w»ÕÆF¡]Anagrelide¡^¡ARopeginterferon alfa-2b¥¼¨Ó¦³±æ¦¨¬°ET±wªÌ¥ÎÃĪº·s¿ï¶µ¡C

­ìµo©Ê¦å¤pªO¼W¦h¯g¬°°©Åè¼W¥Í©Ê¸~½F¡]MPN¡^¯e¯fªº¤@ºØ¡A¯f¤H¼Æ»P¯u©Ê¬õ¦å²y¼W¦h¯gªº¯f¤H¼Æ¬Ûªñ¡CRopeginterferon alfa-2b¥Î©óªvÀø­ìµo©Ê¦å¤pªO¼W¦h¯gªº²Ä¤T´ÁÁ{§É¸ÕÅç¹w­p±N¦¬160¦ì¨ü¸ÕªÌ¡A¥Ø«e¦¬®×¤H¼Æ¤w¹L¥b¡A¸ÕÅç«ùÄò¶¶§Q¶i®i¤¤¡A¬°¥[³t¦¬®×¡A°£«ùÄò¦b¬ü°ê©M¨È¬w¦U¦a¦¬®×¡A¤é«e§ó±N¦¬®×¯¸ÂIÂX®i¨ì¥[®³¤jªº¸ÕÅ礤¤ß¡A¥þ®×¹w­p±N©ó2022¦~©³¦¬®×§¹¦¨¡C

Ropeginterferon alfa-2b¤§¦w¥þ©Ê¦b¯u©Ê¬õ¦å²y¼W¦h¯g¯f¤H¤¤¤w¦³³sÄò¬I¥´¤C¦~¥H¤Wªº¼Æ¾Ú¦õÃÒ¡A¨Ã¤wÀò¼Ú·ù¡B¥xÆW¡B·ç¤h¡B¥H¦â¦C¡BÁú°ê¤Î¬ü°êFDA®Ö­ã¨Ï¥Î©ó¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g±wªÌ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/27 ¤W¤È 09:11:14²Ä 9915 ½g¦^À³
¥»¤H¬Ý¨ìªº¬O6446¨­®Ç¤@°ïªº¤ôµí¡A¦Û¨p¤S³g°ýÁy¥Ö«pªº¤H¡A¤½¶}¼W¸ê¤£¦æ¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10148182  µoªí®É¶¡:2021/12/27 ¤W¤È 08:50:49²Ä 9914 ½g¦^À³
ªL°êÄÁ µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü (02)26557688

¥D¦®

¥»¤½¥qRopeginterferon alfa-2b (P1101)¤§­ìµo©Ê¦å¤p

ªO¼W¦h¯g(ET)²Ä¤T´ÁÁ{§É¸ÕÅçÀò¼Æ¾Ú¦w¥þºÊ·þ©e­û·|(DSMB)

¥¿­±¦^À³¡A´N¥Ø«e¼Æ¾Ú½T©w¦w¥þ©ÊµL¸·¡A«Øij«ùÄò¦¬®×

²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 110/12/24

»¡©ú

1.¨Æ¹êµo¥Í¤é:110/12/24

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥qRopeginterferon alfa-2b¡]P1101¡^¤§­ìµo©Ê¦å¤pªO¼W¦h¯g

¡]Essential Thrombocythemia, ET¡^²Ä¤T´ÁÁ{§É¸ÕÅç¸g¼Æ¾Ú¦w¥þºÊ

·þ©e­û·|¡]Data and Safety Monitoring Board, DSMB¡^¼f¬d¡AÀò

¥¿­±¦^À³¡C´N¥Ø«e¸ÕÅç¼Æ¾Ú¡A½T©w¦w¥þ©ÊµL¸·¡ADSMB¨Ã«Øij¥i¨Ì·Ó

­ìÁ{§É­pµeÄ~Äò¶i¦æ¡C

¥»¤½¥qRopeginterferon alfa-2b¥Î©óªvÀø­ìµo©Ê¦å¤pªO¼W¦h¯g¤§²Ä¡@

¤T´ÁÁ{§É¸ÕÅç¦W¬°¡uSURPASS ET¡v¡A¥»Á{§É¸ÕÅç¨Ì¾Ú³W½d³]¥ß¼Æ¾Ú

¦w¥þºÊ·þ©e­û·|¡A¨Ã¨Ì·|ij³¹µ{©w´ÁÁ|¿ì·|ij¡A¥Ñ°ê»Ú¦å²G¯f±M®a

¤Î²Î­p±M®a¦@¦P¼f¬d¸ÕÅç¶i¦æ¤¤¤§¦w¥þ©Ê¼Æ¾Ú¤Î¹ï¯f¤Hªº§Q¯q¡þ­·

ÀI¶i¦æµû¦ô¡C

6.¦]À³±¹¬I:µL

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GRopeginterferon alfa-2b¡]P1101¡^

¤G¡B¥Î³~¡GªvÀø­ìµo©Ê¦å¤pªO¼W¦h¯g±wªÌ¡C

¤T¡B¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¶i¦æ²Ä¤T´ÁÁ{§É¸ÕÅç¤Î¥¼¨Ó·sÃĬd

Åçµn°O¡C

¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

¡]¤@¡^´£¥X¥Ó½Ð¡þ³q¹L®Ö­ã¡þ¤£³q¹L®Ö­ã¡þ¦U´Á¤HÅéÁ{§É¸ÕÅç

¡]§t´Á¤¤¤ÀªR¡^µ²ªG¡þµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥ó¡G

Ropeginterferon alfa-2b¤§­ìµo©Ê¦å¤pªO¼W¦h¯g²Ä¤T´Á

Á{§É¸ÕÅç¡C

¡]¤G¡^¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç¡]§t

´Á¤¤¤ÀªR¡^µ²ªG¥¼¹F²Î­p¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·s

ÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G

¤£¾A¥Î

¡]¤T¡^¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç¡]§t

´Á¤¤¤ÀªR¡^µ²ªG¹F²Î­p¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃÄ

¬ãµo¤§­«¤j¨Æ¥óªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î¡C

¡]¥|¡^¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¦Ò¶q¥¼¨Ó¥«³õ¦æ¾Pµ¦²¤¡A«O»Ù

¤½¥q¤Î§ë¸ê¤HÅv¯q¡A¼È¤£¤½¶}´¦ÅS¡C

¤­¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡GRopeginterferon alfa-2b¤§­ìµo

©Ê¦å¤pªO¼W¦h¯g²Ä¤T´ÁÁ{§É¸ÕÅç¡C

¡]¤@¡^¹w­p§¹¦¨®É¶¡¡G

¹w­p2022¦~©³¦¬®×§¹¦¨¡A±©¹ê»Ú®Éµ{±N¨Ì°õ¦æ¶i«×½Õ¾ã¡C

¡]¤G¡^¹w­pÀ³­t¾á¤§¸q°È¡GµL¡C

¤»¡B¥«³õ²{ªp¡G¡]½Ð»¡©ú¥Ø«e¸Ó·sÃÄ©Ò¾AÀ³¯f¯g¤§¥«³õª¬ªp¡B²{¦³

ªvÀø¬Û¦P¯f¯g¤§¥D­nÃĪ«µ¥¸ê°T¡^

­ìµo©Ê¦å¤pªO¼W¦h¯g¡]ET¡^¬°°©Åè¼W¥Í©Ê¸~½F¡]MPN¡^¯e¯fªº

¤@ºØ¡A¯f¤H¼Æ»P¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^ªº¯f¤H¼Æ¬Ûªñ¡C¥Ø«e

ETªº²Ä¤@½u¥ÎÃĬO¥é³æ¼Ð¥Ü¥~ªº·Rªv¡]Hydroxyurea, HU¡^¡A

²Ä¤G½u¥ÎÃÄ«h¬O¦w»ÕÆF¡]Anagrelide¡^¡A¦¹ÃÄ«YFDA©ó1997¦~

®Ö­ã¡A¬ü°êFDA 20¦h¦~¨Ó¥¼§å­ãET·sÃĤW¥«¡C

¤C¡B¨ä¥LÀ³±Ô©ú¨Æ¶µ

¡]¤@¡^Ropeginterferon alfa-2b¤§­ìµo©Ê¦å¤pªO¼W¦h¯g²Ä¤T

´ÁÁ{§É¸ÕÅç¹w­p¦@¦¬¤J160¦ì¨ü¸ÕªÌ¡A¥Ø«e¦¬®×¤H¼Æ¤w

¹L¥b¡A¸ÕÅç«ùÄò¶¶§Q¶i®i¤¤¡C¬°¥[³t¦¬®×¡A°£«ùÄò¦b

¬ü°ê©M¨È¬w¦U¦a¦¬®×¡A¥Ø«e¦¬®×¯¸ÂI§óÂX®i¨ì¥[®³¤jªº

¸ÕÅ礤¤ß¡C

¡]¤G¡^Ropeginterferon alfa-2b¤§¦w¥þ©Ê¦b¯u©Ê¬õ¦å²y¼W¦h

¯g¯f¤H¤¤¤w¦³³sÄò¬I¥´¤C¦~¥H¤Wªº¼Æ¾Ú¦õÃÒ¡A¨Ã¤wÀò¼Ú

·ù¡B¥xÆW¡B·ç¤h¡B¥H¦â¦C¡BÁú°ê¤Î¬ü°êFDA®Ö­ã¨Ï¥Î©ó

¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g±wªÌ¡C

¡]¤T¡^·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A

¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2021/12/27 ¤W¤È 08:50:32²Ä 9913 ½g¦^À³
«¥¤ÞÃzAOP¼Ú¬wºM¦^©t¨àÃĨƥó¡A¤S­«¯¥¤jÅF¨p¶Ò¹úºÝ¡A¦Ó­«¼C¤j¯S¦a´£¥X«Ø¨¥¤Ï¾DÃÕ¿Ø¡AªGµM©¾¨¥°f¦Õ¡C

±µ¤G³s¤T·d¡AÃø«O¯S©w¤H¤£¬O¯S©w¤HÀY?

¡§º×¤¼ºÖ¤§©Ò­Ê¡AºÖ¤¼º×¤§©Ò¥ñ¡C¡¨

----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2020/5/9 ¤U¤È 12:51:55²Ä 8584 ½g¦^À³

[¨p]¨S¤@¦n¼Ëªº!!!

­n«¥»{¦P¨p¶Ò¡A°£«D[¦ÑªÑ+·sªÑ]³£¦C¤J¤T¦~³¬Âê´Á¡C

¥h¬Ý¬ÝÃĵبp¶Ò«e«áªºÄw½X¡A´N²M·¡«¥ªº·N«ä!

¤µ¦~4743¦X¤@»P6446Ãĵس£­n¶Ò¸ê´X¤Q»õ¡A¤@®a±ÄADR¤@®a±Ä¨p¶Ò¡A¤G®a³£¬O·sÃĪѫê«ê¯à¤ñ¸û¤@µf¬Ý¬ÝÅo!!!

.......................................................................................

......................................................................................

·|­û¡GROGER588910148151 µoªí®É¶¡:2019/10/14 ¤U¤È 05:51:43²Ä 7395 ½g¦^À³

¨p(©³¤U»¡¤å¸Ñ¦r¨S¤@¼Ë¦n¦a!)

(1)ÄÝ©ó­Ó¤H¨Æª«ªº¡C¦p¡G¡u¨p¨Æ¡v¡B¡u¨p³¹¡v¡B¡u¨p¦v¡v¡B¡u¨p¹Ñ¡v¡B¡u¨p¥Í¬¡¡v¡B¡u¨p©Ð¿ú¡v¡C

(2)¬°¦Û¤v§Q¯qªº¡B°¾­«¤@¤èªº¡C¦p¡G¡u¦Û¨p¡v¡B¡u¨p¤ß¡v¡B¡u¨p§Q¡v¡C

(3)·t¦Ûªº¡B¯¦±Kªº¡C¦p¡G¡u¨p¦Û¡v¡B¡u¨p¤U¡v¡B¡u¨p°k¡v¡B¡u¨pÂáv¡B¡u¨p©³¤U¡v¡B¡u¨p¬Û±Â¨ü¡v¡B¡u¨p©w²×¨­¡v¡C

(4)¤£¦Xªkªº¡B¤£¥¿·íªº¡C¦p¡G¡u¨p°s¡v¡B¡u¨p³f¡v¡B¡u¨pÆQ¡v¡C

(5)«Dªkªº³fª«¡C¦p¡G¡u¨«¨p¡v¡B¡u½r¨p¡v¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2021/12/26 ¤U¤È 10:24:35²Ä 9912 ½g¦^À³
¨p¶Ò¥i¥H¡A¬O­n¦³§Q©ó¤½¥q¸gÀçµo®iªº ¤ñ¦pªk¤HÆ¿¥Í§Þ°]¹Îµ¥ ¤§«eªº¨p¶Ò´N¬O¨p¬¢¤º³¡¤jªÑªF©Î¼ôÃѪº¤H¡A¤~³y¦¨½æªѻ{·sªÑªº½æÀ£¡I³o³£¬Ý¤£¥X¨Ó¶Ü¡H¤½¥­¥¿¸q­ì«h¹ï«Ýªø´Á«ù¦³ªÑ²¼ªº¤pªÑªF«ÜÃø¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤@²É¦Ì10133199  µoªí®É¶¡:2021/12/26 ¤U¤È 08:25:43²Ä 9911 ½g¦^À³
ÃĵØÃĦb³o¥i¯u¼ö¾x ¬Æ»ò³£¥i¥H´£¥X¨Ó

¦bÃĵØÃĪºLINE¸s ´N¤£¬O¬Æ»ò³£¯àÁ¿ Á¿¨ì¨p¶Ò®× ¥u­n¬O±Ó·Pªº©Î¤£¶¶ª©¥Dªº·N ´N·|³Q§R°£ ³Q°h¸s..

·d±o´N¹³¬O¤@¨¥°ó ²{¦b¦³2600¦h¤H ´X¥G¤]¬O¸TÁn..

¯u¦n¯º ³o­Ó¨p¶Ò®×¤£ª¾¬O¤£¬O¦³¬Æ»ò¤º¹õ ¤£¿U·F¹À©È¤H°Q½×

¦A»¡¤F ¦Ñ¬O»¡¨p¶Ò¨ú²{ª÷¸û§Ö ­Ó¤Hı±o¤]¤£³q

¤W­Ó¤ë©³¿ì²z¼W¸êªÑ¼Æ­Y¨ì¦ì ¥»¤ë©³³o®É¤]À³¸Ó¦¬¨¬¤F ¦ó¥Hµuµu¨â­Ó¤ë¤º´NÁ|¿ì¨p¶Ò¯S©w¤H2¦¸

¥Ø«e¤W¥«Âd¤½¥q ÁÙ¤£´¿¨£»D

¯u¬OÀ³¤F¤@¨Ç«e½úªÑªF­Ì¦Ñ¬O»¡:·PÁ¤½¥q°ª¼h¥Î¤ß¥I¥X.¯uªº«Ü¥Î¤ß

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10141485  µoªí®É¶¡:2021/12/26 ¤U¤È 07:47:02²Ä 9910 ½g¦^À³
¦ó¥²¦p¦¹²´¬õ¡A·íªì¤½¥q­·«BÄÆ·n¡A¸êª÷¯Ê¥F¡A­n¤£¬O¦³³o¨Ç¤Ñ¨Ï§ë¸ê¡A·sÃį൥¨ìFDA ³q¹L?

¤@®M¸êª÷±q¦­´Á§ë¸ê¸j¨ì²{¦b¡A¤£½æªÑ­þ¨Óªº¿ú¦A¤ä«ù¤½¥qµo®i¡A°ò©ó´L­«§ë¸ê²´¥ú¡A»{¥i§Y¥i¡Aµ¥­Ó¤H²{¼W³t«×¤ÓºC¡A·Q­nÄw½X´N¶°¤¤¥«³õ¶R¡A«ÜÃø¶Ü? ¹ê¦b¤£À´~²{ª÷¼W¸ê¥»´N¤£¾A¦X¥xÆW·sÃÄ¥ÍÂåªÑ¡A2016~2020 ¥ÍÂ奫³õ¸êª÷¬\ºÜ¡A³o³£¬Ý¤£¥X¨Ó? ¦h¤Ö¤½¥q³Q­¢½Õ§C²{¼W»ù? ¦³¥»¨Æªº¥ÍÂåªÑ¥»¨Ó´N¬O¦Û¤v§äª÷¥D¡A¤S§Ö¤SÂêÄw½X!! ¥H¤W²L¨£¡A­Ó¤H¤À¨É¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2021/12/26 ¤U¤È 02:41:38²Ä 9909 ½g¦^À³
¨p¶Ò®Ú¥»´N¬O¹Ï§Q¯S©w¤H

³o¨Ç¯S©w¤H¤j³¡¥÷¬O¼ôÃѪº

¨C¦¸ªº¨p¶Ò³o¨Ç¤H¦­¦b¤½¥¬Ãº´Ú´Á­­®É

¤w¦¬¨ìú´Ú³qª¾³æ

¦bú´Ú«e¥ý½æ¦ÑªÑ¥i¥H½æ¨ì°ª»ù¤S¥i¥HÀ£¤UªÑ»ù¥´¤K§é¼W§C»ù¨p¶Ò

¨C¦¸³£¦³®M§QªÅ¶¡

³o¦¸½æ330¤¸~380¤¸¦ÑªÑ»{235¤¸ªº¥­§¡¨CªÑ®M§Q135¤¸¤W¤U

¹ð¸Õ¤£²n¡B¯S©w¤H²n²nÁȦn¦h¦¸

³o¨Ç¤H¦³«Ü¦h®M²{ª÷¶Ü¡H

³£¬O¤@¨Ç¤W¯Z±Ú°h¥ðªº¤@¯ë¤p±d¦¬¤JªÌ

¤p§ÌÃhºÃ¨p¶ÒªÑ¦­¤w¤J¯S©w¤H¶°«O

Âê3¦~¬OÄF¤Hªº¡H

¥sÃÒºÞ·|¥h¬d¡B¥h¦~¨p¶Ò®×¤½¥q¤Î¯S©w¤H¦³¨S¦³¦b¥~¬y³q

³o¨Ç¨p¶Ò¹ï¶H¦­¤w½æ¥X«ùªÑÁÙ¤U¦¸ªº

¤½¥q¤í¯Ê¸êª÷²{¦b´N¥i²{ª÷¼W¸ê

ªÑªF·|¤£®¼¡H¦A»¡¥¼ÃºªÌ¦A¥Ñ¸³¨Æªø¬¢¯S©w¤H¤h§Y¥i

«D±o¨C¦¸¨p¶Ò·dµ¹¯S©w¤H®Ú¥»´N¬O¹Ï§Q

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2021/12/25 ¤W¤È 06:42:51²Ä 9908 ½g¦^À³
¤ñ¸û«Øij¤½¥qµo¥iÂà´«¤½¥q¶Å¡A»ù®æ©wªº¤ñ²{¦b°ª¡A¤£·|¦³®M§Q¦æ¬°¡A¤½¥q³o¦¸¬O°µ±o¦³ÂI±¼º£¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õÁ`²Î10135593  µoªí®É¶¡:2021/12/24 ¤U¤È 10:23:52²Ä 9907 ½g¦^À³
¥ý¶i¤j

¥i¯à¤½¥q«æ»Ý¿ú ²{¼W¥Ø«e¤£®e©ö ¤§«áÀ³·|²{¼W¤@¦¸ ¦p¦P¤§«e¤@¼Ë§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/24 ¤W¤È 11:26:32²Ä 9906 ½g¦^À³
¹ªÀy¤pªÑªF­Ì¤@¤H¤@³q¹q¸Ü­n¨DÃĵØÃÄ¿ì²z²{ª÷¼W¸ê¡A¤£­n¦A¤T¨p¶Ò¹Ï§Q¯S©w¤H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/24 ¤W¤È 10:44:14²Ä 9905 ½g¦^À³
«Øij¤pªÑªF­Ì¤@¤H³q¹q¸Ü­n¨DÃĵØÃÄ¿ì²z²{ª÷¼W¸ê¡A¤£­n¦A¤T¨p¶Ò¹Ï§Q¯S©w¤H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/24 ¤W¤È 10:20:21²Ä 9904 ½g¦^À³
¤W¬P´Áªº½æÀ£§ä¥X­ì¦]¤F¡A³o¨Ç¨p¶Ò±i¼Æ¶R·s½æªº§Þ­Ç¦bÃĵØÃĸ̡A¤@¦A­«½Æ¹Ï§Q¯S©w¹ï¶H¡A¦b³o¤è­±¸Û«H«Ü®t

¤½¥q´N¤£¯à¿ì²z²{ª÷¼W¸ê¶Ü¡H©IÆ~ÃĵØÃĤ½¥q°ª¼h¡A¤£­n¤@ª½°µÅý¤pªÑªFı±oäú¤ß¨Ã¤zÃתº¨Æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10148182  µoªí®É¶¡:2021/12/24 ¤W¤È 08:52:09²Ä 9903 ½g¦^À³
ÃĵØÃĸ³¨Æ·|¨Mij110¦~²Ä2¦¸¨p¶Ò663.1¸UªÑ®×¡A¨CªÑ235¤¸¡B°ò·Ç¤é12/30

(2021/12/23 19:38:51)

¤½¶}¸ê°TÆ[´ú¯¸­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q¸³¨Æ·|¨Mij¿ì²z110¦~²Ä2¦¸¨p¶Ò´¶³qªÑ¤§©w»ùº[¼W¸ê°ò·Ç¤éµ¥¬ÛÃö¨Æ©y

1.¸³¨Æ·|¨Mij¤é´Á:110/12/23

2.¨p¶Ò¦³»ùÃÒ¨éºØÃþ:´¶³qªÑ

3.¨p¶Ò¹ï¶H¤Î¨ä»P¤½¥q¶¡Ãö«Y:

(1)À³¶Ò¤H¤§¿ï¾Ü¤è¦¡¡G¨p¶Ò¤§À³¶Ò¹ï¶H¿ï¾Ü¤è¦¡¡G¥H²Å¦XÃÒ¨é¥æ©öªk²Ä43±ø¤§6¤Î­ì°]¬F³¡ÃÒ¨éº[´Á³fºÞ²z©e­û·| 91 ¦~ 6¤ë 13 ¤é(91)¥x°]ÃÒ¤@¦r²Ä0910003455¸¹¨ç³W©w¤§¯S©w¤H¬°­­¡C

(2)°Ñ»P¥»¦¸¨p¶Ò¤§À³¶Ò¤H¦W³æ¤Î»P¥»¤½¥q¤§Ãö«Y¡G

<1>¤¤°ê²Ä¤@¿ûÆl¼tªÑ¥÷¦³­­¤½¥q¡G¥»¤½¥qªÑªF

<2>¥É·s§ë¸êªÑ¥÷¦³­­¤½¥q¡G¥»¤½¥qªÑªF

<3>¶À§ö¯]¡G¥»¤½¥qªÑªF

<4>§õ¦°®p¡G¥»¤½¥qªÑªF

<5>ªô«³³Ç¡G¥»¤½¥qªÑªF

<6>³¯«T¶¯¡G¥»¤½¥qªÑªF

<7>ªô¬üÄõ¡G¥»¤½¥qªÑªF

<8>¹ù¥­«n¡G¥»¤½¥qªÑªF

<9>¶ÀÄR¯u¡G¥»¤½¥qªÑªF

<10>³¯®¦Öö¡G¥»¤½¥qªÑªF

<11>¤ý·y´f¡G¥»¤½¥qªÑªF

<12>³¯ÄR¶²¡G¥»¤½¥qªÑªF

<13>ù«Ø©ú¡G¥»¤½¥qªÑªF

<14>³¯¬Õ¦p¡G¥»¤½¥qªÑªF

<15>³¯¥ÉÄÉ¡G¥»¤½¥qªÑªF

<16>§E·ç¥É¡G¥»¤½¥qªÑªF

<17>³¢¨ÓºÖ¡G¥»¤½¥qªÑªF

<18>·¨¤ë¬î¡G¥»¤½¥qªÑªF

<19>³¯¯à´Ë¡G¥»¤½¥qªÑªF

<20>Âö¨q¬Â¡G¥»¤½¥qªÑªF

<21>³\´ºµM¡G¥»¤½¥qªÑªF

<22>Ĭ«a¦t¡G¥»¤½¥qªÑªF

<23>´å¾îª½¡G¥»¤½¥qªÑªF

<24>³¯­Z°ó¡G¥»¤½¥qªÑªF

<25>¥Ð¬ü²ú¡G¥»¤½¥qªÑªF

<26>¬x©¾¡G¥»¤½¥qªÑªF

<27>ª÷ª÷¸`¯àªA°ÈªÑ¥÷¦³­­¤½¥q¡GµL

<28>Áé¤s§ë¸êªÑ¥÷¦³­­¤½¥q¡GµL

<29>ÃQ«ØÅv¡GµL

<30>³¢¬Õ§Ó¡GµL

<31>±i¾ÇµÏ¡GµL

<32>³¯§±Âè¡GµL

<33>¤ý¼y´É¡GµL

<34>±i¶vÚ¬¡GµL

<35>¨ô§B·½¡GµL

4.¨p¶ÒªÑ¼Æ©Î±i¼Æ:6,631,000ªÑ´¶³qªÑ¡C

5.±o¨p¶ÒÃB«×:¨Ì¥»¤½¥q110¦~08¤ë05¤éªÑªF±`·|¨Mij¡A©ó´¶³qªÑ¤£¶W¹L50,000,000ªÑÃB«×¤º¡Aµø¥«³õÀô¹Ò¤Î¤½¥q¸êª÷ª¬ªp¡A¾Ü¾A·í®É¾÷»PÄw¸ê¤u¨ã¡A®ü¥~¦s°U¾ÌÃҤΡþ©Î²{ª÷¼W¸ê¨p¶Ò´¶³qªÑ¤Î¡þ©Î¨p¶Ò®ü¥~©Î°ê¤ºÂà´«¤½¥q¶Å¾Ü¤@©Î¥H·f°t¤§¤è¦¡¿ì²z¡A©óªÑªF·|¨Mij¥»®×¤§¤é°_¤@¦~¤º¤@¦¸©Î¤À¦¸¡]³Ì¦h¤£¶W¹L5¦¸¡^¿ì²z¡C

6.¨p¶Ò»ù®æ­q©w¤§¨Ì¾Ú¤Î¦X²z©Ê:

A.¨p¶Ò»ù®æ­q©w¤§¨Ì¾Ú¤Î¦X²z©Ê¡G

(1)¥»¦¸¨p¶Ò´¶³qªÑ»{ªÑ»ù®æ¤§­q©w¡A¥H©w»ù¤é«e1¡B3©Î5­ÓÀç·~¤é¾Ü¤@­pºâ»P©w»ù¤é«e30­ÓÀç·~¤é¤§´¶³qªÑ¦¬½L»ù²³æºâ³N¥­§¡¼Æ¦©°£µLÀv°tªÑ°£Åv¤Î°t®§¡A¨Ã¥[¦^´î¸ê¤Ï°£Åv«á¥­§¡¨CªÑªÑ»ù¡A¸û°ªªÌ¬°°Ñ¦Ò»ù®æ¡C

(2)¥»¦¸¨p¶Ò´¶³qªÑ»{ªÑ»ù®æ¥H¤£§C©ó°Ñ¦Ò»ù®æ¤§¤K¦¨¬°¨Ì¾Ú¡C

B.¯÷¥H¥»¦¸¸³¨Æ·|¥l¶}¤é´Á110¦~12¤ë23¤é¬°©w»ù¤é¡A¥H©w»ù¤é«e1¡B3©Î5­ÓÀç·~¤é­pºâ¤§´¶³qªÑ¦¬½L»ù²³æºâ¼Æ¥­§¡¼Æ¤À§O¬°301¤¸¡B293.7¤¸¡B316.8¤¸¡A¾Ü«e3¤é¤§¦¬½L§¡»ù¦©°£µLÀv°tªÑ°£Åv¤Î°t®§¨Ã¥[¦^´î¸ê¤Ï°£Åv«á¤§ªÑ»ù293.7¤¸¬°°ò·Ç¡F¥t¥H©w»ù¤é«e30­ÓÀç·~¤é´¶³qªÑ¦¬½L»ù²³æºâ¼Æ¥­§¡¼Æ¦©°£µLÀv°tªÑ°£Åv¤Î°t®§¨Ã¥[¦^´î¸ê¤Ï°£Åv«á¤§ªÑ»ù243¤¸¬°°ò·Ç¡A¨ú¤W­z¤G°ò·Ç­pºâ»ù®æ¸û°ªªÌ­q¬°°Ñ¦Ò»ù®æ¡A¬G¥»¦¸¨p¶Ò¤§°Ñ¦Ò»ù®æ¬°293.7¤¸¡F¸gºî¦X¦Ò¶q«á¡A­q©w235¤¸¬°¥»¦¸¹ê»Ú¨p¶Ò»ù®æ¡A¬°°Ñ¦Ò»ù®æ¤§80.01%¡A¤£§C©óªÑªF±`·|¨Mij°Ñ¦Ò»ù®æ¤§¤K¦¨¡C

C.¥»¦¸¨p¶Ò´¶³qªÑ¨CªÑ»ù®æ¤§­q©w«Y¥H¥»¤½¥q©ó¶°¤¤¥æ©ö¥«³õ´¶³qªÑ¤§¤@¬q®É¶¡¦¬½L§¡»ù¬°°Ñ¦Ò¨Ì¾Ú¡A¬G¥»¦¸¨p¶Ò»ù®æ­q©w¤è¦¡¤Î±ø¥ó²Å¦Xªk¥O³W©w¡AÀ³ÄݦX²z¡C

7.¥»¦¸¨p¶Ò¸êª÷¥Î³~:¥»¦¸Äw±¹¤§¸êª÷¹w­p¥Î©ó¥R¹êÀç¹B¸êª÷¡B°·¥þ°]°Èµ²ºc¤Î¡þ©Î¶i¦æ·sÃĬãµo¤Î¡þ©ÎÂà§ë¸ê¤Î¡þ©ÎÁʸm©T©w¸ê²£¤Î¡þ©Î¤äÀ³¨ä¥L¦]À³¥»¤½¥qªø´Áµo®i¤§¸êª÷»Ý¨Dµ¥¤@¶µ©Î¦h¶µ¥Î³~¡C

8.¤£±Ä¥Î¤½¶}¶Ò¶°¤§²z¥Ñ:

¦Ò¶q¨p¶Ò¤è¦¡¬Û¹ï¨ã®É®Ä©Ê»P«K§Q©Êµ¥¦]¯À¡A¥B¨p¶Ò¦³»ùÃÒ¨é¤T¦~¤º¤£±o¦Û¥ÑÂàÅý¤§³W©w±N§ó¥i½T«O¤½¥q»PÀ³¶Ò¤H¶¡¤§ªø´ÁÃö«Y¡F¥t³z¹L±ÂÅv¸³¨Æ·|µø¤½¥qÀç¹B¹ê»Ú»Ý¨D¿ì²z¨p¶Ò¡A¥ç±N¦³®Ä´£°ª¥»¤½¥qÄw¸ê¤§¾÷°Ê©Ê»PÆF¬¡©Ê¡A¦]¦¹¥H¨p¶Ò¤è¦¡¿ì²z¨ã¦³¥²­n©Ê¡C

9.¿W¥ß¸³¨Æ¤Ï¹ï©Î«O¯d·N¨£:µL¡C

10.¹ê»Ú©w»ù¤é:110/12/23

11.°Ñ¦Ò»ù®æ:293.7¤¸

12.¹ê»Ú¨p¶Ò»ù®æ¡BÂà´«©Î»{ÁÊ»ù®æ:235¤¸

13.¥»¦¸¨p¶Ò·sªÑ¤§Åv§Q¸q°È:

¥»¦¸¨p¶Ò·sªÑ¤§Åv§Q¸q°È»P¥»¤½¥q¤wµo¦æ¤§´¶³qªÑ¬Û¦P¡A±©¨ÌÃÒ¨é¥æ©öªk²Ä43±ø¤§8³W©w¡A¥»¦¸¨p¶Ò´¶³qªÑ°£²Å¦X¯S©w±¡§Î¥~¡A¤£±o¦Û¥ÑÂàÅý¡C©ó¸Ó¨p¶Ò¦³»ùÃÒ¨é¥æ¥I¤é©Î¹º¼·¤é°_º¡¤T¦~«á©l±o¦Û¥ÑÂàÅý¡A¨Ã©ó¨p¶Ò´¶³qªÑ¥æ¥I¤é°_º¡¤T¦~«á¡A±ÂÅv¸³¨Æ·|¨Ì¬ÛÃöªk¥O³W©w¥Ó³ø¸É¿ì¤½¶}µo¦æ¤Î¤WÂd¥æ©ö¡C

14.ªþ¦³Âà´«¡B¥æ´«©Î»{ªÑªÌ¡A¨ä´«ªÑ°ò·Ç¤é:¤£¾A¥Î¡C

15.ªþ¦³Âà´«¡B¥æ´«©Î»{ªÑªÌ¡A¹ïªÑÅv¥i¯àµ}ÄÀ±¡§Î:¤£¾A¥Î¡C

16.ªþ¦³Âà´«©Î»{ªÑªÌ¡A©ó¨p¶Ò¤½¥q¶Å¥æ¥I¥B°²³]¥þ¼ÆÂà´«©Î»{ÁÊ´¶³qªÑ«á¹ï¤WÂd´¶³qªÑªÑÅv¤ñ²v¤§¥i¯à¼vÅT¡]¤WÂd´¶³qªÑ¼ÆA¡BA/¤wµo¦æ´¶³qªÑ¡^:¤£¾A¥Î¡C

17.«e¶µ¹w­p¤WÂd´¶³qªÑ¥¼¹F500¸UªÑ¥B¥¼¹F25%ªÌ¡A½Ð»¡©úªÑÅv¬y³q©Ê°¾§C¤§¦]À³±¹¬I:¤£¾A¥Î¡C

18.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¥»¦¸¨p¶Ò´¶³qªÑ¤§ªÑ´Úú¯Ç´Á¶¡¬°110¦~12¤ë23¤é¦Ü110¦~12¤ë29¤é¡C

(2)¥»¦¸¨p¶Ò´¶³qªÑ¤§¼W¸ê°ò·Ç¤é¬°110¦~12¤ë30¤é¡C

(3)¹ê»Ú¨p¶Ò¹ï¶H¤Î»{ÁʪѼƵøú´Ú±¡§Î¦Ó©w¡AÀÀ±ÂÅv¸³¨Æªø¥þÅv³B²z¤§¡C

(4)¬°°t¦X¥»¦¸¨p¶Ò´¶³qªÑ¡AÀÀ±ÂÅv¸³¨Æªø¥Nªí¥»¤½¥qñ¸p¤@¤Á¦³Ãö¤§«´¬ù©Î¤å¥ó¤Î¿ì²z¤@¤Á¬ÛÃö¨Æ©y¡A¦p¦³¥¼ºÉ¨Æ©y¤Î¦]ªk¥O©Î¥DºÞ¾÷Ãö­n¨D¦Ó¦³©ÒÅܧ󤧥²­n®É¡A±ÂÅv¸³¨Æªø¥þÅv³B²z¤§¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/20 ¤U¤È 08:56:14²Ä 9902 ½g¦^À³
¥»¤H¬Ýªk¡A³oªi¤j¶qºDÀ£¤âªk¡AµLºÃ¬O°µ¤âÀ£§C¦Y³f¡A³o»ò©úÅã~¥q°¨¬L¤§¤ß¡AÃĵØÃÄ­Y¤£¬O¥Í§Þ¬ÉªºË³Ë³ªÌ¡A¦ó¥²©O¡H

·í¶^°±¶}§Y©Ôº¦°±¡A¥»¤H¦ôÂI¸¨¦b245¤¸¤W¤U¤j¤Ï¼u

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10148182  µoªí®É¶¡:2021/12/20 ¤U¤È 06:16:15²Ä 9901 ½g¦^À³
2021/12/19 08:10:00

¸gÀÙ¤é³ø °OªÌÁ¬f§»¡þ¥x¥_³ø¾É

¥xÆW¥Í§Þ·sÃĤ½¥q³v¨B¦b®ü¥~¶}ªáµ²ªG¡A¦Û²Õ¾P°â¹Î¶¤·m§ð¥«³õ¦¨¬°·sÁͶաCÃĵØÂåÃÄ¡]6446¡^¨u¨£¯e¯f·sÃÄBesremi¡]P1101¡^11¤ë12¤é®³¨ì¬ü°êÃÄÃÒ«á¡A¤½¥q¥´³y°ê¤º²Ä¤@®a¦Û¦æ¬ãµo¡B¦Û¦æ¥Í²£¡B¦Û¦æ¾P°âªº¤@±øÀs·sÃĤ½¥q¡AÃĵØÃĦb¬ü°êªº¾P°â¹Î¶¤¤w¥Ñ¥h¦~©³ªº40¤H¼W¦Ü¥Ø«e70¤H¡A¥Ø«e¤w±µ¨ì¤Q¦hµ§­q³æ¡A±N¦Û12¤ë°_³v¨B°^Äm·~ÁZ¡C

ÃĵØÃĦÛ11¤ë°_ªÑ»ù¦Û¤E¤Q¦h¤¸¤@¸ôötº¦¦Ü¹O¤T¦Ê¤¸¡A¥«­È±q200¦h»õ¤¸¼É½Ä¦Ü³Ì°ª¹F¨ì¤d»õ¤¸¡A17¤é¦¬½LÁö¶^°±333¤¸¦¬¡A¥«­È¤]¦³970¦h»õ¤¸¡A¹Gªñ¤d»õ¤¸¡A¤£¨ì¨â­Ó¤ë¡AÃĵØÃÄ¥«­È¼É¼W800»õ¤¸¡C

ÃĵØÃĤW©P¤w¶}©l¥X²{½L¾ã¡A¥«³õ¹w´ú¸Ó¤½¥qªº¡u¥»¹Ú¤ñ¡v±N³v¨B°h¿N¡A²{¦b¥¿­n¶}©lÀ˵ø¤½¥qªº¡u¤ñ¯q¤ñ¡v¡A±µ¤U¨ÓÃĵØÃÄ­n¦p¦ó¸¨¹ê¨ä¾P°â¦¨ÁZ¡H²{¦³ªºµ¦²¤³W¹º¦ÜÃö­«­n¡C

°ê¤º·sÃĬãµo¤½¥qªñ¦~¨Ó³v¨B¥æ¥X¦n¦¨ÁZ¡A2014¦~¦Ü¤µ¤w¦³¤C¶µ·sÃĦb®ü¥~¤W¥«¡A¤£¹L³o¨Ç·sÃÄ¥´¤J°ê»Ú¥«³õ«e¡Aµ´¤j¦h¼Æ·|±ÂÅvµ¹°ê»ÚÃļt©Î¤j«¬¾P°â¤½¥q¡A¥D¦]·sÃĤW¥««á¾P°âªùÂe«Ü°ª¡AµL±j¤jªº¾P°â¹Î¶¤¤Î¸êª÷°µ«á¬Þ¡A¹ï¥H¬ãµo¬°¾É¦Vªº¥»¤g¥Í§Þ·~¨Ó»¡¡AÄÝ©ó¥t¤@¤j¬D¾Ô¡C

¦ý¦Û¤µ¦~12¤ë°_¡AÃĵØÃĦ¨¬°°ê¤º²Ä¤@®a¦Û¦æ¬ãµo·sÃÄ¡B¦Û¦æ¥Í²£¡B¦Û¦æ¦b®ü¥~¾P°âªº¤½¥q¡A¤½¥q©w¦ì±q¥Í§Þ¡]Bio¡^¬ãµo¤½¥q¤É¯Å¦Ü»sÃÄ¡]Pharma¡^¼t¡A¦b¬ü°êªº¾P°â¹Î¶¤¡A§ó¥Ñ¥h¦~©³ªº40¤H¼W¦Ü¥Ø«eªñ80¤H¡CÃĵØÃÄ»¡©ú¡A¾P°â¹Î¶¤¥]¬A¥|¦ìÂåÃľdzN±M­û¡]MSL¡^¡B¤­¦ì°Ï°ìÁ`ºÊ¡]RBD¡^¤Î34¦ì¾P°â¥Nªí¡C

¨­¬°¥xÆW²Ä¤@®a¦Û¦æ¦b®ü¥~¾P°âªº·sÃĤ½¥q¡AÃĵØÃıq¥h¦~©³´N¤w¶}©l«Ø¥ß¾P°â¹Î¶¤¡C¤½¥qªí¥Ü¡A·í®É¤w¦³¬Û·í¤jªº§â´¤¡A»{¬°BesremiÀ³¥i¥H³q¹L¬ü°êFDA¼f¬d¡A¥¿¦¡¨ú±o¬ü°ê¥«³õÃÄÃÒ¡A¥B¨Ì·Ó¼f¬d¶i«×¡A¦ô­p®³¨ìÃÄÃÒªº®É¶¡ÂI¬O¤µ¦~3¤ë¡A¦]¦¹ÃĵØÃĦb¥h¦~©³¶}©l¥l§L¶R°¨¡A§Æ±æ¥Î¤T­Ó¤ëªº®É¶¡°w¹ï³o§å¾P°â¹Î¶¤¶i¦æ±Ð¨|°V½m¡C

¤£®ÆFDA¦b¤µ¦~3¤ë«e§iª¾ÃĵØÃÄ¡A¦]¨ä¼f¬d¤å¥ó»Ý­n¸É¥ó¡A¦]¦¹¾ã­Ó¤W¥«¬yµ{©ì©µ¤U¨Ó¡Aª½¨ì¤µ¦~9¤ë©³¨â¦ìFDA©x­û¨Ó¥x§¹¦¨ÃĵØÃÄ¥x¤¤¼t¬d¼t«á¡A¦Ü¤µ¦~11¤ë¤~¥¿¦¡§å­ãÃĵØÃĪºBesremi¥i¥H¤W¥«¡C

¬°¤Fªï¾ÔBesremi¦b¬ü°êªº¤W¥«¡AÃĵØÃıq¥h¦~12¤ë´N¶}©l¨î©w¤F¤W¥««e¡B¤W¥««á²Ä¤@­Ó¤ë¨ì¤W¥««á²Ä¤@¦~µ¥¤£¦P¶¥¬qªº±À¼sµ¦²¤¡C

­º¥ý¦b¤W¥««eªº±À¼s¶¥¬q¡A­«ÂI¬O¦V¬ü°êPVªvÀøÅv«Â¡A³z¹L¾Ç³N¬ã°Q·|¤Îºô¯¸¬[³]¶i¦æ±À¼s¡F¨ä¦¸¬O¤W¥««á²Ä¤@­Ó¤ë¶¥¬q¡A­n³z¹L¼Æ¤Q¦ì±M®a¥Nªí¡AÂê©w¼Æ¤d¦ìPVÂå®v¡A¥H¤Î¦h¶¡°©Åè¼W¥Í©Ê¸~½F¡]MPN¡^ªvÀø¤¤¤ß¡A¥þ¤O®i¶}¾P°â¥¬§½¡F³Ì«á¬O¤W¥««á¤@¦~¡A±Nª§¨úP1101¯Ç¤J¬ü°êNCCNªvÀø«ü¤Þ¡AÂX¤j©Ó«O½d³ò¡A´î¤Ö¯f±w¨ú±oÃÄ«~ªº®É¶¡¡A°õ¦æ¯f±w¤ä«ù­pµe¡AÀ°§U¯f±w«ùÄò±µ¨üªvÀø¡C

¦¹¥~¡A¸g¹L¼Æ¦~·Ç³Æ¡A¥Ø«eÃĵØÃĤw¨ú±o¥þ¬ü°ê¦U¦{ªº¾P°â°õ·Ó¡A¤]»Pµ´¤j¦h¼ÆÃöÁä«OÀI¤½¥q¬¢½Í¦X§@¡A¥Ø¼Ð­nª§¨úµ´¤j¦h¼ÆPV¯f±w±Ú¸sªº«OÀIµ¹¥I¡C

¦b¤H¨Æ¥¬§½¤è­±¡AÃĵØÃĦb¥h¦~12¤ë®É¡A¸u½Ð¬ü°ê³Ì¤jÃļt½÷·ç¤½¥qªº«e¦æ¾P³Bªø¡BBaxter¤½¥q¥þ²y¦å¤Í¯f¦æ¾P°ÆÁ`Meredith Manning¾á¥ô¬ü°ê¤l¤½¥qÁ`¸g²z¡F°w¹ïÁ{§Éµo®i¤ÎÂåÀø¨Æ°È¥DºÞ¡A¤]¸u½Ð´¿©ó¬ü°ê½÷·ç¤l¤½¥qªºRay UrbanskiÂå®v¾á¥ô¤½¥qªºÂåÀø¨Æ°Èªø¡C

¤@ª½¨ì12¤ë7¤é¡AÃĵصئA«×«Å¥¬¡A¬ü°ê¤l¤½¥q¥¿¦¡±Ò°Ê¯f¤Í¤ä´©­p¹º¡A°w¹ï¦³¸gÀÙ§xÃøªº±wªÌ±µ¨üªvÀø¡A±N´£¨Ñ±¾¸¹¶O/©wÃB¤âÄò¶O¡]co-pay¡^ »P¦Û¥IÃB¡]co-insurance¡^¬ÛÃö¨ó§U¡AÀ°§U¦³¸gÀÙ§xÃøªº±wªÌ¡C¤º®e¥]¬A´£¨Ñ0¬ü¤¸ªº©wÃB¥d (copay card) µ¹¦³°Ó·~«OÀIªº±wªÌ¡B¦b«OÀI©µ¿ð¤Î/©Î©Ó«O½d³ò¤£¨¬ªº±¡ªp¤U´£¨ÑÀ³«æÃÄ«~¡B¬°¥¼§ë«O©M§ë«O¤£¨¬ªº±wªÌ§K¶O´£¨ÑÃĪ«¡B¥H¤Î®Ú¾Ú±¡ªp´£¨Ñ¥²­nªºÃB¥~¨ó§Uµ¥¡C

ÃĵØÃĪí¥Ü¡AºI¦Ü¥Ø«e¬°¤î¡A¬ü°ê¥«³õ¤w±µÀò¤Q¾l±i­q³æ¡A¥¿·Ç³ÆÂà¹B¦Ü¤U¹F­q³æªº±M¬ìÃħ½¡]Specialty Pharmacy, SP¡^©M¯S®íÃÄ«~¸g¾P°Ó¡]Specialty Pharma Distribution, SD¡^¡A·íÃÄ«~±qÖפT¤èª«¬y¤¤¤ß°e¹F±M¬ìÃħ½©Î¯S®íÃÄ«~¸g¾P°Ó®É¡A¤½¥q´N¥i»{¦CÀ禬¡C¦ý¬OÃĵØÃıj½Õ¡A¥ô¦ó·sÃĪº¾P°â¦¨ÁZµ´¤£¥i¯à¤@­¸½Ä¤Ñ¡A§Æ±æµ¹¤©§ó¦h®É¶¡ÃÒ¹êBesremi¹ï¬ü°êÂåÃÄ¥«³õªº¼vÅT¤O¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10148182  µoªí®É¶¡:2021/12/14 ¤U¤È 04:04:32²Ä 9900 ½g¦^À³
ÃĵØÃĵn¥ÍÂåªÑ¤ý 660.2¸UªÑ¨p¶Ò®×¦A§U«Â

ÃĵØÃÄÀò¬ü®Ö­ã P1101 ÃÄÃÒ¦@­p¹F¦¨¤T¶µ³ÐÁ|¡A­º¥ý¬O²Ä¤@­ÓÀò FDA ®Ö­ãµL½× PV ±wªÌ¥ý«e¬O§_±µ¨ü¹L¨ä¥LªvÀø¤è¦¡§¡¥i¨Ï¥ÎªºÃÄ«~¡F¨ä¦¸¬O²Ä¤@­ÓÀò FDA ®Ö­ã©Ò¦³¦¨¤H PV ±wªÌ§¡¥i¨Ï¥ÎªºÃÄ«~¡F²Ä¤T¬O²Ä¤@­ÓÀò FDA ®Ö­ã±Mªù¥Î©óªvÀø PV ªº¤zÂZ¯ÀÀø

¹d¦ëºô·s»D¤¤¤ß

2021¦~12¤ë14¤é ¶g¤G ¤W¤È10:51

ÃĵØÃĪñ´Á¦]Àò¬ü°êÃÄÃÒ§U§ðªÑ»ù©Ôªø¬õ¡A¹ð¹ð³Ð¤Uµn¿ý¤WÂd¥æ©ö¥H¨Ó³Ì°ªªÑ»ù¬ö¿ý¡C¤é«e¡AÃĵØÃĤ½§i¤µ¦~²Ä¤@¦¸¨p¶Ò´¶³qªÑ¡A¨CªÑ©w»ù 177 ¤¸¡B¦@ 660.2 ¸UªÑ¨p¶Ò®×¡A¤w©ó 10 ¤é¦¬¨¬ªÑ´Ú¡A13 ¤é¬°¼W¸ê°ò·Ç¤é¡A¸êª÷¥Î©ó¥R¹êÀç¹B¸êª÷¡B°·¥þ°]°Èµ²ºc¡C®ø®§¤@¥X¡A13 ¤éª½§ðº¦°±¡A¤µ¤é¶}½LªÑ»ù¤w¦Ü 422 ¤¸¡A©~¥ÍÂåªÑ¤ýÄ_®y¡CÃĵØÃĹw­p¤µ¦~¥þ¦~À禬¦³±æ¦A½Ä°ª¡B¶W¶V¥h¦~¡A¥[¤WÃĵØÃĤµ¦~¦¬ÀòÁú°ê¤Î¬ü°êÂùÃÄÃÒ¡A®i±æ 2022 ¦~À禬¦¨ªø§ó¬O«á¶Õ¥i´Á¡C

¥ÑÃĵØÃÄ Besremi ¦b 11 ¤ë 13 ¤éÀò±o¬ü°ê¤W¥«³\¥i«á¡A¾ú¸g¤@­Ó¤ë¨ì 12 ¤ë 13 ¤é¡AÃĵØÃĪѻù¤w¤jº¦ 3 ­¿¡A¬Q¦¬¦b 369 ¤¸¡A¦¨¬°²Ä 4 ©uº¦¶Õ³ÌµLªkÀɪº¥Í§ÞªÑ¡Aªñ¤é¨p¶Ò®×¶¶§Q¶i¦æ¡AÅ㨣ªk¤H¹ï¨u¨£¦åÀù·sÃÄ Ropeginterferon alfa-2b¡]§Y P1101¡^Àò¬ü FDA ®Ö­ã¡A¨É¦³ 7 ¦~¥«³õ¿W¥eÅvªºªø½u·~ÁZ¬Ý¦n¬Ý©ô¡C

ÃĵØÃĪº P1101¡A¬°³Ð·sªø®Ä«¬¤zÂZ¯ÀÃĪ«¡A¥Ø«e³Q®Ö­ãªvÀø¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^±wªÌ¡A¨Ã¨É¦³¤C¦~¥«³õ¿W¥eÅv¡F¥t¥~¡A¦b¬ü°ê«OÀIµ¹¥I³\¥i¤U¡A³o¶µÃÄ«~¹w­p©w»ù¨C¾¯ 6,988 ¬ü¤¸¡AÀøµ{»Ý­n 26 ¾¯¡AÁ`¶O¥Î¬ù 18.2 ¸U¬ü¤¸ (¬ù·s¥x¹ô 507 ¸U¤¸¡^¡A¥Ñ©ó¥þ¬ü°ê¦@¦³ 16 ¸U¦W PV ±wªÌ¡A ÃĵØÃĪº¥Ø¼Ð¯f±w±Ú¸sÂê©w 8 ¸U¦W¡A±N·m§ð¹O 4,000 »õ¤¸¥«³õ°Ó¾÷¡A¥B±wªÌ±µ¨üªvÀø«á¶·²×¨­¥ÎÃÄ¡A¥ç§YÀ禬Àò§Q¤£¬O¤@¦¸©Ê¡A¦Ó¬OÀHµÛ·~°È¶i®i»P¤£¦P¾AÀ³¯gÃÄÃÒ¶i®i²Ö¶i¦¨ªø¡C¥Ø«e¤w³z¹LÃĵØÃĬü°ê¤l¤½¥q³q¸ô®i¶}¾P°â¡C

­È±o¤@´£ªº¬O¡A¦¹¦¸ÃĵØÃÄÀò¬ü®Ö­ã P1101 ÃÄÃÒ¦@­p¹F¦¨¤T¶µ³ÐÁ|¡A­º¥ý¬O²Ä¤@­ÓÀò FDA ®Ö­ãµL½× PV ±wªÌ¥ý«e¬O§_±µ¨ü¹L¨ä¥LªvÀø¤è¦¡§¡¥i¨Ï¥ÎªºÃÄ«~¡F¨ä¦¸¬O²Ä¤@­ÓÀò FDA ®Ö­ã©Ò¦³¦¨¤H PV ±wªÌ§¡¥i¨Ï¥ÎªºÃÄ«~¡F²Ä¤T¬O²Ä¤@­ÓÀò FDA ®Ö­ã±Mªù¥Î©óªvÀø PV ªº¤zÂZ¯ÀÀøªk¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/14 ¤U¤È 01:01:17²Ä 9899 ½g¦^À³
¬Û«H¤µ¤Ñªº¾_¾Ù±Ð¨|¤j®a³£¦³À~¨ì¤F¡A©ñ¤ß°Õ~¦æ±¡¤£·|¤î©ó¾P°â«e

ÃĵØÃĤ~­nÁÚ¦¨ªø´Á¡A¥ú¬O¬ü°ê¤H¤f±wªÌ±N±a¨ÓÃe¤jªº§Q¯q¡A¦A¨ÓÁÙ

¦³©ú¦~¤j³°¡B¤é¥»ªºÃÄÃÒ¥[¤J¡AÃĵØÃĦ^ÀɧY«K¬O¶RÂI........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬Ý©x10141406  µoªí®É¶¡:2021/12/14 ¤W¤È 09:52:29²Ä 9898 ½g¦^À³
°£¤FP1101À禬¦¨ªø­_§§¥~

¥¿¦b¤T´Á°µÁ{§É¨ä¥¦¾A应¯g

¥ç¥¿¦b§V¤O±À°Ê¤¤

ªÑ»ù¤Wº¦¤]¦b¹w®Æ·í¤¤¦p¥ý¶i¤j©Ò¨¥¥[³t«e¶i¤¤

·íªìªºªL¥_«ç»ò¤£¥X¨Óªk¹ªªø»ï¤F¡H¶ã©I«s«v¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­¸¯T10148959  µoªí®É¶¡:2021/12/14 ¤W¤È 08:47:28²Ä 9897 ½g¦^À³
¥ý«e¼ÐÃD¤@ª½»{¬°«D±`¦³¥i¯à

¦ý·sÃĬãµo­·ÀI«Ü°ª ©Ò¥H·íªì§ï¼ÐÃD´N¤£¦^À³

²{¦b±¡¶Õ«Ü©úÅã °£«D¥«³õ¦³ÅÜ¼Æ ¥|¦ì¼ÆÀ³¸Ó¤£¬O¹Ú

·PÁÂ¥ý¶i¤jµ¥ ½Ñ¦ì¤j¤j ¤£§[¤À¨É¸ê°T ¤~¦³«H¤ß©ê¨ì²{¦b

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GºÖ«°10145527  µoªí®É¶¡:2021/12/13 ¤U¤È 07:41:27²Ä 9896 ½g¦^À³
¥[³t...ÁÙ¥ý¶i¤j(ªø´Á«ù¦³ÃĵØÃÄ500)ªº¤½¹D...............

¦ý§Ú´Á³\¤@¦~¤º,ÃĵØÃÄ´N¯à¦¨¬°¥xÆWªÑ¤ý..................

¬Æ¦ÜÁÙ­n¶W¶V¤j¥ß¥ú©Ò³Ð¤U(¥xÆWÃÒú³¥v¤W6020ªº¤Ñ»ù)........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/13 ¤W¤È 10:29:10²Ä 9895 ½g¦^À³
¥[³t¤¤~©êºò©ê¨c¡Aºò´¤«ùªÑ¥Ø¼Ð5¦~«á¦¨¬°¥xÆW¤§¥ú~ªÑ¤ý
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õÁ`²Î10135593  µoªí®É¶¡:2021/12/10 ¤U¤È 02:44:48²Ä 9894 ½g¦^À³
§ë¸êÃÄµØ §Ú­Ì³£¥i§â¥¼¨Ó·l¯q¦ôºâ¥X¨Ó²M²M·¡·¡ ©ú©ú¥Õ¥Õ ÆgÆgÆg
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/10 ¤U¤È 01:13:14²Ä 9893 ½g¦^À³
¬ü°ê±wªÌ¦³¤Q¤»¸U¤H¡B¾Ö¦³«OÀIµ¹¥Iªº¦³12¸U¤H¡Bpv±wªÌ¤@¦~1¤HªºªvÀø¶O¥Î500¸U¥x¹ô¡BÃĵØÃĬü°ê¤l¤½¥qµû¦ô¦³¤Q¸U¤H·|¨Ï¥ÎÃĵØÃĪºpv¤@½uÃĪ«

§Ú­Ìµû¦ô¤£¥Î¤Q¸U¤H¡B¤@¸U¨Ï¥Î´N¦n¡B500¸Ux10000¤H¦~À禬¬°500»õ¡BÃĵØÃĪѥ»30»õ¥H¤U¤ò§Q²v75%¡BEPS¥iÁÈ120¤¸¥H¤W¡B­Y¬O¤Q¸U¤H¨Ï¥ÎEPS¬°1200¤¸¥H¤W¡B©ú¦~¤S¦³¤j³°¡B¤é¥»pvÃÄÃÒ¤J³U¡B·Q¹³ÃĵØÃÄ·|¦h»ò«G²´¡BªÑ»ùµL¥i­­.......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/10 ¤U¤È 12:57:01²Ä 9892 ½g¦^À³
©êºò³B²z¡AÂ÷¤§«e¼ÐÃD¶V¨Ó¶Vªñ¤F~·P®¦
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GºÖ«°10145527  µoªí®É¶¡:2021/12/10 ¤W¤È 10:27:35²Ä 9891 ½g¦^À³
¹L°}¤l,´N­nÁÙ¥ý¶i¤j¤@­Ó¤½¹D¤F..............

¥ý«eÃĵØÃĪø¤[¤W¬Ý500¼ÐÃD..................

³Q¬Y¨Ç´X¦ì¤j¤j¹G­¢­×§ï.......................

¨º®É,§Ú¥»¨­±q¨S¦³°w¹ï³o500¸ÜÃD,»Ä¹L¥ý¶i¤j.........

¦]¬°,ªø¤[§ë¸êªÑ²¼¥H¨Ó,§Ú»{¬°500»ù¦ì¹ï·sÃĨÓÁ¿,¥ô¦ó¨Æ³£¦³¥i¯à·|µo¥Í...........

¥u¬O¦¹¦¸ÃĵØÃÄötº¦,¯uªº¬O(¤Ñ®É.¦a§Q.¤H©M)°Ú..............................

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/9 ¤U¤È 01:26:31²Ä 9890 ½g¦^À³
Vivi~®¥³ß¥ý¶i¤j...ª¾¹D§A«ù¦³ÃĵØÃĦh¦~¤F.

................................­W¦u´H½`¤Q¸ü¡Aµ¥«Ýªº´N¬O³o¤@¨è¡A§Æ±æ¸òµÛ¥»¤H«ù¦³ÃĵØÃĪº§ë¸ê¤H¡A¦@¦P¨É¨ü³o¥÷ºaÄ£¤Î²¢¬ü¦¨ªG

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2021/12/8 ¤U¤È 09:50:24²Ä 9889 ½g¦^À³
±µ¤U¨ÓÁÙ¬O¤ñ­@¤ß¡A¬Ý½Ö©ê±o¤[¡A·íµM¤¤³~ÁÙ¬O­nª`·NÀ禬ª¬ªp¡I½T»{¤è¦V¬O§_¥¿½T¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GºÖ«°10145527  µoªí®É¶¡:2021/12/8 ¤U¤È 09:29:19²Ä 9888 ½g¦^À³
·Q¨ì¥h¦~¤C¤ë©³®É,ÃĵØÃıH¨Ó²{ª÷¼W¸ê»{ªÑú´Ú®Ñ..............

¥i»{ªÑ¼Æ4±i¦h,ÁÙ­n¦Aú¯Ç40´X¸U.............................

¨º®É­Ô,¤ß¸Ì¦³±Ã¤ã,¨ì©³­n¤£­n»{ªÑ.............................

«á¨Ó,³Ì«á¤@¤ÑÁÙ¬O¥h¦X§@ª÷®wú¿ú,¤§«á¥þ³¡´X¤Q±i,³£¤£ºÞ¥¦ªºº¦¶^.........

²{¦b·Q·Q¯u¬OÁȨì¤F..........................

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gvivi10030401  µoªí®É¶¡:2021/12/7 ¤W¤È 09:50:42²Ä 9887 ½g¦^À³
®¥³ß¥ý¶i¤j...ª¾¹D§A«ù¦³ÃĵØÃĦh¦~¤F...
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/6 ¤U¤È 12:56:11²Ä 9886 ½g¦^À³
¶W¶}¤ß~¶W±j¨«¶Õ¡A¥»¤H¤@¦A±j½Õ¡A©êºò©ê¨c¡A¤â¤¤µL«ù¯ëªº´M§ä§CÂI¥[½X¡A°ò¥»«ùªÑ­n¦³........­«ªðºaÄ£
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10148182  µoªí®É¶¡:2021/12/5 ¤U¤È 04:57:02²Ä 9885 ½g¦^À³
ÃĵØÃÄ11¤ëÀ禬2.25»õ¤¸³Ð¾ú¥v·s°ª ¬Ý¦n©ú¦~«á¶Õ¥i´Á

2021-12-05 15:14 Áp¦X³ø / °OªÌªL®ü¡þ¥x¥_§Y®É³ø¾É

ÃĵØÃĤ½§i11¤ëÀ禬¹F2.25»õ¤¸¡A³Ð¾ú¥v·s°ª¡A¦~¼W3.02%¡B¤ë¼W431.5%¡A²Ö­p1¦Ü11¤ë¦X¨ÖÀ禬¹O5.44»õ¤¸¡A¦P¼Ë¬O¾ú¥v·s°ª¡A¹w­p¤µ¦~¥þ¦~À禬¦³±æ¦A½Ä°ª¡B¶W¶V¥h¦~¡A¥[¤WÃĵØÃĤµ¦~¦¬ÀòÁú°ê¤Î¬ü°êÂùÃÄÃÒ¡A®i±æ2022¦~À禬¦¨ªø§ó¬O«á¶Õ¥i´Á¡C

ÃĵØÃĪí¥Ü¡A¦¹¦¸À禬¥D­n¨Ó¦Û©ó¼Ú¬w¥X³f¡A¨Ã±Ä¹w¦¬´Ú«á¥X³f¡A¦Û³Ð·sÃÄRopeginterferon alfa-2b¡]§YP1101¡A²ºÙRopeg¡^Àò±o¼Ú·ù¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^ÃÄÃÒ«á¡A¼Ú¬w¥«³õ¹ïRopeg»Ý¨D¶qí°·¦¨ªø¡A®Ú¾Ú¥«½Õ¾÷ºc¬ã¨s³ø§i«ü¥X¡A¥þ¼Ú¬wPV±wªÌ¬ù20¸U¤H¡A¥­§¡¨C¦W±wªÌ¨Ï¥ÎRopeg¤§¤@¦~Àøµ{ÃÄ»ù¬ù10¸U¼Ú¤¸¡]¬ù¬°300¸U¤¸¥x¹ô¡^¡C

ÃĵØÃĤ]»¡¡A°£¶¶§Q©Ý®i¼Ú¬w¥«³õ¥~¡ARopeg¤]©ó¤µ¦~10¤ë13¤éÀòÁú°êÃÄÃÒ¡A©ó11¤ë13¤éÀò±o¬ü°êÃÄÃÒ¡A¥æ¥X«G²´¦¨ÁZ³æ¡C¬ü°êFDA¯S§Oµo¥¬·s»D½Z¡A»¡©ú¦¹¦¸®Ö­ãRopeg PVÃÄÃÒ¡A¦@¹F¦¨ÀòFDA®Ö­ãµL½×PV±wªÌ¥ý«e¬O§_±µ¨ü¹L¨ä¥LªvÀø¤è¦¡§¡¥i¨Ï¥ÎªºÃÄ«~¡BÀòFDA®Ö­ã©Ò¦³¦¨¤HPV±wªÌ§¡¥i¨Ï¥ÎªºÃÄ«~¡BÀòFDA®Ö­ã±Mªù¥Î©óªvÀøPVªº¤zÂZ¯ÀÀøªkµ¥¤T¶µ³ÐÁ|¡C

ÃĵØÃĪí¥Ü¤w±µÀò¤Q¾l±i­q³æ¡A¥¿·Ç³ÆÂà¹B¦Ü¤U¹F­q³æªº±M¬ìÃħ½¡]Specialty Pharmacy, SP¡^©M¯S®íÃÄ«~¸g¾P°Ó¡]Specialty Pharma Distribution, SD¡^¡A·íÃÄ«~±qÖפT¤èª«¬y¤¤¤ß¡]3PL)°e¹F±M¬ìÃħ½©Î¯S®íÃÄ«~¸g¾P°Ó®É¡A¤½¥q´N¥i»{¦CÀ禬¡C

ÃĵØÃÄ«ü¥X¡Aªñ´Á¦]Àò¬ü°êÃÄÃÒ§U§ðªÑ»ù©Ôªø¬õ¡A¹ð¹ð³Ð¤Uµn¿ý¤WÂd¥æ©ö¥H¨Ó³Ì°ªªÑ»ù¬ö¿ý¡A12¤ë3¤é·í¤é¥H243.5¤¸§@¦¬¡A½L¤¤¤@«×¹F249.5¤¸¡A¦b¼Ú¬ü­q³æ»Ý¨D±a°Ê¤U¡A¥[¤W¼Ú¬w¥X³f³f´Ú¤w¤J³U¡A¥«³õ¬Ý¦nÃĵØÃÄÀç¹B«e´º¡A¤£¦ý¤µ¦~¥þ¦~À禬¦³±æ¶W¶V¥h¦~¡A2022¦~§ó±Nªï¨Ó¬ð¯}©ÊÀ禬¦¨ªø´Á¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10148182  µoªí®É¶¡:2021/12/5 ¤U¤È 04:44:10²Ä 9884 ½g¦^À³
ÃĵØÃÄ11¤ëÀ禬¤ë¼W4­¿ Àò¬ü¡BÁúÃÄÃÒ ±Ò°Ê°ª¦¨ªø¤O¹D

14:532021/12/05 ¤u°Ó §ù¿·»T

ÃĵØÃÄ¡]6446¡^¨ü´fªv¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^·sÃÄRopeg¡A¼Ú¬w¥«³õ¾P°â¨Î¡A±a°Ê11¤ë¦X¨ÖÀ禬¥H¹O2.25»õ¤¸¡A¥æ¥X¤ë¼W431.5%¡B¦~¼W3.02%¨ÎÁZ¡C¥Ñ©ó¸Ó¤½¥q¤µ¦~¤wÀòÁú°ê¡B¬ü°êÃÄÃÒ¡Aªk¤H¬Ý¦nÀç¹Bªø±Ò°Ê°ª¦¨ªø¤O¹D¡C

¸Ó¤½¥q²Ö­p¤µ¦~«e11¤ë¦X¨ÖÀ禬¹O5.44»õ¤¸¡A¦~¦¨ªø4.25%¡C11¤ë©M«e11¤ëÀ禬§¡³Ð¤U¾ú¥v·s°ª¡C

ÃĵØÃĪí¥Ü¡A11¤ëÀ禬¥D­n¨Ó¦Û©ó¼Ú¬w¥X³f¡A¨Ã±Ä¹w¦¬´Ú«á¥X³f¡CÃĵØÃĦ۳зsÃÄRopeginterferon alfa-2b¡]§YP1101¡A²ºÙRopeg¡^Àò±o¼Ú·ù¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^ÃÄÃÒ«á¡A¼Ú¬w¥«³õ¹ïRopeg»Ý¨D¶qí°·¦¨ªø¡C

®Ú¾Ú¥«½Õ¾÷ºc¬ã¨s³ø§i«ü¥X¡A¥þ¼Ú¬wPV±wªÌ¬ù20¸U¤H¡A¥­§¡¨C¦W±wªÌ¨Ï¥ÎRopeg¤§¤@¦~Àøµ{ÃÄ»ù¬ù300¸U¥x¹ô¡]10¸U¼Ú¤¸¡^¡C

°£¶¶§Q©Ý®i¼Ú¬w¥«³õ¥~¡ARopeg¤]©ó¤µ¦~10¤ë13 ¤éÀòÁú°êÃÄÃÒ¡A©ó11¤ë13¤éÀò±o¬ü°êÃÄÃÒ¡A¥æ¥X«G²´¦¨ÁZ³æ¡C

ÃĵØÃĪºRopeg ¡A¬O²Ä¤@­ÓÀòFDA®Ö­ãµL½×PV±wªÌ¥ý«e¬O§_±µ¨ü¹L¨ä¥LªvÀø¤è¦¡§¡¥i¨Ï¥ÎªºÃÄ«~¡F¬O­º­ÓÀòFDA®Ö­ã©Ò¦³¦¨¤HPV±wªÌ§¡¥i¨Ï¥ÎªºÃÄ«~¡F¤]¬O²Ä¤@­ÓÀòFDA®Ö­ã±Mªù¥Î©óªvÀøPVªº¤zÂZ¯ÀÀøªk¡Cªì¦ô±wªÌ¨C¦~ÃÄ»ù¬ù500¸U¥x¹ô¡]18¸U¬ü¤¸¡^¡C¥Ø«eÃÄ«~¤]¤w¹B°e¦Ü¬ü°êªºÀx¦s­Ü®w¡]§Y²Ä¤T¤èª«¬y¤¤¤ß Third Party Logistics ²ºÙ3PL¡^¡C

ÃĵØÃĪí¥Ü¡A¤w±µÀò¤Q¾l±i­q³æ¡A¥¿·Ç³ÆÂà¹B¦Ü¤U¹F­q³æªº±M¬ìÃħ½¡]Specialty Pharmacy SP¡^©M¯S®íÃÄ«~¸g¾P°Ó¡]Specialty Pharma Distribution SD¡^¡C·íÃÄ«~±qÖפT¤èª«¬y¤¤¤ß¡]3PL)°e¹F±M¬ìÃħ½©Î¯S®íÃÄ«~¸g¾P°Ó®É¡A¤½¥q´N¥i»{¦CÀ禬¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2021/12/2 ¤W¤È 10:58:49²Ä 9883 ½g¦^À³
ÃĵØÃĤ½¥qRopeginterferon/besremi(P1101)

ªvÀø­ìµo©Ê¦å¤pªO¼W¦h¯g(Essential thombocythemia )±¡§Î?

(¸ê®Æ¨Ó·½¤Þ­zºô¸ôÂk¯Ç¾ã²z¦p¤U¡A­Y¦³¿ù»~½Ð¥H¤½¥q©x¤è¥¿¦¡¤½§i¬°·Ç)

³ü¡B¦ó¿×­ìµo©Ê¦å¤pªO¼W¦h¯g(Essential thombocythemia )»PªvÀø

¤@¡BWhat is Essential Thrombocythemia (ET)?

(¤°»ò¬O­ìµo©Ê¦å¤pªO¼W¦h¯g (ET)¡H)

­ìµo©Ê¦å¤pªO¼W¦h¯g (ET) ¬O¤@ºØºC©Ê°©Åè¼W¥Í©Ê¸~½F (MPN)¡A¨ä¯S¼x¬O¦å²G¤¤¦å¤pªO¼Æ¶q¼W¥[¡CET ³Ì±`¨£©ó 50 ·³¥H¤Wªº¤k©Ê¡A»P°©Å褤¦å¤pªO«eÅ骺¼W´Þ¦³Ãö¡A¨Öµo¯g³q±`¥]¬A¦å²G¾®©T©M/©Î¥X¦å¡CET «á´Á¤£¤Ó±`¨£ªº«áªG¥]¬AÂà¤Æ¬°°©ÅèÅÖºû¤Æ¡]°©Åè½I²ª§Î¦¨¡^©Î«æ©Ê¥Õ¦å¯f¡C

¤G¡BWhat Are the Available Treatments for ET?

(ET ¦³­þ¨Ç¥i¥ÎªºªvÀø¤èªk¡H)

(¤@) ·í»Ý­nªvÀø®É¡AET ±wªÌ¥i¥ÎªºªvÀø¿ï¾Ü¥]¬A¡G

1. Low-Dose Aspirin(§C¾¯¶qªü¥q¤ÇªL)

2.Hyroxyurea

3. Anagrelide(ªü¨º®æ¹p)

4. Interferon(¤zÂZ¯À)

(¤G) Novel Therapies and Treatments

(·sÀøªk©MªvÀø)

¥Ñ©óµo²{¤F JAK2 ¬ðÅÜ»P ET µo¯f²v¤§¶¡ªºÁpô¡A¥Ø«e¥¿¦b¶}µo©M´ú¸Õ¼ç¦bªº ET ·sÀøªk¡C»E¤A¤G¾J¤Æ¤zÂZ¯À¬O¤@ºØ°Æ§@¥Î§ó¤Ö¡Bµ¹Ãħó®e©öªº¤zÂZ¯Àª©¥»¡A³Q»{¬°¬O°ª¦M¤H¸sªº¤@ºØªvÀø¿ï¾Ü¡C

¸ê°T¨Ó·½¡G

www.mpnresearchfoundation.org/essential-thrombocythemia-et/

¶L¡GÃĵØÃÄET(Essential thombocythemia)°õ¦æ±¡§Î¡G

¤@¡BRopeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)

Ropeginterferon Alfa-2b (P1101) »Pªü¨º®æ¹p¦bßm°ò脲­@ÃĩΤ£­@¨üªº­ìµo©Ê¦å¤pªO¼W¦h¯g±wªÌ¤¤ªº¤ñ¸û (SURPASS ET)

Estimated Study Completion Date :March 2023

¹w­p¬ã¨s§¹¦¨¤é´Á ¡G 2023 ¦~ 3 ¤ë

¸ê°T¨Ó·½¡Gclinicaltrials.gov/ct2/show/NCT04285086

¤G¡BBBCµn¥x±Ä³X¨u¨£¦å²G¯e¯fªvÀø ¯f¤Í¡G°Ñ»PÃĵØÃÄ®¦·OÀøªk¡A¥Í¬¡­«¦^±`­y¡C

(³Æµù¡G¤§«e±qYOUTUBE¬Ý¹LÃĵØÃÄÁ|¿ì¥_¡B¤¤¡B«nªk»¡·|¡A¦³¯f¤Í²{¨­»¡ªk¡A­Y¨S°O¿ù¸Ó¯f¤Í«YEssential thombocythemia¡A¸Ó¼v¤ù¤w¤U¬[)¡C

¸ê°T¨Ó·½¡Gpharmaessentia-tpe.com/tw/patients/ÂåÀø«O°·

¤T¡B¥»¤½¥q¥¿¦b¶i¦æRopeginterferon alfa-2b ( P1101) ¥Î©óªvÀø­ìµo©Ê¦å¤pªO¹L¦h¯g¡]Essential Thrombocythemia¡A²ºÙET¡^¤§¥þ²y¦h°ê¦h¤¤¤ß¤T´ÁÁ{§É¸ÕÅç¡A¹w­p¦@¦¬¤J160¦ì¨ü¸ÕªÌ¡A¥Ø«e¦¬®×¤H¼Æ¤w¹L¥b¹F87¦ì¯f±w¡A¹w­p2022¦~²Ä¤G©u§¹¦¨¦¬®×¡C

¥|¡BCOMPASSIONATE USE OF ROPEGINTERFERON TO TREAT MYELOPROLIFERATIVE NEOPLASMS IN TAIWAN(Author: Chih-Cheng Chen)

(¥xÆW®¦·OÀøªk ROPEGINTERFERON ªvÀø°©Åè¼W¥Í©Ê¸~½F)

(¤@) µ²ªG¡G1 ¦W­ìµo©Ê¦å¤pªO¼W¦h¯g±wªÌ/¦b¨ä¥L±wªÌ¤¤¡A¤]Æ[¹î¨ì¦å¤pªO­p¼Æ´î¤Ö¡]§Y¨Ï¦b¥ý«eªvÀø©è§Üªº¦å¤pªO¼W¦h¯g¤¤¡^©M¯gª¬§ïµ½¡C

(¤G) µ²½×¡GP1101 ªí²{¥X¨}¦nªº­@¨ü©Ê©MÅãµÛÀø®Ä/Æ[¹î¨ìªºÀø®Äªí©ú P1101 ¬O¤@ºØ¦³§Æ±æªºªvÀø¿ï¾Ü¡C

¸ê°T¨Ó·½¡Glibrary.ehaweb.org/eha/2019/24th/267627/oleh.zagrijtschuk.compassionate.use.of.ropeginterferon.to.treat.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1

°Ñ¡B2021 ASH½×¤åµoªí¦³Ãö¤zÂZ¯À(interferon)ªvÀø­ìµo©Ê¦å¤pªO¼W¦h¯g(Essential thombocythemia )µ²½×­«ÂIºK­n¡G

Outcomes with Interferon in Essential Thrombocythemia: A Systematic Review and Meta-Analysis

(¤zÂZ¯ÀªvÀø­ìµo©Ê¦å¤pªO¼W¦h¯gªºµ²ªG¡G¨t²Îµû»ù©M¤ÀªR)

µ²½×¡G¤£¦P°t¤è¤¤ªº¤zÂZ¯À¦b­ìµo©Ê¦å¤pªO¼W¦h¯g±wªÌ¤¤ªí²{¥X¤@­P¥B°ª¬¡©Ê¡C¥¦¾É­P¤FÁ{§É¤ÏÀ³¥H¤Î¤À¤l¤ÏÀ³¡C¤£¦P³ø§i¤¤ªº°Æ§@¥Î¯S¼x¬O¤@­Pªº¡A¨Ã¥B¬O¥i¥H¦X²z­@¨üªº¡C¦³¤j¶qÃÒ¾Ú¤ä«ù³oºØ¤èªk¦b¤£¦Pªº ET ±wªÌ¸sÅ餤ªº¿n·¥©Ê©M¦w¥þ©Ê¡C

¸v¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/12/1 ¤W¤È 11:11:23²Ä 9882 ½g¦^À³
¶}¤ß~¦A«×±j¶Õº¦°±,¨S§¹¨S¤F......©êºò§O³QºL¤U¨®
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2021/11/30 ¤U¤È 05:08:11²Ä 9881 ½g¦^À³
Ä~Äò©êµÛ¡AÅý¿úºu¿ú¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/30 ¤W¤È 10:57:37²Ä 9880 ½g¦^À³
¶}¤ß~Â꺦°±¡A«ùªÑ8¦~¦³¾l¡A°í«ùµ¥®³¨ìFDAÃÄÃÒ¡A¨É¨ü¬üÄRªº¦¨ªG¡A¦A°í«ù¤U¥h......©ú¦~¤j³°¡B¤é¥»PVÃÄÃÒ¤J³U¡Aº¦¯}¥ý«e¥»¤H¼ÐÃD»ù¡uªø´Á«ù¦³¥Ø¼Ð500¤¸¥H¤WÆÁ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2021/11/23 ¤U¤È 06:44:10²Ä 9879 ½g¦^À³
§Æ±æ¦p¦¹¡A·Ç³Æ©êµÛµ¥¡A´Á«Ýµu¤¤ªø´ÁÀò§Qº¦¡C¥u¬O©_©Ç³o´X¤Ñ¥~¸êÁÙ½æ¡C¬Ý¤£À´.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/23 ¤W¤È 10:08:14²Ä 9878 ½g¦^À³
½L¾ã2~3¤Ñ«á¦A¥[¶Õ§ð°í¡A§O¤p¬Ý«á¥«ªº¼Éµo¤O¡A¤ò§Q°ª¡B»Ý¨D¤j¡B7¦~¿W½æÅv
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/22 ¤U¤È 12:16:24²Ä 9877 ½g¦^À³
¤µ¤é¤j¶q´«¤â¬~²M¯BÃB¬O¦n¨Æ¡A«ùªÑ­n¦³«H¤ß¡A¥b¦~«á´N¬ÝÀ禬¼É½Ä........¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2021/11/22 ¤W¤È 06:25:45²Ä 9876 ½g¦^À³
PharmaEssentia SOURCE ´£¨Ñ­Ó©Ê¤Æªº¤ä«ùªA°È¡A¦®¦bÀ°§U±z¦¨¥\¶}©l¨Ã°í«ù¨Ï¥Î BESREMi¡]ropeginterferon alfa-2b-njft¡^¡C

pharmaessentiasource.com/#

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/21 ¤W¤È 10:47:09²Ä 9875 ½g¦^À³
¬üPV¨u¯fÃÄ¥«³õÃz¬õ µØº¸µóºVªù¥xÆWÃĵØÃÄ

article image

ProtagonistªÑ»ù¤@¦~¥bÃzº¦9­¿¡A§l¤ÞµØº¸µóÃöª`¨u¯fÃÄÃzµo¤O¡A¨Ï±o¦P¼Ë§ðPV¤@½u¥Î¼Öªº¥xÆWÃĵØÃÄ·sÃÄP1101¡A¦b¬ü°ê§ë¸ê¥«³õ¨ü¨ì«C·ý¡B¸ß°Ý«×öt¤É¡C(¹Ï¡þ³ø¨t¸ê®Æ·Ó)

¥»¤å¦@2343¦r

2021/07/26 19:21

¸gÀÙ¤é³ø ¶µ®aÅï

ªñ´Á¬ü°êProtagonist¤½¥qªºPTG-300¦b¥Í§Þ»sÃĬɱȰ_¤õ¼ö°Q½×¡A¦]¦b¥h¦~ªº¬ü°ê¦å²G¾Ç¦~·| (American Society of Hematology, ASH)¤Îªñ´Áªº¼Ú¬w¦å²G¾Ç¦~·| (European Hematology Association, EHA)µoªíªº¯u©Ê¬õ¦å²y¼W¦h¯g(PV)¤G´ÁÁ{§É¸ÕÅç´Á¤¤¼Æ¾Ú¥¿¦V¡A¤ÞÃzProtagonist¤½¥qªÑ»ù±q¥h¦~3¤ëªº¬ü¤¸5¶ô¦h¡A¨ì¤µ¦~7¤ë¡A¼Éº¦¨Ó¨ìªñ50¬ü¤¸¡A¤£¨ì¤@¦~¥bº¦´T¬ù¦³9­¿¤§ÃСA¤½¥q¥«­È¹F22»õ¬ü¤¸¡C¥¿­ÈPTG-300Ãz¬õ¤§»Ú¡A¤]¤ÞµoµØº¸µó¥Í§Þ°òª÷¤j©@ª`·N¨ìPV¨u¯f·sÃÄÃe¤jªº¥«³õ¼ç¤O¡A¯É¯É¿Ô¸ß¬ü°êªvÀøPVªºÂå®v»â³S¸s¡C¾Ú±x¡A¨Ó¦Û¥xÆW¡B¹w­p¦~©³´N¯à»â¥ýPTG-300¡A¨ú±oPV¤@½u¥ÎÃĬü°êÃÄÃÒªºÃĵØÃÄP1101¡]Ropeginterferon alfa-2b¡^¡AÀò±o¥«³õ°ª«×ªº§ë¸ê¿³½ì¡C

µØº¸µó¤j©@¬Ý¦nP1101 °ê¤º¥Í§Þªk¤H®¶¾Ä¡I

µØº¸µóª÷¥D¿Ô¸ßªºPVÂå®v»â³S¸s¡A¤]¥¿¬O°Ñ¥[ÃĵØÃĥثe¥¿¦b¥þ²y¶i¦æªºP1101ªvÀø¦å¤pªO¹L¦h¯g(ET)²Ä¤T´ÁÁ{§É¸ÕÅ窺¥D«ù¤H¡A°£ªí¥Ü¹ïPTG-300ªºªÖ©w¥~¡A§ó¬°±À±R©M´Á«ÝÃĵØÃÄP1101¡IÅýµØº¸µóªø´ÁÃöª`·sÃĪº¤j©@§ë¸êªÌ­Ì¯É¯É¥D°ÊºVªùÃĵØÃÄ¥xÆWÁ`³¡¤Î¦b¬ü°ê³Â¦{ªº¤l¤½¥q¡Aªí¹F¨ä°ª«×ªº§ë¸ê¿³½ì©M¸ß°Ý¦b¬ü±¾µPªº¥i¯à©Ê¡A¨ä¤¤¤£¥F§ë¸ê¾Ö¦³PV¤G½u¥ÎÃÄJAKAFIªºIncyte¤½¥qª÷¥D¦b¦C¡C

¡]money.cnn.com/quote/shareholders/shareholders.html?symb=INCY&subView=institutional¡^

Incyte«ùªÑ¥e¤ñ«e5¤j§ë¸êªÌ¸ê®Æ¡C¡]¹Ï¡þºI¦ÛCNN·s»Dºô¡^

Incyte«ùªÑ¥e¤ñ«e5¤j§ë¸êªÌ¸ê®Æ¡C¡]¹Ï¡þºI¦ÛCNN·s»Dºô¡^

¥t¾ÚÁA¸Ñ¡A¦b¦aªºBoston¥Í§Þ°òª÷µ¥¤j©@¡A¤]¥[¤JºVªùÃĵØÃĪº¦æ¦C¡CÃĵØÃĤ½¥q°ª¼h³Ìªñ¦b°ê¤º¬Ì±¡ÄY®m±¡ªp¤U¤´¿Ë¦Û­u¬ü¡A¥«³õ¤]²q´ú»P³o¤@ªiPV°Ó¾÷Ãz¬õ¦³°ª«×ÃöÁp¡A³o¨Ï±o°ê¤º¥Í§Þªk¤H·P¨ì°ª«×ªº®¶¾Ä¡I

§ð¤@½u¥ÎÃÄ ÃĵØÃÄP1101ÃÄÃÒ¶i«×»â¥ýPTG-300

­È±oª`·Nªº¬O¡A´X®a¬ü°êª¾¦W¤ÀªR¤½¥qªº¥Í§Þ²£·~¤ÀªR®v¹Î¶¤¡A¤w¨Ì¾ÚProtagonistµoªíªºPTG-300 PV¤G´ÁÁ{§É¸ÕÅç¼Æ¾Ú¡A¶W«e³¡¸p±Àºâ¨äÀ禬¡A±À¦ôPTG-300³Ì¼ÖÆ[¥i©ó2024¦~¨ú±o¬ü°êÃÄÃÒ¡A¤W¥««á¼Æ¦~§Y¥i½Ä¯}40»õ¬ü¤¸¡]¤d»õ¥x¹ô¡^¤jÃö¡I¶¡±µ¦LÃÒ¨u¨£¦å²G¯f·sÃÄ¥«³õ¨ã¦³¦Ê»õ¨ì¤d»õÀ禬ªº¼ç¤O¡C

¦P¼ËºË·Ç¤@½u¥ÎÃÄ¡AÃĵØÃÄP1101»PProtagonist¥Ø«eÁÙ¦b¶i¦æ¤G´ÁÁ{§ÉªºPTG-300¬Û¸û¡A¦³¨â¤jÀu¶Õ¡G¡]¤@¡^ÃĵØÃÄP1101¤µ¦~©³«e´N±N·m¥ý¨ú±o¬ü°êÃÄÃÒ¡A±N¬O¥«­±¤W°ß¤@³Q¬ü°êFDA®Ö­ãªºPV¤@½u¥ÎÃÄ¡A¦¬³ÎPV¤@½u¥ÎÃÄ¥«³õ¡C¡]¤G¡^ÃĵØÃÄP1101¬°³Ð·sªø®Ä«¬¤zÂZ¯À¡A°£¥iÅý±wªÌ¹F¨ì§¹¥þ¦å²G¾Ç¤ÏÀ³ (CHR) ¡A§YÅý¦å²G«ü¼Æ³£ºû«ù¨ì¥¿±`­È¡A¦­´Á¬I¥´¥iªvÀø¯e¯f®Ú·½¡A¤]¥i´î¤Ö¬Æ¦Ü§K°£±wªÌ©ñ¦å»Ý¨D¡A½w¸Ñ¯gª¬ªº¦P®É¤]¯u¥¿ªvÀø¯e¯f¡CPTG-300«h¬O½Õ¸`¦å²G¤¤¡uÅK¡v¥NÁ¾÷¨î¥H±±¨î¬õ¦å²y¼Æ¶qªºÃĪ«¡A²{¦bÁÙ¦b¶i¦æ2´ÁÁ{§É¸ÕÅç¡C

¸ê¥»¥«³õ¬Ý¨£¨u¨£¦å²G¯f¥«³õ¼ç¤O ¤@½u¥ÎÃijƨü´Á«Ý

±´¨s¨u¨£¦å²G¯f¥ÎÃÄ»â°ì¡A¥Ø«e¦b¬ü°êMPN¥«³õ»âÀYªºIncyte¤½¥q¡A¦Û2011¦~ºX¤UJakafiÀò¬ü°êFDA®Ö­ãªvÀø°©ÅèÅÖºû¤Æ(MF)±wªÌ¡A¨äÀ禬±µÄò´X¦~³y¦¨ÅF°Ê¡AµØº¸µó¹ï¸Ó¤½¥qªº¥«­È·¥¬°±·³õ¡A³v¦~¸`¸`¤W¤É¡A´Xªñ¨Õ»õ¬ü¤¸¡A¤D¦]¨ä¥«¦û²v§Ö³tÃk¤É¨ì 50%¡I

2014¦~©³Jakafi¤SÀòFDA®Ö­ã¥Î©ó PV ²Ä¤G½uªvÀø¡AÀA¤W²Kªá¡A¥«­Èª½½Ä¨Õ»õ¬ü¤¸¤jÃö¡CµM¦ÓPV²Ä¤G½u¥ÎÃÄÀø®Ä¤£¦pªvÀø MF ªº¥ß§YÅãµÛ¡A¥B¥i¯à¦]¬°°w¹ï¸û¬°±ß´Áªº¯f¤H¡A°ò¦]¬ðÅÜ­×´_ªº®ÄªG¨ÃµL¥O¤HÅåÆvªºªí²{¡A¥«¦û¤£¤Î20%¡I¦A¸g²`¤Jµo±¸¡A¸Ó¤½¥q¶i¦æ¤¤ªº¤G´Á ET Á{§É¸ÕÅç¤w¸g¦³7¡B8 ¦~(clinicaltrials.gov/ct2/show/NCT03123588)¡A¶i®i«D±`½wºC¡AµØº¸µó¥Í§Þ¤j©@¤@ª½´Á¬ß¦b³o­Ó»â°ì¦³§ó·sªº¡B²Ä¤@½uªºªvÀø¥ÎÃÄ¥X¨Ó¡CPTG-300¥u¦bPVªº¤G´Áµ²ªG´N¨ü¨ì¦p¦¹­«µø¨Ã¤Ï¬M¦b¤½¥q¥«­ÈªºÃzº¦¡A¤w¹F20»õ¬ü¤¸¤§¦C¡A¨ä¨Ó¦³¦]¡I¤]Åý¥«³õ§ó¥[´Á«ÝÃĵØÃÄP1101ªºªí²{¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2021/11/21 ¤W¤È 06:22:38²Ä 9874 ½g¦^À³
BESREMi®¡]ropeginterferon alfa-2b-njft¡^ª`®g²G¥i±q Onco360 Àò±o¡I

BESREMi® ¬O¤@ºØ¤zÂZ¯À alfa-2b¡A¾A¥Î©óªvÀø¦¨¤H¯u©Ê¬õ²Ó­M¼W¦h¯g¡C

¾¯¶q©Mµ¹ÃĤèªk1

±ÀÂË°_©l¾¯¶q¡G¨C 2 ¶g¥Ö¤Uª`®g 100 ·L§J¡]¦pªG±µ¨üßm°ò脲¡A«h¬° ​​50 ·L§J¡^¡C ¨C 2 ¶g¼W¥[ 50 ·L§J¾¯¶q¡]³Ì¦h 500 ·L§J¡^¡Aª½¨ì¦å²G¾Ç°Ñ¼Æí©w,¦pªGµo¥Í¬Y¨Ç¤£¨}¤ÏÀ³¡A¤¤Â_©Î°±¤îµ¹ÃÄ

¾¯«¬©M±j«×

ª`®g¾¯¡G 500 mcg/mL ·»²G¦b³æ¾¯¶q¹w¸Ëª`®g¾¹¤¤(NDC 73536-500-01)

www.onco360.com/oncology-medications/limited-distribution-medications/besremiropeginterferon-alfa-2b-njft-injection/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDreamtiger10145627  µoªí®É¶¡:2021/11/20 ¤W¤È 10:13:53²Ä 9873 ½g¦^À³
·íªì175¶R¡A195½æ¡Aı±o·|¼Q¥X¦b200¤S±µ¦^¨Ó®M¦b³Ì°ªÂI¡A

¨C¦¸¤W¨R¤U¬~³£¦º©ê¤£´±¥ý½æ¦A¶R¤]¿ù¥¢¦n´X¦¸Åu¥­ÂI

¹ï¤½¥qªºª±ªÑ¤âªk¹ê¦b«Ü·P«_...

¦ý¬O¨ä¹ê¬O¦³´Á«Ýªº¡]§Ú½æ±¼Ã­À·¸ò¥Í®i¨Ó¶R¡A¦pªG·íªì¤£½æ¡A²{¦b¤]¤­¤»­¿¤F)

²{¦bªººÃ´bÂI¬O¡A¼Ú¬w¬JµM¤w¸g½æ¤F¤@¦~¡A

¥H¤@¤H¦~¥÷200¸U¡A§C¼Ð¯f¤H1000¤H¦¸­pºâ¡A¤À¼í10%¡A¤]À³¸Ó¶i±b2»õ¡A¥i¥HÀò§Q¤F¡H

¬°¤°»òÁÙ¬O¤@ª½Á«¿ú?¥D­n¶i±b¦n¹³³£¬O¤W¦¸¦X¨Öªº¨º®a¤½¥q¡H

´Á«Ý¦U¦ì¥ý¶iÀ°§Ú¸Ñ´b¤@¤U

¬O¤£¬O½æµ¹aopªº³f³£¨S¦¬¨ì¿ú¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/19 ¤U¤È 08:57:41²Ä 9872 ½g¦^À³
¦ô­pÃĵØÃ妰±¦A3~5¤Ñ«á¡A²q´ú·|¬~Äw½X2~3¤Ñ«áªÑ»ùÄ~Äò©¹¤W§ð°í¡A§ë¸ê¤HÀ³ºò©ê«ùªÑ¡A

­YªÅ¤âªº§ë¸ê¤H¥iµ¥«Ý¦¹®ÉÁʶR¤J³õ¨é¡AÃĵØÃÄ«áÄò´X¤ä­«½SÃÄ¥«³õ§ó¤j¡A¶R¦n¶Rº¡¡A

¤§«á§Ñ¤FÃĵØÃÄ¡Aµ¥«Ý5¦~«áªºªÑ»ù·|«D±`Åå¤H........¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/19 ¤U¤È 01:18:37²Ä 9871 ½g¦^À³
¦ô­pÃĵØÃ妰±¦A3~5«á¡A·|¬~Äw½X2~3¤Ñ«áªÑ»ùÄ~Äò©¹¤W§ð°í¡A§ë¸ê¤HÀ³ºò©ê«ùªÑ¡A

­YªÅ¤âªº§ë¸ê¤H¥iµ¥«Ý¦¹®ÉÁʶR¤J³õ¨é¡AÃĵØÃÄ«áÄò´X¤ä­«½SÃÄ¥«³õ§ó¤j¡A¶R¦n¶Rº¡¡A

¤§«á§Ñ¤FÃĵØÃÄ¡Aµ¥«Ý5¦~«áªºªÑ»ù·|«D±`Åå¤H........¥[ªo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDHL10147526  µoªí®É¶¡:2021/11/19 ¤U¤È 12:41:45²Ä 9870 ½g¦^À³
«D±`¦P·N¡A¥[ªo¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­¸¯T10148959  µoªí®É¶¡:2021/11/19 ¤W¤È 08:44:05²Ä 9869 ½g¦^À³
°ªºÝ³s¤@­Ó°ê»ÚÃÄÃÒ³£¨S®³¨ì ªÑ»ù¥i¥Hª£Â½¤Ñ

ÃĵØÃÄ¥¬¦ý®³¨ì¦h°êÃÄÃÒ ¤]±µ¨ì­q³æ

ÁÙ­Ó¤½¹D¤]ºâ¦X²z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/18 ¤U¤È 01:41:30²Ä 9868 ½g¦^À³
ÃĵØÃÄPV®³¨ìÃÄÃÒ¡A¤â¤W¤´¦³´X¤ä­«½SÃĶi¦æ¤¤¡AÃĵØÃÄ«áÄòµo®i¤£®e¤pòó¡A¼õ¹L³o¬q­·­·«B«Bªº¤é¤l¡A

»Ä¥Á¤]¤£¨£¤F¡AªÑ»ùÁÚ¦V4¦ì¼Æ¬O¥i´Á«Ýªº..........¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/18 ¤W¤È 11:42:19²Ä 9867 ½g¦^À³
PV®³¨ìFDAÃÄÃÒµ¥©ó®³¨ì¥þ¥@¬ÉÃÄÃÒ¡AÃĵØÃÄ­«½SÃĤ´¦b«ùÄò¥Ó½ÐÃÄÃÒ¡A³o5~10¦~ªºÃ¬§Q·|«Ü¥iÆ[¡A

¦³¶R¶iªº§ë¸ê¤H©êºò©ñ²´5~10¦~«á¡A¥Ø¼Ð¦¨¬°¥xÆW¤§¥ú¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2021/11/17 ¤U¤È 05:43:34²Ä 9866 ½g¦^À³
¸ê°T¨Ó·½¡Ghealthunlocked

healthunlocked.com/mpnvoice/posts/147152339/10-facts-mpn-patients-need-to-know-about-fda-approval-of-ropegylated-interferon-alpha2b-besremi-.

MPN ±wªÌ»Ý­n¤F¸Ñ FDA §å­ã Ropegylated ¤zÂZ¯À £\2b (Besremi) ªº 10 ­Ó¨Æ¹ê¡C

Ruben Mesa¡AÂå¾Ç³Õ¤h¡AFACP¡A±ö´µÀù¯g¤¤¤ßªº°õ¦æ¥D¥ô¡AUT °·±d¸t¦wªF¥§¶ø MD ¦w¼w´ËÀù¯g¤¤¤ßªº©Ò¦b¦a¡A¥H¤Î MPN ±M®a©M½Õ¬d­û¡A°Q½×¤F°©Åè¼W´Þ©Ê¸~½F±wªÌ¡]¤×¨ä¬O¯u©Ê¬õ²Ó­M¼W¦h¯g±wªÌ¡^»Ý­n¤F¸Ñªº 10 ­Ó­«­n¨Æ¹ê¤F¸Ñ FDA §å­ã Ropegylated ¤zÂZ¯À alpha2b (Besremi)¡C

¤@¡B±q Pegasys ¨ì Besremi ªº¥æ¤e¾¯¶q«D±`¦³¥Î¡I

¤G¡B·PÁ±z´£¨ÑªºÃì±µ¡C¦Û¥h¦~§Úªº Dx ¥H¨Ó¡A§Ú¤@ª½¦b±K¤ÁÃöª` Ropeg¡C

Mesa ³Õ¤hªº¤@­Ó»¡©ú¬O Besremi ªº PV §å­ã¡§±¹Ãã¬Û¹ï¼eªx¡¨¡C³o¬O¤@¥ó¦n¨Æ¡C¨ä¤¤¤@³¡¤À¬O¡§µL½×¥L­ÌªºªvÀø¥v¦p¦ó¡¨³£¥i¥H¿ï¾Ü¨Ï¥Î¥¦¡C(FDA)¦b§Ú¬Ý¨ìªº©Ò¦³¬ã¨s¤¤¡Aµ¥¦ì°ò¦]­t²ü¦ü¥G¬O¤@­Ó¨S¦³³Q±j½Õªº¦¸­n°ÝÃD¡C¾Ú§Ú©Òª¾¡A³o¤£¬O FDA §å­ãªº¤@­Ó¦]¯À¡C§Ú¨S¦³¬Ý¨ì¹ï¨ä¼vÅTªºª½±µ¬ã¨s¡A³o±N»Ý­n«Ü¦h¦~¡C¦b§Ú¬Ý¨Ó¡A¤@¨Ç±M®a¤]»¡¹L¡Aµ¥¦ì°ò¦]¬O­È±o¦Ò¼{ªº¡A¦]¬°§Ú­ÌÀ³¸Ó¦³¤@ºØ¥Ñµ¥¦ì°ò¦]ÅX°Êªº¯e¯f¡A¦Ó INF ¬O°ß¤@¯à°÷¦b°©Å褤´î¤Ö¥¦ªºÃĪ«¡C§Ú­Ì¦b³o¸Ì¬Ý¨ì¡A­^°ê¨Ã¨S¦³©w´Á¹ï¨ä¶i¦æ±K¤ÁºÊ±±¡C§Ú»s§@¤F Besremi ¬ã¨s¤¤µ¥¦ì°ò¦]¼Æ¾Úªº¹Ïªí¡A¥X©ó¬YºØ­ì¦]¡Aµ¥¦ì°ò¦]¶ÈÅã¥Ü¬°ªí®æ¡C¡]³o±i¹Ï¬O§Ú®Ú¾Ú¯u¹ê¼Æ¾Ú²Ê²¤°µªº¡A¦ý¥¦¤£¬O¦b¥ô¦ó¯u¥¿ªº¬ã¨s¤¤¡^Ropeg INF ªº JAK2 µ¥¦ì°ò¦]Àu¶Õ¦b³o¸Ì¬OÀ£­Ë©Êªº¡A¨Ã¥B°ò©ó INF ¬O¡§ºC°Ê§@¡¨¡C§Úªº¬Ýªk¬O¡A§Y¨Ï§Aªº¦å¶q¹ï HU «Ü¦n¡A³o¸Ì¬Ý¨ìªºÀu¶Õ¨Ï Besremi «D±`­È±o»P§Aªº³Õ¤h°Q½×¡C§Ú»{¬°³o¶µ¬ã¨s¥»¨­¤]¬OÃö©ó HU »Pµ¥¦ì°ò¦]ªº§ó¦nªº¬ã¨s¤§¤@¡CPEG ¤]¦³µ¥¦ì°ò¦]´î¤Ö¡A¦ý§Ú¬Û«H³o¨Ç¬ã¨s¨S¦³¨º»òªø´Á©Î¨º»ò¤j¡C

½Ð°Ñ¾\§Ú¤U­±ªº©«¤l¡A¤F¸Ñ¦b¤@¶µ¬ã¨s¤¤¹ï¥Í¦s©M¶i®iªº¼vÅT¡AÅã¥Ü INF ªº¨}¦n®ÄªG¡C

¤T¡BBesremi ªºµ¥¦ì°ò¦]­t²ü¤ÏÀ³«D±`¦n¡A¦ý¥¦¤ñ Pegasys §ó¦n¶Ü¡H®Ú¾Ú§Ú­Ì¤¤¤@¨Ç¤H¹ï Pegasys ªº¤À¤l¤ÏÀ³¡A¥¦©¹©¹¤ñ Besremi §ó¦n¡C³]ªk¦b 30 ­Ó¤ë¤º±N¥Lªº AB ±q 80% ´£°ª¨ì 12%¡C¤µ¤Ñ¡A§Úªº¦å¬õ¯À§i¶D§Ú¡A§Úªº JAK2 ¦b 24 ­Ó¤ë¤º¤U­°¤F 86%¡]84 ¨ì 11¡^¡C©Ò¥H§Ú¤£½T©w¶È¶È¦]¬°³o­Ó­ì¦]¡ABesremi À³¸Ó¤ñ Pegasys §ó¨üÅwªï¡C

¥|¡B§Ú§¹¥þ¦P·N¡Cªºµ²ªGµ¹§Ú¯d¤U¤F²`¨èªº¦L¶H¡A§Aªºµ²ªG¼W¥[¤F§Ú­ÌÃö©ó Voice ªº¯u¹ê¥Í¬¡¼Ë¥»¡C¥i¯à¬O PEG ¹ê»Ú¤W®ÄªG§ó¦n¡C«OÀI cos ©M¤@¨ÇÂå¥Íªº°ÝÃD¬O¨S¦³§¹¦¨ PEG »P MPN ªº²Ä 3 ¶¥¬q¬ã¨s¡]¦pªG¦³¤Hª¾¹D¤@¨Ç·|«D±`¦³À°§U¡^¤W¹Ï¦Ü¤Ö¹ï©ó INF ªº¿ô¥Øµøı«H®§¬O¦nªº¡C**¦pªG³o¸Ì¦³§ó¦h±a¦³«e/«áµ¥¦ì°ò¦]¼Æ¾Úªº Voicers¡A§Ú­Ì«Ü·Qª¾¹D¡AµL½×µ¥¦ì°ò¦]ÅTÀ³¦nÁÙ¬O¤£¦n¡CBesremi¡]¦b§Ú¬Ý¨Ó¡A¹ê»Ú¤W¬O Euro group AOP¡^ªá¤F¿ú¶i¦æ¤F²Ä 3 ¶¥¬q¡C¥L­Ì¦³´X­Ó±wªÌªº¦º¤`²v§C©ó 2%¡C¹ï©ó¤@¨Ç¬ã¨s¤H­û¨Ó»¡¡A³o¦ü¥G¬O¤@­Ó¯«©_ªº¼Æ¦r¡A¦Ó¦Ü¤Ö¨Ó¦Û ContiPV (Besremi) ªº¤@¥÷³ø§iªí©ú 10%¡C¡]½Ð°Ñ¾\¤U­±ªº¤Þ¥Î©MÃì±µ¡C¡^±z©M«Où¤]«Ü¥i¯à³q¹L PEG ¹F¨ì 2%¡CBesremi ÁnºÙªº¤@­ÓÃöÁäÀu¶Õ¬O§ó¦nªº­@¨ü©Ê¡A¦ý¦pªG¤@­Ó¤H¯à°÷­@¨ü PEG¡A¨º»ò¦³¤°»ò°ÝÃD©O¡HPEG ªº¦¨¥»¤]¥i¯à§ó«K©y¡C

¤­¡B¡§¬Û·í¤j¤ñ¨Òªº PV ±wªÌ¦b±µ¨ü 5 ¦~ªºropeginterferon alfa-2b ªvÀø«á¹ê²{¤F¤â³Nªv·U¡C°ò½u®É¸û§Cªº¦~ÄÖ©M¸û§Cªºµ¥¦ì°ò¦]­t²ü¹w´ú 5 ¦~®Éªºµ¥¦ì°ò¦]­t²ü <10%¡Aªí©úÀ³¸Ó¦b PV ¦­´Á¶}©l¨Ï¥Î Ropeginterferon alfa-2b ¥HÀò±o³Ì¤jªºªø´Á¯q³B¡C¡¨

¤»¡B ¤w¸g¬O 2%¡C²z½×¤W§¹¥þ®Ú°£´c©Ê§J¶©¬O¥i¯àªº¡C

« ¦b¼Ò«¬¤¤¡A´c©Ê·F²Ó­Mªº¼Æ¶q¦b²Ä 12 ¦~®ø¥¢¡CµM¦Ó¡AÀË´ú¤U­­¬° 0.01%¡AÀË´ú´c©Ê²Ó­Mªº¤U­­¦b²Ä 7 ¦~¹F¨ì¡A¦ÓÀË´ú¤U­­¬° 0.1%­­¨î¦b²Ä 4 ¦~¥ª¥k¹F¨ì¡C¦]¦¹¡A¸Ó¼Ò«¬¹w´úÀù¯g¦b²Ä 12 ¦~®Ú°£¡A¦Ó´c©Ê·F²Ó­Mªº¼Æ¶q¦b²Ä 4 ¦~©Î²Ä 7 ¦~¤§¶¡ÅܱoµLªkÀË´ú¡A¨ãÅé¨ú¨M©ó´ú¶qªº·Ç½T©Ê¡C»12¦~¬O¤@¬q«Üªøªº®É¶¡¡C³o´N¬O Besremi ¸û§Cªº¬r©Ê¦p¦¹­«­nªº­ì¦]¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/17 ¤U¤È 02:57:57²Ä 9865 ½g¦^À³
¡m¥ÍÂåªÑ¡nÃĵØÃÄPV·sÃÄ FDA­ã¤W¥«

2021-11-14 11:06:51

¸Ô²Ó丨

6446ÃĵØÃÄ ·s»D­q¾\:

·s»D®É¶¡:2021-11-14 11:06

¡i®É³ø-¥x¥_¹q¡jÃĵØÃÄ13¤é«Å¥¬¡A¬ü°êFDA¤w®Ö­ã¨ä·sÃÄRopeginterferon alfa-2b¡]P1101¡^¡A¥Î©óªvÀø¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^¡C³o¬O²Ä¤@­ÓÀòFDA®Ö­ã±Mªù¥Î©óªvÀøPVªº¤zÂZ¯ÀÀøªk¡A¸ÓÃĦb¬ü°êÃÄ»ù¬°¨C¤H¨C¦~¬ù·s¥x¹ô500¸U¤¸¡]¬ù18¸U¬ü¤¸¡^¡A¼ç¦b¥Ø¼Ð¯f±w±Ú¸s¥H10¸U¤H¦ôºâ¡A°Ó¾÷¤W¬Ý¦Ê»õ¤¸¡C ¡@¶´¤O¥Í§Þ¡]National Resilience¡^³Ð¿ì¤H¡BÃĵØÃÄ¿W¥ß¸³¨Æ·¨¨|¥Áªí¥Ü¡A³o¬O¥xÆW¤H¤§¥ú¡A§Æ±æ¦¹¤@¥@¬É¯Åªº¦¨ªG¡A¬°¥i¥H¥xÆW¥Í§Þ²£·~¬É¾ð¥ß¤@­«­nªº¨½µ{¸O¡C ¡@ÃĵØÃÄ°õ¦æªøªL°êÄÁ¤]»¡¡AP1101¬°°ê¤º¥ÍÂå²£·~®³¤U¤T­Ó­«­nªº·N¸q¡A¤À§O¬O¡G¤@¡B¸Ó·sÃĬO²Ä¤@­ÓÀòFDA®Ö­ã±Mªù¥Î©óªvÀøPVªº¤zÂZ¯ÀÀøªk¡A¥é³æ¨Ï¥Î½d³ò¸û¼Ú·ù§ó¼s¡A©Ò¦³PV¯f±w¡A¥]¬AµÊŦ¸~¤j±wªÌ¡A§¡¥i¨Ï¥Î¡A¥Ø¼Ð¯f¤H¼Æ¤ñ­ì¥»¹w¦ô¤H¼Æ§ó¦h¡C ¡@¤G¡BP1101¨C¤H¨C¦~ÃÄ»ù¬ù·s¥x¹ô500¸U¤¸¡A¬ü°ê¬ù¦³16¸U¾l¦WPV¯f±w¡A®Ú¾Ú¬ü°ê¤l¤½¥q¥«³õ¬ã¨s¡A¦ô­pP1101±N¨ÓªvÀøªº¥Ø¼Ð¯f±w±Ú¸sÀ³¥i¹F10¸U¤H¡A¸Ó·sÃĤ]³Ð¤U¥xÆW¬ãµo»s³y·sÃĦۦæ¦b¬ü¤W¥«¾P°â¦¨¥\­º¨Ò¡C ¡@¤T¡B¥Ñ©óP1101¤w¨ú±o¬ü°ê©t¨àÃĸê®æ¡AÀòFDA®Ö­ã«á¦b¬ü°ê¥«³õ¨É¦³¤C¦~ªº¥«³õ¿W¥eÅv¡C ¡@¬ü°êFDAÃÄ«~¼fµûº[¬ã¨s¤¤¤ß«D´c©Ê¦å²G¯e¯f³¡¥D¥ô¦wªk·çº¸Âå¥Íªí¥Ü¡G¡u¬ü°ê¦³¶W¹L7,000ºØ¨u¨£¯e¯f¡A¼vÅT¶W¹L3,000¸U¤H¡C¨ä¤¤¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^¨C¦~¼vÅT¤j¬ù6,200¦W¤H¡C³o¶µ¦æ°Ê¡A¥YÅã¬ü°êFDA¹ï©óÀ°§U¨u¨£¯e¯f±wªÌ¡AÀò±o·sªºªvÀø¤èªkªº©Ó¿Õ¡C¡v ¡@ªL°êÄÁ¤]»¡¡AÃĵØÃĬü°ê¹Î¶¤¾Ö¦³Â×´I¦æ¾P¸gÅç¡AÃÄ«~¨ÑÀ³Ãì¤w·Ç³Æ¦n¡A¥ß§Y±Ò°ÊP1101¦b¬ü¾P°â¡A±N©ó¼Æ©P¤º¶}©l¾Q³f¡A®i¶}¤W¥««á¦b¬ü°ê¦U¦aªº¦æ¾P¬¡°Ê¡A·m§ð¬ü°êPV¥«³õ¡C¹w­pP1101¦b¬ü°ê¤W¥««á§Y¥i°^ÄmÀ禬¡C ¡@ªk¤H¹ï¦¹ªí¥Ü¡AP1101¤wÀò±o¼Ú·ù¡B¥xÆW¡B·ç¤h¡B¥H¦â¦C¤ÎÁú°êÃÄÃÒ¡AÀò¬ü°êÃÄÃÒªº·N¸q¦b©ó¡A¶i­x¥þ²y³Ì¤j·sÃÄ¥«³õ¡A2022¦~°_Àç¹B¥iÁÚ¤J·sªº¨½µ{¸O¡A¶i¤JÀò§Q¤¸¦~¡C¡]·s»D¨Ó·½¡G¤u°Ó®É³ø¢w°OªÌ§ù¿·»T¡þ¥x¥_³ø¾É¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/15 ¤U¤È 11:49:31²Ä 9864 ½g¦^À³
Á©ú´Ü1115¸`¥Ø(µL±ÀçY¤§·N)9¤À16¬í°_¦Ü24¤À¡A¤ÀªRÃĵØÃÄ

youtu.be/M4hWUUB7nIs

Ãö¤ßÃĵØÃĪº§ë¸ê¤H¤@©w­n¬Ý§¹

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2021/11/15 ¤U¤È 04:53:14²Ä 9863 ½g¦^À³
Eric¤j¡A¯u¥¿ªº­«ªðºaÄ£ÁÙ»Ý2¦~¡A­Y­n¤j¶ã¤j©ñ¦¨¬°¥xÆW¤§¥ú¡A­n¦³Ã¬§QÅã²{¡A¦ô­p¹F¦¨«e¼ÐÃD¥Ø¼Ð¡A¥»¤H¦ôºâ2¦~«á......¥[ªo¡A«ùÄò©êºò
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2021/11/15 ¤U¤È 01:10:39²Ä 9862 ½g¦^À³
³s¾h10~20¤ÑÀs±²­·

¯uªº¥i¨ì«e¼ÐÃD¬°³Ì§C¥Ø¼Ð¤F

®¥³ß¥ý¶i¤j~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2021/11/15 ¤U¤È 12:58:10²Ä 9861 ½g¦^À³
¥à¬Û¦b¦¹®¥³ß¦U¦ì

°_­·¤F

³s¾h10~20¤Ñ

­n§¤Ã­¤F!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gonly10135877  µoªí®É¶¡:2021/11/13 ¤U¤È 10:12:28²Ä 9860 ½g¦^À³
jakafi ¤@­Ó¤ëÃÄ»ù

www.drugs.com/price-guide/jakafi

ÃÄ»ù¨Ã¨S¦³¤ñ¸û°ª

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2021/11/13 ¤U¤È 08:33:38²Ä 9859 ½g¦^À³
¤@¦~18¸U¬ü¡A¤ñ¤G½uJakafiÁÙ°ª

¤£ª¾¹D³o¼Ëªº©w»ù¯à·m¨ì¦h¤ÖJakafiªº±wªÌ¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GºÖ«°10145527  µoªí®É¶¡:2021/11/13 ¤U¤È 03:41:24²Ä 9858 ½g¦^À³
¥ý¦Ü¤Ö¨Ó5®Úº¦°±ªO§a.................

µM«á¦AÄ~Äò¥[ªoºCºC¹Ô°ª............

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2021/11/13 ¤U¤È 03:33:10²Ä 9857 ½g¦^À³
¥»¤½¥qBesremi¡]Ropeginterferon alfa-2b¡^Àò¬ü°êFDA ®Ö­ã¨Ï¥Î©ó¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^

1.¨Æ¹êµo¥Í¤é:110/11/13

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q©ó¬ü°ê®É¶¡2021¦~11¤ë12¤é¥¿¦¡±µÀò¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^³qª¾¡A¥»¤½¥qBesremi¡]Ropeginterferon alfa-2b, §YP1101¡^ÀòFDA®Ö­ã¨Ï¥Î©ó¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^¡CÃÄ»ù­q¬°¨C¤H¨C¦~¬üª÷¬ù 18¸U

¤¸¡A¬ù·s¥x¹ô500¸U¤¸¡C

6.¦]À³±¹¬I:µo¥¬¥»­«¤j°T®§

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GBesremi¡]Ropeginterferon alfa-2b, §YP1101¡^

¤G¡B¥Î³~¡GRopeginterferon alfa-2b«Y·s¤@¥N³Ð·sªø®Ä«¬¤zÂZ¯ÀÃĪ«¡A¥Î©óªvÀø¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g±wªÌ¡C

¤T¡B¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¤£¾A¥Î¡C

¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

(¤@)´£¥X¥Ó½Ð¡þ³q¹L®Ö­ã¡þ¤£³q¹L®Ö­ã¡þ¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)

µ²ªG¡þµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥ó¡G

Àò¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^®Ö­ã¥Î©óªvÀø¦¨¤H¯u©Ê¬õ¦å²y¼W¦h¯g±wªÌ¡C

(¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¥¼¹F²Î­p¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î

(¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¹F²Î­p¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G

¥»¤½¥q¤§¬ü°ê¤l¤½¥q¥¿¦¡±Ò°ÊRopeginterferon alfa-2b¬ü°ê¥«³õ¾P°â·~°È

¡A¨Ã¨Ì·Ó³Wµe®i¶}¤W¥««á¦b¬ü°ê¦U¦aªº¦æ¾P¬¡°Ê¡C

(¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¦Ò¶q¥¼¨Ó¥«³õ¦æ¾Pµ¦²¤¡A«O»Ù¤½¥q¤Î§ë¸ê¤HÅv¯q¡A¼È¤£¤½¶}´¦ÅS¡C

¤­¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G¤£¾A¥Î

(¤@)¹w­p§¹¦¨®É¶¡¡G¤£¾A¥Î¡C

(¤G)¹w­pÀ³­t¾á¤§¸q°È¡GµL¡C

¤»¡B¥«³õ²{ªp¡G(½Ð»¡©ú¥Ø«e¸Ó·sÃÄ©Ò¾AÀ³¯f¯g¤§¥«³õª¬ªp¡B²{¦³ªvÀø¬Û¦P¯f¯g¤§¥D­nÃĪ«µ¥¸ê°T)

¯u©Ê¬õ¦å²y¼W¦h¯g¡]PV¡^¬°°©Åè¼W¥Í©Ê¸~½F¡]MPN¡^¯e¯fªº¤@ºØ¡A¯e¯f¶iµ{¥i¯à¥Ñ¦å²G¿@¸Y¡BµÊŦ¸~¤j¡B¤Þµo¦å®ê¡B¤¤­·¦MÀI¡AÄY­«¥iºtÅܬ°«æ©Ê°©Åè¥Õ¦å¯f¡]AML¡^¡A¼vÅT¯f±w¦s¬¡»P¥Í¬¡«~½è¡C¬ü°êMPN Research Foundation©ó2010¦~¶i¦æªº½Õ¬d¼Æ¾ÚÅã¥Ü¡A¦b¬ü°ê¬ù¦³15¸UPV±wªÌ¡C®Ú¾ÚÁ{§É«ü¤Þ¡APV¥i¤À¬°°ª­·ÀI¤Î§C­·ÀI±Ú¸s¡C¨ä¤¤°ª­·ÀI±Ú¸s©w¸q¥]§t°ªÄÖ¡]60·³¥H¤W¡^©Î´¿¦³¦å®ê¯f¥v¡A¨ä¦³¸û°ªªº¤ß¦åºÞ¯e¯f­·ÀI¡C

PVÁ{§É¥ÎÃÄ¿ï¾Ü·¥¬°¦³­­¡A¥Ø«e¬ü°ê¦bPV¾AÀ³¯g¤W¶È¦³¤G½u¥ÎÃÄJakafi¡]Ruxolitinib¡^ÀòFDA®Ö­ã¡CRopeginterferon alfa-2b¬°¥»¤½¥q¦Û¦æ¬ãµo¥Í²£¤§·s¤@¥N³Ð·sªø®Ä«¬¤zÂZ¯À¡A¤w©ó2012¦~¨ú±o¬ü°ê©t¨àÃĸê®æ¡AÀòFDA®Ö­ã«á¦b¬ü°ê¥«³õ¨É¦³¤C¦~ªº¥«³õ¿W¦ûÅv¡CRopeginterferon alfa-2b¬O²Ä¤@­ÓÀòFDA®Ö­ã¥Î©ó©Ò¦³PV±wªÌªºÃĪ«¡A¤]¬O²Ä¤@­ÓÀòFDA®Ö­ã±Mªù¥Î©óªvÀøPVªº¤zÂZ¯ÀÀøªk¡C

¤C¡B¨ä¥LÀ³±Ô©ú¨Æ¶µ¡G·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
12345678910¤U¤@­¶¤U¤Q­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

ÃĵØÂåÃÄ

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!